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ABSTRACT 
Previous studies have suggested that glutamine may be a conditionally essential amino 
acid during critical illness. The aim of this study was to use L_[2_15N] glutamine as a 
tracer to investigate glutamine kinetics in critically ill patients and to determine 
whether nutritional support and combined growth hormone/insulin-like growth factor-I 
(GH/IGF-I) treatments have any adverse or beneficial effects on glutamine metabolism. 
Initial studies in healthy controls indicated glutamine appearance rate (RagIn) expressed 
per kg body weight was lower in elderly (>60 years) compared to young «35 years) 
subjects (p<0.05), but RagIn expressed per kg lean body mass was not different. 
Glutamine kinetics were measured in critically ill patients and matched healthy 
controls. Although RagIn was similar in both groups, the proportion of RagIn arising 
from protein breakdown (Bg1n; p<0.05) and the glutamine metabolic clearance rate 
(MCRgIn; p<O.OOl) were higher, whereas plasma glutamine concentration was lower in 
the patients than in the control group (p<O.OOl). The lower plasma glutamine 
concentration and unaltered plasma RagIn suggest that although BgIn was higher this was 
insufficient to meet the increased demand for glutamine in these patients. 
The effects of total parenteral nutrition (TPN), and TPN supplemented with glutamine 
(TPNGLN, 0.4 g kg-1dail), on glutamine metabolism were studied in critically ill 
patients. RagIn and MCRgIn were not altered by either treatment. Plasma glutamine 
concentration (p<0.001) and glutamine uptake (RdgIn; p<0.05) both increased with 
glutamine supplementation. These results suggest there is an increased requirement for 
glutamine in critically ill patients. 
The effects of treatment with TPNGLN and combined GH (0.2 IU kg-1dail)/IGF-I 
(160 J.lg kg-1dail) therapy (TPNGLN+GH/IGF-I) were also investigated. 
TPNGLN+GH/IGF-I did not alter RagIn and the increase in glutamine concentration 
(p<0.05) and RdgIn (p<0.05) were similar to that achieved in the TPNGLN group. This 
suggests that combined GH/IGF -I treatment did not have adverse effects on glutamine 
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Glutan1ine is a five carbon amino acid with an anhydrous molecular weight of 146.15 
(Figure 1.1). At physiological pH the carboxyl group of glutamine carries a negative 
charge whereas the amino group is protonated, this results in the molecule carrying a 
net zero charge and the classification of glutamine as a neutral amino acid. Because of 
its h\'o nitrogen side chains, an a amino group and an amide group, glutamine can also 
be classified as an amino acid amide. 
amino N amide N 
Figure 1.1. The molecular structure of glutamine. 
Glutamine is the most abundant free amino acid in the human body. In plasma 
glutamine has the highest amino acid concentration (typically 400-900 ).lmol rl) and 
accounts for approximately 20 % of the total circulating amino acid pool (Smith and 
Wilmore 1990). In skeletal muscle, which contains about half the total free amino 
acids in the body, glutamine constitutes approximately 60 % of the free amino acid 
pool, excluding taurine (Bergstrom et al 1974). 
As glutamine can be synthesised endogenously and has such a high natural abundance, 
it has been traditionally classified as a non-essential amino acid. This definition 
implies sufficient glutamine can be produced endogenously to meet the glutamine 
requirements of the body. However, free glutamine concentrations are very labile and 
marked decreases have been reported in a variety of catabolic states (Vinnars et al 
1975, Askanazi et al 1980). This suggests that during serious illness a deficiency in 
glutamine availability may develop and has led to the idea that glutamine is a 
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conditionally essential amino acid (Lacey and Wilmore 1990). In the last two decades 
glutan1ine n1etabolism, its influence on metabolic control and the body's response to 
dietary supplementation has become a major experimental and clinical research area. 
Glutamine nletabolism 
The importance of glutamine was emphasised by Hans Krebs in 1980 when he stated, 
"Most amino acids have multiple functions but glutamine appears to be the most 
yersatile". 
Glutamine is an illlportant intermediate in a number of metabolic pathways and plays a 
key role in nitrogen homeostasis. Some of the major functions of glutamine 
metabolism in man are listed below:-
• Because of its two amino moieties glutamine is considered to be the principal carrier 
of nitrogen from peripheral tissues to the visceral organs. 
• Glutamine plays an important role in hepatic ureagenesis. 
• Glutamine plays a key role in acid-base homeostasis as an important substrate for 
renal ammoniagenesis. 
• Glutamine is an important energy source for rapidly growing cells such as the 
mucosal cells of the intestinal mucosa, lymphocytes and most cultured cells. 
• Glutamine is also a nitrogen donor in the synthesis ofnucleotides such as ATP, and 
purine and pyrimidine synthesis and is therefore essential for cell proliferation. 
• Glutamine is an important precursor for the antioxidant glutathione. 
There are numerous enzymes involved in glutamine metabolism; the two key enzymes 
which are involved in the inter-conversion of glutamine and glutamate, are shown in 
Figure 1.2. Phosphate-dependent glutaminase is bound to the inner mitochondrial 
membrane and catalyses the hydrolysis of glutamine to glutamate and ammonia. There 
appear to be two major forms of glutaminase, the renal and the hepatic forms which 
have different kinetic properties and protein structure (Neu et aI1996). Glutamine 
synthetase is located primarily in the cytoplasm and catalyses the biosynthesis of 
glutamine from glutamate and ammonia. This reaction is energy dependent, requiring 
one mole of ATP per mole of glutamine synthesised. The different intracellular 
location of these two enzymes is appropriate for their metabolic functions; glutaminase 
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catalyses the utilisation of glutamine as an energy source whereas glutamine synthetase 












































Figure 1.2. Reactions catalysed by glutaminase and glutamine synthetase. 
Although most tissues contain both enzymes many are either predominantly glutamine 
consumers and contain relatively high amounts of glutaminase (i.e. gut mucosal cells, 
endothelial cells, lymphocytes, renal tubular cells) or net glutamine producers and 
contain relatively high amounts of glutamine synthetase (i.e. skeletal muscle, lung, 
brain and heart). Because of the large mass of skeletal muscle in the body, skeletal 
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n1uscle glutan1ine synthetase catalyses the synthesis of almost 30 % of the total 
circulating glutamine (Neu et al 1996). The liver can act as either a net glutamine 
consun1er or producer depending on the metabolic state, and regulates the activity of 
glutaminase or glutamine synthetase accordingly. 
Glutamine and nluscle 
Skeletal n1uscle is the largest protein pool in the body and accounts for 30-40 % of the 
total body \veight in humans. Assuming the free glutamine concentration in all skeletal 
muscle is about 20 111mol per litre of intracellular water, it has been estimated that 
skeletal muscle (25 kg of muscle, ---80 % water, in a 70 kg man) contains about 
400 mmoles or 60 g of free glutamine (Souba 1992). This glutamine pool remains 
fairly constant during conditions of health but marked falls have been observed in 
catabolic conditions associated with protein wasting (Vinnars et a11975, Askanazi et al 
1980, and Roth et al 1982). 
Amino acids are not released from muscle in the same proportion in which they are 
present in the contractile proteins. In the post-absorptive state more than 50 % of the 
amino acids released from skeletal muscle consist of glutamine and alanine (Ruderman 
and Berger 1974). This is due to the de novo synthesis of these two amino acids from 
amino acids and other substrates. The branched chain amino acids and glutamate are 
the most important nitrogen donors for the de novo synthesis of glutamine (Darmaun 
and Dechelotte 1991). 
Animal studies have suggested a relationship between glutamine concentration and 
protein synthesis. Infusion of glutamine reduced the post-operative efflux of amino 
acids from the dog hind limb (Kapadia et al 1985). A positive correlation has been 
shown between free glutamine levels in muscle and the protein synthesis rate in the 
perfused rat hind limb in the presence, or absence, of insulin (MacLennan et al 1987). 
Using a similar rat skeletal muscle model Jepson and co-workers (Jepson et al 1988) 
demonstrated the relationship between muscle glutamine concentration and protein 
synthesis rate existed in a number of catabolic states including dietary restriction or 
endotoxin inj ection. This correlation is specific for glutamine and has not been 
observed with other amino acids. The fall in muscle glutamine concentration was 
highly correlated with the decrease in ribosomal concentration and activity (Jepson et 
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al 1988). MacLennan and co-workers have also demonstrated glutamine inhibition of 
protein degradation, again in the rat skeletal tissue model. Elevated concentrations of 
glutamine in the perfusate diminished the dilution of the [15N] phenylalanine tracer, 
suggesting an inhibition of muscle protein breakdown (MacLennan et al 1988). 
However. several groups have failed to observe a correlation between muscle 
glutan1ine concentration and the protein fractional synthetic rate in various models of 
stress in the rat. Infusion of glutamine in post-absorptive rats in vivo did not stimulate 
protein synthesis (Garlick and Grant 1988). In a more recent study a glutamine 
synthetase inhibitor (n1ethionone sulphoximine) was used to decrease glutamine levels 
in rats (Olde Damink et al 1999). The decrease in plasma glutamine (40 %) and 
intracellular muscle glutamine (60 %) levels had no effect on whole body protein 
tumoyer or muscle protein kinetics (measured using [2,6-3H] phenylalanine). This 
study suggests that it is unlikely that the intracellular muscle glutamine concentration is 
a major regulating factor in muscle protein kinetics 
Glutamine and the intestinal tract 
Early in vitro experiments investigating the oxidation of various 14C labelled substrates 
by incubated ileum discs showed that glutamine was oxidised to an equal or greater 
extent than glucose in a number of animal species, including the monkey, rat and rabbit 
(Neptune 1965). Windmueller and Spaeth demonstrated the importance of glutamine as 
a major respiratory fuel for the gut in vascularly perfused gut preparations from fasted 
rats (Windmueller and Spaeth 1974) and in situ, autoperfused, isolated jejunum 
sections in both fasted and fed rats (Windmueller and Spaeth 1978 and 1980). Most of 
the glutamine uptake occurs in the small intestinal mucosal cells which have high 
glutaminase activity (Windmueller and Spaeth 1974). 
In the post-absorptive state the gut lumen is relatively empty so the vast majority of 
glutamine must be extracted from the blood stream. In the post-prandial state 
glutamine is also taken up by the gut from the lumen, across the brush border. The fate 
of glutamine carbons has been traced by infusing [U_14C] glutamine into the lumen of 
rat isolated jejunum sections and measuring the specific activity of carbon products 
released into the venous blood (Windmueller and Spaeth 1975). Approximately one 
third (34 %) of the infused glutamine was recovered unchanged in the venous blood 
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collected from the segments. About 56 010 of the carbon from the metabolised 
glutamine was recovered in the blood as CO2, 20 % as organic acids (mostly lactate) 
and 15 % in other amino acids (proline, citrulline, alanine, ornithine and glutamate). 
A sinlilar distribution of products was found in earlier experiments when the [U_14C] 
glutanline \vas administered to the vascular side of the rat intestine (Windmueller and 
Spaeth 1974). These results suggest glutamine is metabolised similarly whether it 
enters the mucosal cells from the luminal side or the blood stream. Nitrogen taken up 
by the jejunum as glutamine can be accounted for by the net release of ammonia, 
citrulline, alanine, proline, glutamate and ornithine (Windmueller and Spaeth 1980). 
Most of the information on glutamine metabolism by the intestinal tract has been 
deriyed from in vitro and in vivo animal experiments. The relative inaccessibility of 
the portal vein has made the in vivo study of intestinal glutamine metabolism in 
humans difficult. Early balance studies in humans, which sampled blood from the 
brachial artery and an hepatic vein, demonstrated net uptake of glutamine by the 
splanchic bed as a unit, but did not separate the contributions of the gut and liver 
(Marliss et al1971, Felig et alI973). Felig and co-workers also took blood samples 
from the brachial artery and the hepatic portal vein in a small group (n=4) of patients 
undergoing elective cholecystectomy. The positive arterio-portal venous glutamine 
balance (533 + 30 vs. 460 + 24 /-lmol rl) indicated net glutamine uptake by intestinal 
tissues (Felig et al 1973). However sampling from the portal vein includes other portal 
drained viscera such as the spleen and pancreas. 
Several more recent studies have confirmed the prominent role of the small intestine in 
glutamine metabolism in humans. Using a whole body stable isotope tracer technique 
Darmaun and co-workers (1991a) showed that whole body glutamine utilization was 
reduced by 20 % in patients who had undergone extensive small bowel resection. In 
contrast the whole body glutamine appearance rate (RagIn) was increased (13 %) in 
adult patients with active coeliac disease (Messing et al 1998). Glutamine fractional 
extraction rates (i.e. percentage of glutamine extracted from arterial blood) have been 
measured in patients undergoing elective surgery for gastrointestinal malignancies 
(Van der Hulst et al 1997). Extraction rates of24, 9, and 8 % were obtained for the 
jejunum, ileum and colon, respectively, suggesting glutamine is a more important fuel 
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in the proxin1al gut compared with the distal gut. Splanchnic bed utilisation of 
glutamine tracers, given by nasogastric tubes to fasted adults, has been estimated at 
54 % (Matthews et al 1993) and 73 % (Hankard et al 1995). 
An important function of the gut is to prevent the translocation of bacteria and 
endotoxins from the gut lumen into the systemic circulation that can trigger sepsis 
(Meakins and Marshall 1986). The mucosal epithelium is a dynamic rapidly dividing 
tissue \yhich is highly dependent on adequate nutritional supply. Delivery of adequate 
amounts of glutamine n1ay be necessary for maintenance of the gut mucosal integrity. 
Intestinal glutamine uptake may be concentration dependent, Van der Hulst and 
co-workers showed glutamine extraction by the ileum was correlated with arterial 
glutamine concentrations (Van der Hulst et al 1997). A reduced uptake of glutamine 
by the gut may be present in disease states characterised by low plasma glutamine 
concentrations. This may be particularly important during catabolic illnesses when 
there may be severe glutamine depletion and oral nutrition may be interrupted. 
Standard parenteral nutrition, which does not contain glutamine, has been associated 
\yith marked atrophy of the intestinal mucosa. The addition of glutamine to parenteral 
nutrition prevents the deterioration of gut permeability and preserves mucosal structure 
(Van der Hulst et al 1993). 
Glutamine and the liver 
The liver plays a central role in glutamine metabolism, as it can act as an organ of net 
glutamine uptake, release, or balance depending on several factors such as ammonia 
concentration, pH and the metabolic requirements. There are two distinct hepatocyte 
populations which contain different enzyme systems. 
The portal blood flow initially comes into contact with the periportal cells (,...., 93 % of 
hepatocytes) which contain glutaminase and the enzymes of the urea cycle. These low 
affinity, high capacity cells take up glutamine and ammonia and synthesise urea. The 
glutaminase in the periportal hepatocytes is structurally, kinetically and 
immunologically different to glutaminase found in other tissues, such as the kidney. 
Unlike renal glutaminase hepatic glutaminase is activated by ammonia and is not 
inhibited by glutamate. Periportal glutamine breakdown increases flux through the 
urea cycle by amplifying the mitochondrial supply of ammonia for the first enzyme of 
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the urea cycle, carbamoylphosphate synthetase. In the perivenous cells ("'7 % of 
hepatocytes) close to the hepatic vein glutamine synthetase synthesises glutamine from 
anlmonia and glutamate. These high affinity cells act as "scavengers" for ammonia 
that has escaped the initial extraction for urea synthesis in the periportal cells. 
Under normal non-stressed physiologic conditions (balanced acid-base situation) the 
breakdown and synthesis of glutamine by the liver (intercellular glutamine recycling) 
are roughly matched and the liver acts as an organ of glutamine balance (Haussinger 
1990). Flux through the intercellular glutamine cycle increases in situations known to 
increase urea production, such as an increase in the portal ammonia load. However, 
during acidosis urea synthesis is decreased and glutamine synthesis is favoured in order 
to provide glutamine for the renal ammoniagenesis. 
Glutamine and the kidneys 
In the renal tubular cells glutamine deamidation (by the enzyme glutaminase) generates 
ammonia which diffuses into the lumen of the tubules where it combines with a proton 
to form the ammonium ion. The ammonium ion is excreted in urine along with an 
anion such as chloride. During metabolic acidosis the rate of renal glutamine 
consumption is increased to support ammoniagenesis and the kidneys become the 
major organ of glutamine utilisation (Souba 1992). In extreme acidic conditions 
glutamate can be deaminated (via the enzyme glutamate dehydrogenase) to generate 
additional ammonia (Lacey and Wilmore 1990). In contrast, renal glutamine uptake is 
decreased during alkalosis. 
Glutamine and the immune system 
Glutamine is a key substrate for both lymphocytes and macrophages. In vitro 
experiments have shown glutamine to be essential for the normal functioning of these 
cells in the immune response (Parry-Billings et al 1990). Glutamine plays a dual role 
providing an energy source via oxidation and nitrogen precursors for the synthesis of 
purine and pyrimidine nucleotides for DNA and RNA. 
Lymphocytes that have not been exposed to an immune stimulus are often called 
"resting" lymphocytes which implies that they exist in a relatively quiescent metabolic 
state. The metabolism of these cells is accelerated in response to an immune stimulus, 
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to support cell division and the secretion of antibodies, cytokines and other soluble 
protein mediators. Macrophages are terminally differentiated white cells which do not 
characteristically divide in response to an immune stimulus. However, when "active" 
they have high rates of RNA and protein synthesis, associated with production of 
secretory proteins (interleukins and lysosomal enzymes) and membrane recycling 
(phagocytosis ). 
In lymphocytes glutamine is only partly oxidised, yielding mainly glutamate, aspartate 
and lactate, a process termed "glutaminolysis" (Ardawi and Newsholme 1985). Very 
little glutamine is oxidised via acetyl-CoA and the "classic" Krebs cycle, despite the 
presence of the Krebs cycle enzymes. The possible reason for this is that generation of 
a high ATP concentration would inhibit key reactions in glutaminolysis 
(e.g. oxoglutarate dehydrogenase). In vitro experiments have shown the rate of 
glutaminolysis and hence glutamine utilisation is much higher than is necessary for the 
proyision of intermediates for biosynthetic pathways (Szondy and Newsholme 1989). 
It has been suggested that the high flux of glutamine allows optimal response when the 
immune system is activated, so that high rates of purine and pyrimidine synthesis can 
be achieved without depleting the concentrations of the metabolic precursors 
(glutamine and aspartate). 
Glutamine transport 
Amino acids are transported into and out of cells by distinct transport proteins located 
in the cell plasma membrane. Table 1.1 lists some of the major amino acid transport 
systems for glutamine and other neutral amino acids (McGivan 1996, Palacin et al 
1998). None of the transport systems are specific for glutamine or any amino acid, but 
they transport structurally related amino acids. Many of these transporters are sodium 
dependent, and require initial binding of the sodium ion prior to binding of the amino 
acid. The electrochemical potential gradient of sodium ions drives the amino acid 
accumulation across the plasma membrane. The identification of amino acid 
transporters was originally based on functional characteristics such as their kinetically 
detennined amino acid specificity, ion dependence and pH dependence (Ahmed et al 
1993). Since the beginning of the 1990s complementary DNA clones have been 
isolated for several members of the systems Land ASC transporter families, and the 
first member of the system A family has recently been identified (Varoqui et al 2000). 
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A number of different transport systems with overlapping specificity may occur in the 
sanle cell membrane. The three major amino acid transport systems for neutral amino 
acids in nlammalian tissues are systems A, ASC and L, which are present in almost all 
cell types (McGivan and Pastor-Anglada 1994). Some of the amino acid transporters 
appear to be more tissue specific. For example in hepatocytes glutamine uptake is 
mediated by system N in both rats (Kilberg et al 1980) and humans (Bode et al 1995). 
A system with sinlilar properties has been identified in rat skeletal muscle and has been 
designated system Nm (Hundal et al 1987). System Nm has also been characterised in 
sarcolemnlal vesicles isolated from human skeletal muscle, however in humans system 
Nm is pH sensitive (Ahmed et al 1993). 
An important feature of system A is that its activity is highly regulated in many cell 
tJpes (McGivan and Pastor-Anglada 1994, Palacin et aI1998). Insulin, glucagon, 
catecholamines and glucocorticoids have been shown to upregulate system A activity 
(Palacin et aI1998). System N activity also appears to be highly regulated. In 
hepatocytes system N is upregulated by hormones such as insulin, glucagon and 
glucocorticoids (Bode et aI1990). Growth hormone treatment has been shown to 
decrease system A activity in both human and rat hepatocytes, but does not affect 
system N (Pacitti et al 1992). In muscle cells cultured in glutamine free media system 
Nm shows increased transport activity to compensate for the reduced glutamine supply 





Table 1.1. Some of the major transport systems for neutral an1ino acids (Modi fled from McGivan 1996, Palacin et al 1998) 
System Specificity Distribution Comments 
+ Na dependent 
System A Small aliphatic amino acids Widespread pH sensitive. 
Preferred substrates: Highly regulated, inducible by hormones, amino 
alanine, serine, glutamine acid deprivation, osmotic stress. 
System ASC Small aliphatic amino acids Widespread pH insensitive. 
Preferred substrates: Not usually inducible. 
alanine, serine, cysteine 
System N Glutamine, histidine, Liver pH sensitive. 
asparagIne Inducible by hormones, osmotic stress. 
System Nm Glutamine, histidine, Skeletal muscle pH sensitive (human), insensitive (rat). 
asparagIne Inducible by insulin amino acid deprivation, 
osmotic stress. 
System B Most neutral amino acids Renal and intestinal Transepithelial transport. 
brush borders 
Na+ independent 
System L Mainly branched chain and Widespread Not usually inducible. 
aromatic amino acids 
Critically ill patients 
Critical illness is defined as any condition requiring support of failing vital organs, 
\vithout which death would occur (Van den Berghe 1999). This definition includes a 
nlultitude of catabolic states such as sepsis, trauma, bums and major surgery (Jenkins 
and Ross 1996). The role of the intensive care unit (lCU) is to manage patients with 
acute life threatening illnesses and to restore their previous quality of health and life 
(Griffiths et al 1995). Admission of patients to an ICU is usually unplanned and 
typically features a period of crisis involving shock or sepsis followed by a period of 
organ support to maintain life while normal function is re-established (Griffiths et al 
1995). This support can involve the use of mechanical aids, for example mechanical 
ventilators or dialysis machines, or pharmacological agents, such as inotropes or 
vasopressors (Vanden Berghe 1999). Critically ill patients are often elderly, not 
physically active, and suffer from an underlying disease, with a generally compromised 
health state. These patients are distinct from metabolically healthy patients with stable 
circulation and minimal preoperative blood loss undergoing planned operative 
intervention (standardised surgical procedures: e.g. elective cholecystectomy). 
~Ietabolism and endocrine changes in critical illness 
Critical illness is associated with profound hormonal and metabolic alterations which 
result in the development of a hypercatabolic state. Increased amounts of free amino 
acids are mobilised from skeletal muscle for high priority use in other tissues such as 
the gastrointestinal tract, liver, and kidneys (Kinney and Elwyn 1983). The amino 
acids are used as metabolic fuels, substrates for gluconeogenesis, ammoniagenesis and 
anabolic processes such as synthesis of acute phase proteins and wound healing. The 
clinical observation of muscle wasting in ICU patients is well documented and is of 
considerable clinical importance as skeletal muscle fatigue results in difficulties in 
weaning the patient off a ventilator (Gamrin et al 1996). The progressive loss of 
muscle mass is associated with disturbed wound healing and tissue repair and an 
increased susceptibility to infection 
In the short term the changes observed in the neuroendocrine axis of critically ill 
patients are generally adaptive and provide optimal intravascular volume, perfusion 
pressure and substrate availability to facilitate healing and recovery (Rolih and Ober 
1995). However if the illness is prolonged these changes can contribute to a worsened 
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clinical outcome. The complete spectrum of changes seen in critically ill cannot be 
explained by the neuroendocrine response alone (Pittoni et al 1997). In addition to 
hom10nes the cytokines and the inflammatory mediators (prostaglandins, leukotreines 
and platelet activating factor) mediate the hypercatabolism seen in severe illness. The 
exact relationship between the cytokines, the inflammatory mediators and the 
traditional hOffilones in the generation and maintenance of the hypercatabolism of 
critical illness has not yet been established. 
It is yery difficult to study hOffilonal changes in critically ill patients for a number of 
reasons:-
• the heterogeneity of the patient groups. 
• lack of knowledge of the pre-illness metabolic state which may include underlying 
malnutrition. 
• the use of therapeutic agents which can potentially affect neuroendocrine function 
such as dopamine (Van den Berghe et al 1994a and 1994b). 
• there may be damage to organs directly involved in the endocrine response or to 
those involved in hOffilone metabolism. 
A number of mechanisms may be involved in the endocrine changes seen in critically 
ill patients. These include changes in hOffilone production rates, half-lives, binding 
protein levels and affinities, receptor binding, post-receptor signalling mechanisms and 
feedback loops, some of these changes are summarised in Table 1.2 (Jenkins and Ross 
1996). 
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Table 1.2. Characteristics of hormone changes seen in critical illness (Jenkins and 
Ross 1996). 
The pituitary-adrenal axis 
• Cortisol level increased with loss of diurnal variation 
• Biphasic ACTH response initially high then falls 
• Cortisol binding globulin level decreased 
• Glucocorticoid receptor affinity decreased 
The thyroid tLyis 
• Free T 3 decreased 
• Free T -+ decreased or normal 
• rT 3 increased 
• TSH leyels decreased or normal 
• Thyroxine binding globulin affinity decreased 
• Thyroid hormone receptor expression increased 
The growth hormone-insulin-like growth factor-I axis 
• GH levels increased 
• IGF -I levels low 
• IGFBP-l levels high and IGFBP-3 levels low 
• IGFBP-3 protease present 
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The pituitary-adrenal axis 
The nlajor glucocorticoid in humans is cortisol. In healthy adults cortisol production 
depends on stimulation of the adrenal cortex by adrenocorticotrophic hormone (ACTH) 
also known as corticotrophin. ACTH is secreted by the corticotrophs of the anterior 
pituitary in a distinctive diurnal pattern which cortisol secretion mirrors. The 
corticotrophs are stimulated by corticotrophin releasing hormone (CRR), from the 
hypothalanlus, to produce ACTH. Glucocorticoids provide negative feedback on 
ACTH and CRR secretion and in addition CRR secretion is modulated by stress. The 
majority of circulating cortisol (80-90 0/0) is bound to serum proteins, primarily 
corticosteroid binding globulin and albumin and as such is not active (Rolih and Ober 
1995). 
Numerous studies have reported elevated cortisol levels in critically ill patients and 
sho\vn that the degree of hyper corti solemi a is related to the severity of illness (Jurney 
et al 1987, Vermes et al 1995). There are several reasons for the hypercortisolaemia 
including an increased production rate, altered pituitary glucocorticoid feedback and 
loss of the circadian rhythm (Ross et al 1991 b, Reincke et al 1993). In the initial phase 
of critical illness the high serum cortisol concentrations are associated with increased 
levels of ACTH. However, after 3-5 days the ACTH levels fall to below normal levels, 
whereas the cortisol levels remain elevated (Vermes et al 1995). Cortisol protein 
binding levels are also low in critical illness, so there may be a greater elevation in free 
cortisol levels than indicated by the increase in total cortisol levels (Perrot et al 1993). 
Hypercortisolism increases gluconeogenesis and lipolysis and decreases protein 
synthesis to provide metabolic substrates for vital organs and postpone anabolism in 
other tissues (Van den Berghe et al 1998). In addition the immune response is 
inhibited by cortisol which is interpreted as an attempt to protect against over-
responsiveness of the inflammatory cascade (Munck et al 1984). 
The thyroid axis 
Thyroxine (T4) is the major circulating thyroid hormone (normal range 5-10 /-Lg dr1), 
however more than 99 % circulates bound to binding proteins (globulin and albumin) 
and is physiologically inactive. In the peripheral tissues T 4 is converted to the more 
active fonn tri-iodothyroxine (T3). The majority of circulating T3 originates from this 
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peripheral conversion and less than 20 % is directly secreted by the thyroid gland. 
Nomlal total TJ levels are 100-200 ng dr l and similarly more than 99 % is protein 
bound. T4 can also be converted to reverse T3 (rT3) which only has 1 % of the activity 
of T 4· The production of thyroid hormones is stimulated by thyroid stimulating 
homl0ne (TSH) from the anterior pituitary. The thyroid hormones have direct effects 
on nletabolism by stimulating intracellular metabolic activity and indirect effects by 
potentiating the effects of other hormones such as the catecholamines and insulin. 
The changes in the hypothalamo-pituitary-thyroid axis in critical illness are known as 
non-thyroidal illness or "sick euthyroid syndrome" (Rolih and Ober 1995). The most 
common thyroid abnormality associated with critical illness is characterised by low T 3, 
nOffi1al T 4 levels, increased rT 3 and normal or low TSH levels. In about 20 % of lCU 
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patients the T 4 levels are also low. The initial changes in thyroid function during 
critical illness appear to be mainly changes in peripheral metabolism, binding and 
receptor occupancy of thyroid hormones (Van den Berghe et al 1998). Although TSH 
leyels usually remain normal, T 3 levels drop rapidly, partly due to decreased 
conversion ofT4 to T3 (Chopra et a11985) and/or increased turnover of thyroid 
hOffi1ones (Kaptein et al 1981). The magnitude of the fall in T 3 levels within the first 
24 hours appears to reflect the severity of the illness (Rothwell and Lawler 1995). The 
increase in rT 3 levels is partly due to decreased degradation (Chopra et al 1985). 
The changes in thyroid hormone levels seen in critically ill patients have been 
suggested to be an attempt to reduce energy expenditure and alleviate catabolism 
(Jenkins and Ross 1996). 
The growth hormone-insulin-like growth factor-I axis 
Growth hOffi1one (GH) is a 191 amino acid single chain peptide secreted by the 
somatotropes of the anterior pituitary gland. The GH profiles of normal adults consist 
of peaks every 3-4 hours alternating with virtually undetectable levels between the 
peaks, with the majority of the GH secretion being at night. This pulsatile GH 
secretion is controlled by the stimulatory action of hypothalamic growth hormone 
releasing honnone (GHRH), the inhibitory action of somatostatin and several neural 
and honnonal feedback loops which act directly, or indirectly on pituitary GH synthesis 
and/or release. A significant proportion (45-80 %) of the GH in plasma is attached to 
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binding proteins (GHBP) (Baumann et al 1988). Bound GH is cleared more slowly 
than free GH and prolongs GH bioavailability by creating a circulating reservoir of GH 
(Baumann et al 1987). High affinity GHBP represents the extracellular domain of the 
GH receptor and is thought to reflect GH receptor expression or abundance (Baumann 
1999). 
Although for n1any years GH was only considered to be important in the growth of 
children it is now well recognised that GH has important metabolic actions in adults, 
particularly in the maintenance of normal body composition. GH deficient adults have 
reduced lean body mass, increased fat mass (Salomon et al 1989) and decreased bone 
mineral density (Holmes et al 1994). 
In critically ill patients GH profiles are characterised by reduced pulse amplitude and 
eleyated baseline levels and are associated with low circulating levels of insulin-like 
growth factor I (IGF-I) (Ross et aI1991a). The elevated GH levels and low IGF-I 
leyels are interpreted as resistance to GH. Reduced GH binding protein activity, which 
is thought to reflect decreased GH receptor expression, has also been reported in 
critically ill patients (Ross et al 1991 b). 
In recent years, with the development of recombinant DNA technology, large quantities 
of synthetic GH have become available for therapeutic use. GH has been demonstrated 
to have protein anabolic effects in normal subjects (Fryburg et a11991) and GH 
deficient adults (Russell-Jones et aI1993). Administration ofGH has been shown to 
improve nitrogen balance in healthy adults receiving hypocaloric intravenous nutrition 
(Manson and Wilmore 1986) and in patients receiving hypocaloric or full intravenous 
support (Ziegler et al 1988, Douglas et al 1990, Ponting et al 1990, Berman et al 1999). 
GH therapy has also been shown to improve nitrogen balance in leu patients receiving 
nutritional support (Ziegler et al 1990b, J eevanandam et al 1996). 
Many of the actions ofGH are mediated by IGF-I expression in tissues or circulating 
IGF-I produced by the liver. The bioavailability and clearance oflGF-1 are regulated 
by a series of binding proteins (IGFBP-1 to 6), the most important of which appear to 
be IGFBP-1 and 3. 
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The vast ll1ajority of circulating IGF-I is associated with IGFBP-3 which further 
associates with a glycopeptide called the acid-labile subunit (ALS). The synthesis of 
these three polypeptides is normally increased by GH. Ternary complexed IGF-I is 
estinlated to have a half-life of 15 hours, whereas binary IGF-IGFBP-3 complexes are 
estinlated to have half-lives of 15-25 minutes and free IGF-I has a half-life of only a 
few nlinutes. In acute critical illness the concentration of IGFBP-3 is low due to an 
increase in a specific protease (Timmins et al 1996). This protease may explain the 
shorter half-life reported for subcutaneous IGF-I injections in post-operative patients 
compared to normal subjects (Miell et al 1992). IGFBP-l is found at higher levels in 
conditions of stress and is inversely modulated by insulin (Ross et al 1991 b). 
Recombinant human IGF-I was also available for use in human studies, but compared 
to GH there have been relatively few clinical trials with IGF-I since its commercial 
deyelopment was stopped in 1995. A 16 hour IGF-I infusion in calorically restricted 
subjects improved nitrogen balance (Clemmons et aI1992). Infusion ofIGF-I 
overnight in fasted, normal subjects demonstrated that like insulin IGF-I inhibits 
protein degradation and protein synthesis (Turkalj et al 1992). However, if sufficient 
substrate is provided in the form of an amino acid infusion, IGF -I infusion stimulates 
protein synthesis but has no effect on protein degradation in normal post-absorptive 
adults (Russell-Jones et al 1994). 
Glutamine metabolism in critical illness 
The metabolic response to critical illness is characterised by net catabolism of protein 
which results in an increased flow of amino acids from skeletal muscle, mainly 
glutamine and alanine, to the visceral organs. It has been suggested that muscle protein 
degradation provides glutamine for rapidly dividing cells such as immunocytes and 
enterocytes and possibly cells involved in wound healing (Soeters 1994). In addition, 
glutamine utilisation by the kidney is increased as the ammonia produced facilitates the 
excretion of acid equivalents (Van Acker et al 1997) 
As early as 1975 Vinnars et al reported that muscle free glutamine concentrations were 
significantly reduced (by more than 35 %) in patients 3 days after major abdominal 
surgery compared to healthy subjects, whilst plasma glutamine levels remained 
unchanged. In healthy individuals undergoing moderate elective surgery this decrease 
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in muscle free glutamine levels was detectable 12 hours postoperatively (Essen et al 
1992). The decrease in muscle free glutamine was shown to be still present on the 10th 
day following surgery and levels were slowly restored to preoperative levels over 20 to 
30 days (Petersson et al 1992). 
Critically ill patients have an extremely low level of free glutamine in skeletal muscle. 
Gamrin et al 1996 measured free glutamine concentrations in muscle biopsy and blood 
samples from a group of critically ill patients who had been in an reu for 3 to 14 days. 
Intracellular glutamine concentrations were depleted by 72 %, whereas plasma levels 
,vere only decreased by 23 0/0. The decrease in muscle free glutamine concentration is 
greater than for any other amino acid and persists during recovery when other amino 
acids have normalised. Although critically ill patients are a very heterogeneous group 
the decrease in muscle glutamine concentration is quite uniform between patients and 
is independent of the severity of illness (Gamrin et al1996). 
The fall in free glutamine concentration suggests endogenous glutamine synthesis is 
unable to meet the increased metabolic demand. Inability to meet the increased 
glutamine demand may have severe consequences for tissues consuming glutamine at 
high rates such as the gut and the immune system (Van Acker et al 1997). This has led 
to questioning of the non-essential character of glutamine (i.e. glutamine is 
"conditionally essential") and further research into the possible benefits of an 
exogenous supply of glutamine during times of increased metabolic demand. 
leu and nutritional support 
Nutritional support is an important therapy which has greatly improved the care of 
critically ill patients. Nutritional and metabolic support is provided during critical 
illness to reduce the net negative nitrogen and energy balance (Evans 1994). A variety 
of parenteral and enteral solutions containing various amounts of amino acids, glucose, 
lipid, micronutrients and electrolytes have been used (Souba 1997). Parenteral 
nutrition is used when enteral nutrition is not suitable or as a supplement to enteral 
nutrition if adequate nutrient administration is not possible by enteral nutrition alone 
(Cerra et al 1997). Although parenteral solutions are not as nutritionally complete as 
enteral formulas, nutritional targets are more often achieved by the use of total 
parenteral nutrition (TPN). However TPN is associated with increased incidence of 
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infection and is known to result in atrophy of intestinal mucosa and to promote 
bacterial translocation from the intestinal lumen (Neu et aI1996). 
Despite aggressive enteral and parenteral nutritional support, it is often difficult to 
attenuate the catabolic response in critically ill patients (Streat et al 1987). Strategies 
to prevent the loss of lean tissue are constantly under investigation and include the 
proyision of "conditionally essential amino acids" such as glutamine, and the use of 
anabolic hormones, such as GH and IGF-I. 
Glutamine supplements 
In early parenteral nutrition solutions, in which the amino acids were derived from 
casein hydrolysates, glutamine was present at low concentrations reflecting its levels in 
most animal and plant proteins (-7 % of total amino acids) (Lacey and Wilmore 1990). 
\Vhen synthetic amino acids preparations beacame available glutamine was omitted 
from TPN solutions for two main reasons:-
• Firstly, glutamine administration was not considered necessary because glutamine 
was originally classified as a non-essential or nutritionally dispensable amino acid. 
This classification implied glutamine could be synthesised in adequate quantities from 
other amino acids and precursors. 
• Secondly, there were a number of pharmaceutical reasons for not including 
glutamine in commercially available TPN. Free glutamine is considered to be unstable 
in aqueous solution at room temperature and is also heat labile, undergoing ring 
condensation to form pyroglutamate and ammonia. In addition the low solubility of 
free glutamine (36 g rl at 20°C) considerably increased the volume of fluid to be 
infused into the patients (Furst et al 1989). 
Much research has been directed to the use of more chemically stable sources of 
glutamine such as dipeptides and analogues of glutamine as supplements for TPN. 
Dipetides such as L-alanyl-L-glutamine and glycyl-L-glutamine are stable when heat 
sterilised, and are well tolerated and are rapidly converted to glutamine when 
administered intravenously to heathy adults (Albers et a11988, Furst et a11989, Hubl 
et al 1989). These dipetides also have the advantage of increased solubility for 
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exan1ple the solubility ofL-alanyl-L-glutamine is 568 g rl in H20 at 20°C (Furst et al 
1989). Ornithine-a-ketoglutarate and a-ketoglutarate have also been used as 
precursors of glutan1ine to supplement TPN (Wernerman et al 1989, 1990). a-
Ketoglutarate can be transaminated readily to glutamate which can then be amidated by 
glutan1inase synthetase. 
Ho,vever. Hardy and co-workers have recently shown that the widely reported that 
instability of free glutamine during storage in aqueous solutions is a misconception, 
and glutan1ine is stable if the correct pharmaceutical and sterilisation techniques are 
used (Hardy et al 1993). Aseptically prepared and filter-sterilised glutamine solutions 
can be stored in oxygen impermeable bags for up to 30 days at 4 °C (Hardy et aI1992). 
Glutamine losses were less than 0.05 % per day, pyroglutamate formation was less than 
0.02 % per day and ammonia formation less than 0.01 mmol rl dail. Stability of the 
glutamine 'vas not adversely affected by incorporation into TPN; the glutamine content 
remained at 98.2 % of the original level after 30 days. 
Concern also existed about glutamine administration because of its close biochemical 
relationship to ammonia. Ziegler and colleagues investigated the clinical safety, 
pharmacokinetics and metabolic effects of L-glutamine administration in healthy adults 
(Ziegler et al 1990a). These studies showed administration of glutamine both orally 
and intravenously as a short-term infusion (4 hours) was well tolerated without clinical 
or biochemical side effects. The safety of glutamine as a component of parenteral 
nutrition (5 days) in normal subjects and patients undergoing bone marrow 
transplantation (3-5 weeks) has also been confirmed (Ziegler et aI1990a). The 
glutamine solutions were cold sterilised by membrane filtration and stored up to 
10 days at 4°C. Solution stability studies demonstrated no appreciable ammonia 
generation during storage. 
In vivo measurement of glutamine kinetics 
Blood and tissue concentrations of metabolites are carefully controlled by various 
regulatory processes and many vary little in healthy adults. Observations based on 
these apparently static metabolite levels provide no insight into the rates of endogenous 
production or disappearance via metabolism. Much of the information on glutamine 
metabolism has been obtained from in vitro and in vivo animal experiments. In vivo 
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nleasurement ofhunlan glutamine metabolism has relied on two important techniques: 
1) organ balance techniques and 2) whole body tracer dilution methods. 
Organ balance techniques 
Using the organ balance technique the net balance (net uptake or release) of glutamine 
across a specific organ is calculated from the arterio-venous substrate concentration 
differences and blood flow rates. The first published data on human glutamine 
metabolism used this technique and showed glutamine to be released from muscle and 
taken up by the splanchnic bed and kidney (Marliss et a11971, Felig et a11973, and 
O\yen and Robinson 1963). Major drawbacks of this technique are that it requires 
difficult catheterisation which has limited its use in humans. It also measures the net 
effects of glutamine handling by the organ, and does not provide information on the 
rates of glutamine uptake or release. 
JJ7,ole body tracer dilution methods 
Quantitative information about the turnover of a metabolite in vivo can be obtained by 
labelling one or more of its constituent atoms with an isotope of that atom to form a 
tracer. The tracer can be injected or infused intravenously, or ingested orally, and its 
metabolism can be followed by monitoring the levels in blood, urine or breath samples 
at timed intervals (Umpleby and S6nksen 1987). The tracer and the non-labelled 
metabolite (tracee) are assumed to be indistinguishable to biological systems. 
The whole body appearance rate (Ra) of an individual amino acid can be determined in 
vivo by measuring the systemic dilution of a continuously infused tracer. In this basic 
model the assumption is made that the Ra of the amino acid and the infusion of the 
tracer occur into, and sampling is from, a single, homogeneous, instantly mixing pool 
(Wolfe 1992). The tracer is infused at a constant rate over a period of several hours 
until an isotopic equilibrium or a "steady state" level is achieved in plasma. 
Measurement of the tracer enrichment in plasma samples yields a rising curve which 
approaches a plateau at steady state. During this plateau the rate of appearance of the 
tracee and tracer into the plasma pool are equal to their rate of removal from the 
system, so the isotopic enrichment remains "steady". Only small numbers of samples 
need to be taken during the isotopic plateau. The infusion time can be shortened by the 
inj ection of a priming dose of tracer immediately before the beginning of the infusion. 
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The tracer is usually administered in an antecubital vein and blood samples are taken 
from a contra-lateral peripheral vein. Subjects are normally studied following an 
overnight fast to ensure that the measurements are made in a steady state (Umpleby and 
S6nksen 1987). It is generally assumed that there is no recycling of the tracer during 
the time course of the study. A drawback of this method is that it provides little 
information of contribution of specific organs to the whole body changes. 
The use of stable isotopes as kinetic tracers in vivo predates the use of radioisotope 
tracers by almost 20 years (Wolfe 1992). However, because of the limited supplies of 
stable isotope tracers at the time and their relatively difficult methods of analysis, most 
kinetic studies used radioisotope labelled tracers. Increasing awareness of the health 
hazards of radioisotopes severely limited the total dose that could be administered, thus 
restricting studies to short periods and precluding repeat studies. Furthermore 
radioisotope tracers cannot be used in children or women of childbearing age. 
Radioisotope tracer studies of glutamine metabolism were difficult to interpret. 
l-+C was considered an inappropriate label, because glutamine, glutamate and 
a-ketoglutarate all have the same five carbon skeleton and the metabolism of these 
three compounds could not be confidently separated (Golden et aI1982). 
In the past two decades stable isotopes have been increasingly used as tracers in 
metabolic research studies in man. Advances in electronic instrumentation and 
computer technology led to the development of simple to operate, relatively 
inexpensive, mass spectrometers for the measurement of isotopic enrichment in 
biological samples. Also stable isotope tracer supplies have generally become cheaper 
and more widely available. 
The majority of elements exist in a stable form, the term stable isotope is used to 
describe those that occur at low natural abundance e.g. 13C 1.1 %. These can be used 
as tracers when incorporated into metabolite molecules at high enrichments. The use 
of stable isotopes overcomes the ethical and safety problems of radioisotope tracers 
and has several other advantages. These advantages include the ability to measure 
isotope enrichment and substrate concentration in the same sample, the ability to label 
the metabolite with multiple tracers and the ability to infuse several labelled 
metabolites simultaneously in the same subject. In addition the half-life of 
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l3N (9.9 minutes) and 150 (2.07 minutes), the radioisotope equivalents to 15N or 170 
and 180 , were considered to be too short to be used in metabolic studies of several 
hours duration (Young and Ajami 1999). However these radioisotopes are now being 
en1ployed in studies using positron emission tomography. A minor disadvantage is 
that stable isotopes are naturally occurring so tracer enrichments must be measured 
above this basal or background level. The infusion of a stable isotope tracer cannot 
nom1ally be considered to be massless and the calcuated Ra has to be corrected for the 
tracer infusion. 
1\ lass spectrometry 
When stable isotope tracers are used in metabolic studies the steady state enrichment of 
the metabolite is most often determined by a mass spectrometer. There are many types 
of mass spectrometers that have widely varying capabilities and applications but they 
all measure the abundance of ionised particles at specified masses. Because of the 
versatility and small sample size requirements (/-11 of plasma) the isotopic enrichment 
in plasma samples is usually measured by combined gas chromatography mass 
spectrometry (GCMS) with a quadrupole mass analyser. The GC inlet allows 
separation of the metabolite of interest from other metabolites in a complex biological 
sample. In the MS the molecules are ionised which allows them to be controlled by 
voltages and electrical fields. The MS is generally operated in the selected ion 
monitoring (SIM) mode in which the analyser acquires data from a few specific 
masses, increasing the accuracy. GCMS analysis requires the formation of volatile 
derivatives of the metabolite. The derivatising agents often contain isotopes which 
also contribute to the background ratio for example the popular tert-butyldimethylsilyl 
derivatives contain Si and C which both have relatively high proportions of stable 
isotopes (l3C 1.1 %, 29Si 4.7 %, 30Si 3.1 %). 
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AIMS 
The ainls of the present study were:-
• To establish a protocol using L_[2_15N] glutamine as a tracer to measure whole body 
glutamine turnover. 
• To measure whole body glutamine turnover in critically ill patients in the leU at St 
Thomas' Hospital. 
• To investigate the effects of glutamine supplementation on glutamine metabolism in 
critically ill patients receiving parentetal nutrition. 
• To investigate the additional effects of GH and lGF-l treatment on glutamine 




Subjects and ethical consent 
Normal subjects (11=12) were recruited from staff in the Department of Diabetes, 
Endocrinology and Internal Medicine and their relatives. Critically ill subjects were 
recnlited from newly admitted patients in the ICU (Mead Ward) at St Thomas' 
Hospital in whon1 the clinical decision had been made to use TPN. Exclusion criteria 
included diabetes, malignancy, renal failure, myopathy, and liver disease. Nineteen 
severely ill patients were initially studied, two patients died before the completion of 
the second study, data is only presented from the seventeen patients who survived to 
complete both studies. However as indicated in Table 7.1, one patient died later in the 
ICU. 
All normal subjects provided informed written consent and informed written consent 
\vas obtained from relatives of the ICU patients. The studies were approved by the 
West Lambeth Health Authority Ethics Committee. 
The metabolic tracer studies in the healthy subjects and patients required the assistance 
of a clinically qualified colleague, Paul Carroll. The protocol included the use of 
L-[ 1-13C] leucine as a tracer to permit quantitation of whole body protein turnover. 
The protein turnover data will form part of Paul Carroll's MD thesis and therefore is 
not discussed in the present thesis. However, the leucine appearance rate (a measure of 
whole body protein breakdown) has been used to estimate the proportion of the 
glutamine appearance rate (RagIn) derived from protein breakdown and de novo 
synthesis (Chapter 3). 
Preparation of tracer solutions 
L_[2_15N] glutamine (99 %) and L-[I-13C] leucine (99 %) were purchased from 
MassTrace (Somerville, MA, USA). Sterile solutions of the tracers were prepared by 
the Pharmacy Department at St Thomas' Hospital. Accurately weighed amounts of 
glutamine or leucine were dissolved in known amounts of sterile, pyrogen free 0.9 % 
saline to give 25 mg mrl and 15 mg mrl solutions respectively. These solutions were 
filtered (0.22 /-Lm) into sterile vials which were then aseptically sealed; a random 
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salnple of vials underwent sterility and pyrogen testing. The glutamine vials were 
stored at -20°C and the leucine vials at room temperature. 
On the day of the study the stock tracer solutions were diluted with 0.9 % saline in 
50 ml sterile syringes to give infusion rates of2.5 mg kg-I hr-I for glutamine and 
1 n1g kg-1 hr- I for leucine. 
Study Protocol 
lYorlllal subjects 
The nonnal subjects were admitted to the research area of the Diabetes and Endocrine 
Day Centre follo\ying an overnight fast. Height and weight were recorded and body 
composition was measured by bioelectrical impedance (Tanita, Tokyo, Japan) 
(Luskaski et al 1986). Subjects were studied in a semi-recumbent position. A cannula 
\yas inserted into an antecubital vein for the isotope infusion and another cannula was 
placed in a superficial vein of the contra-lateral hand for blood sampling. "Aterialised" 
venous blood was obtained by placing the hand in a heated box (air temperature 60°C) 
during the sampling period (Abumrad et al 1981). Following baseline sampling a 
-+ hour continuous infusion of [2_I5N] glutamine 2.5 mg kg-I hr-I and a primed 
(l mg kg-I) constant infusion of [1-l3C] leucine 1 mg kg-I hr- I were started using a 
Harvard pump (Harvard Apparatus, MA, USA). Blood samples were taken at 210, 
215, 220, 225, 230 and 240 minutes for steady state measurement of glutamine and 
a-ketoisocaproic acid (KIC) enrichment and glutamine concentration. 
Blood samples were also taken at baseline and steady state for the measurement of 
substrate and honnone levels (glucose, insulin, C-peptide, GH, IGF-I, IGFBP-l and 3, 
cortisol, glucagon, thyroid honnones, amino acids). 
To establish the optimal infusion protocol, extra blood samples were taken at 30, 60, 
90, 120, 150, 180, 250, 260, 270, 280, 310 and 330 minutes for the measurement of 
glutamine enrichment in five of the nonnal subjects. 
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Critical(l' ill patients 
All the patients were fasted for at least 12 hours before the start of the first study 
(Study 1). An identical infusion protocol to the nonnal subjects was used in the 
critically ill patients however, the blood samples were taken from in-dwelling arterial 
lines. At the end of the baseline study the nutritional + honnonal treatment was 
comn1enced. Following 72 hours of treatment a second turnover study (Study 2) was 
perfolmed using the same tracers and infusion rates as the initial study. In this second 
study the patients were not fasted as nutritional support was continued throughout the 
protocol (Figure :2.1). The patients were sedated and mechanically ventilated (Servo 
900; Sien1ens, Berlin, Gennany) throughout both studies. 
Sanlple collection and storage 
Blood samples \vere taken with sterile syringes and added to vacutainers containing 
various anticoagulants. Blood for glutamine, KIC and amino acid samples were 
collected in lithium heparin tubes. Glucose samples were collected in fluoride oxalate 
tubes and C-peptide samples in ethylenediaminetetra-acetate tubes with added 
Trasylol. Plasma samples were mixed and kept on ice prior to centrifugation at 
1500 g, 4 °C for 10 minutes. Blood samples for the measurement of insulin, cortisol, 
thyroid honnones, GH, IGF-I, IGFBP-1 and 3 were all collected in plain tubes. Serum 
samples were left at room temperature for 30 minutes prior to centrifugation at 
1500 g, 4 °C for 10 minutes. Plasma and serum samples were transferred to small 
plastic tubes for storage. 
For glutamine analysis, two separate 0.5 ml plasma aliquots were mixed with 
1 00 ~l internal standard (laO nmol L-[U-13Cs] glutamine, Bioquote Ltd., UK) before 
storage. Plasma for amino acid analysis was deproteinised with an equal volume of 
10 % sulphosalicylic acid containing the internal standard norleucine (loa nm mrl). 
The samples were incubated on ice for 30 minutes before re-centrifugation after which 
the supernatant was transferred to small plastic tubes for storage. All samples were 
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Figure 2.1. Study protocol for critically ill patients. 
l\leasurement of lean body mass 
The body composition of the healthy subjects was measured using the technique of 
bioelectrical in1pedance analysis (Tanita, Tokyo, Japan) (Luskaski et aI1986). This 
n1ethod depends on the principal that fat is a very poor conductor of electricity whereas 
the fat free mass or lean body mass (LBM) is a good conductor as it contains virtually 
all the water and conducting electrolytes in the body. Prediction equations which take 
into account body weight height and gender, are used to convert the measured 
impedance into an estin1ate of total body water. The hydration of lean tissue is 
assumed to be constant allowing the calculation of LBM. Fat mass is then calculated 
as the difference between total body weight and LBM. 
A.PACHE II and TISS scores 
AP ACHE II (Acute Physiology and Chronic Health Evaluation) and TrSS (Therapeutic 
Intervention Scoring System) are the systems for scoring the severity of illness in lCU 
patients \yhich are currently used at St Thomas' Hospital. 
The APACHE II score consists of a total of three scores (Knaus et al 1985):-
1) twelve routine physiological measurements 
2) age 
3) previous health status 
The physiological measurements consist of variables such as core temperature, blood 
pressure, heart rate, respiratory rate and specific blood tests which include markers of 
the current health status (e.g. white blood cell count, arterial pH, serum sodium and 
potassium levels). The worst score for each of the physiological measurements (either 
increase or decrease from a standard reference range) over a 24 hour period is 
recorded. There are precise criteria for defining the presence of a chronic illness for 
example renal insufficiency is present if the patient is receiving long term 
haemodialysis or peritoneal dialysis. The chronic illness is also scored depending on 
whether the patient has undergone planned elective surgery or is a non-surgical or 
emergency surgical patient. The APACHE II score is used to predict outcome and 
define the lCU case mix. 
The TrSS score is based on a series of eighty statements which assess the level of 
therapeutic intervention required (Cullen et al 1974). For example these include the 
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use of central lines, the need for organ support such as dialysis, nutritional support 
(enteral or parenteral), and the level of nursing required (e.g. 1: 1). The statements are 
scored a value of 1-4 depending on the level of managed input they require. The TrSS 




l\lass spectrometry analysis 
Measurement of glutamine enrichment and concentration 
Background 
In 1982 Golden and co-workers reported the first study of whole body glutamine 
kinetics in hun1ans using a stable isotope tracer. The method involved the enzymatic 
hydrolysis of amide nitrogen of glutamine to ammonia, oxidation of the resulting 
ammonia to N2 gas and measurement of lSN enrichment by dual inlet, isotope ratio 
mass spectron1etry. This procedure was long, tedious and the volume of blood 
required (20 ml per sample) made it impractical for clinical studies. 
Several investigators have reported methods for measuring lSN glutamine enrichments 
by GeMS (Yudkoffet a11982, Nissim et a11984, Darmaun et a11985, Anderson et al 
1987). GCMS analysis should allow amino acid separation and isotopic enrichment to 
be measured in a single step. However, GCMS requires the derivatisation of amino 
acids before analysis and unfortunately most derivatisation reactions deamidate 
glutamine to glutamate so plasma glutamine and glutamate need to be separated prior 
to derivatisation (Darmaun et al 1985). 
In the present study the tertiary-butyldimethylsilyl derivatives (TBDMS) were chosen 
for quantification of and isotopic enrichment measurements of glutamine by GCMS 
(Chaves Das Neves and Vasconcelos 1987, Anderson et aI1987). TBDMS derivatives 
are popular in GCMS, the electron impact (El) mass spectra are normally dominated by 
large [M-57]+ ions produced by loss of a tertiary butyl group. These ions contain the 
entire skeleton of the original compound and are very suitable for quantitative 
measurements by selected ion monitoring when using stable isotope tracers (Schwenk 
et al 1984). The added advantage of this derivative is that it leaves the glutamine 
molecule intact and should allow the measurement of lSN enrichment of glutamine by 
GCMS without the need for separation from glutamate prior to derivatisation. 
Glutamine concentration was determined by reverse isotope dilution using L-[U-13CS] 
glutamine (98 %, Bioquote Ltd., Yorks., UK) as the internal standard (Darmaun et al 
1985, Anderson et aI1987). 
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11 [aterials 
All chemicals and reagents were purchased from Sigma-Aldrich Ltd. (Dorset, UK) or 
BDH-Merck Ltd. (Leics.,UK) unless stated otherwise. Helium (CP grade) and 
N~ (oxygen free) gases were purchased from BOC Gases (Lanes., UK) 
Illstrzllllentation 
All GCMS analysis was performed on a Hewlett Packard 5971A Mass Selective 
Detector (Hewlett-Packard, Berkshire, UK). The system was equipped with a 
5890 Series II gas chromatograph fitted with a 25 m, 0.25 mm i.d., RtX-l capillary 
colun1n (crossbonded dimethyl polysiloxane; Thames Chromatography, Berks., UK) 
using helium as the carrier gas (8 psi, 1 ml min-I). The transfer line to the mass 
spectrometer \yas held at 280°C and the column was directly coupled to the ion source 
of the mass spectrometer. Samples (1J.ll) were injected by hand or a Hewlett Packard 
7673 injector in the splitless mode. The injector temperature was held at 250°C. The 
column was held at 100 °c for 0.75 minutes, then programmed at 25°C min-I to 300°C 
and held for 4 minutes at 300 DC. The mass spectrometer was operated in the positive 
ion E1 mode (70eV). The E1 mass spectra were obtained by scanning at 1.0 scan S-I 
from mlz 50 to 650. 
Derivatisation of standards 
Stock solutions (1 mg mrI) of glutamine, [2_ISNJ glutamine, [U-I3CsJ glutamine and 
glutamate were prepared in distilled water, ali quoted and stored frozen at -70°C. 
Working solutions in the range 10- 100 J.lg mrI were prepared from these. 
As a first stage in the validation of the glutamine assay, TBDMS derivatives of 
glutamine ( and glutamate) standard solutions were prepared and the E1 mass spectra 
recorded on the GCMS. This allowed GC conditions to be established that separated 
glutamine from glutamate and confirmation of the ions to monitor for quantification 
and isotopic enrichment measurements. 
Aliquots of the glutamine and glutamate standards were derivatised with 100 J.lI 
N_methyl-N-(tert-butyldimethylsilyl)-tritluroacetamide (MTBSTFA) and 
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100 ~ll acetonitrile at 120°C for 2 hours and scanned on the above GCMS system. The 
structure of the TBDMS derivative of glutamine is shown in Figure 3.1, the derivatised 
glutan1ine contains three TBDMS groups attached to the carboxyl, amino and amide 
groups. 
The tri-TBDMS glutamine was chromatographically separated from the tri-TBDMS 
glutamate, the total ion chromatograms (TIC) showed a peak at 9.5 minutes for 
glutamate and 10.2 minutes for glutamine (Figure 3.2). There were no corresponding 
peaks in the derivatisation blanks (Figure 3.3). The electron impact mass spectra of 
tri-TBDMS glutan1ine and tri-TBDMS glutamate are shown in Figure 3.4 and 
Figure 3.5 respectively. The glutamine mass spectra showed a weak molecular ion 
peak at mlz .+88 and a weak [M-15t ion at mlz 473. The glutamate mass spectra also 
showed a molecular ion peak at mlz 489 and a weak [M-15t ion at mlz 474. Both 
spectra showed the [M-159t ions, corresponding to [M-C02TBDMS], at mlz 329 for 
glutamine and mlz 330 for glutamate. Except for the low mass ion observed at mlz 73 
the most abundant ion in each spectrum was the [M- butylt ion at mlz 431 for 
glutamine, and at mlz 432 for glutamate. Figure 3.6 and Figure 3.7 show the EI mass 
spectra of [2_1SN] glutamine and [V_l3Cs ] glutamine. The 431 ion was shifted to 
(i) 432 in the spectrum of [2_1SN] glutamine and (ii) 436 in the spectrum of [V_l3Cs] 
glutamine. 
The [M-butyl]+ fragment ion was chosen for subsequent selected ion monitoring for the 
quantification and isotopic enrichment measurements. Ions were monitored at mlz 
431, 432, and 436 for glutamine, [2_1SN] glutamine and [V_l3Cs] glutamine 
respectively, using a dwell time of 20 msec giving 8.55 cycles per sec. 
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Figure 3.7. Electron impact mass spectra at 70 eV of the tri-TBDMS derivative of [U-13CsJ glutamine. 
Calculatioll of isotopic ellrichlllent 
The areas of the peaks at m/z 432 (M+ 1) and 431(M) corresponding to the labelled and 
unlabelled glutmnine were used to calculate the enrichment (of labelled glutamine) 
expressed as atom percent excess (APE %) 
APE (%) Rs-Rb * 100 
(Rs-Rb)+ 1 
where Rs and Rb are the area ratios of (M+ 1 )/(M) for the enriched and baseline 
san1ples, respectively. 
Calibratioll curves 
To confirm a linear response for the glutamine enrichment measurements, standards 
containing 0.3 ~mol glutamine enriched with C5N] glutamine in the range 0-10 APE 
\vere prepared and analysed on the GeMS. The observed enrichments were calculated 
from the 15N glutamine/glutamine area ratios and plotted against the theoretical 
enrichments to obtain an enrichment calibration curve. A typical calibration curve is 
sho\vn in Figure 3.8. A linear relationship (r2=0.9995) was observed with a slope close 
to unity (1.10). The slope of the curve was used to monitor day to day instrumental 
drift and tuning. 
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Figure 3.8. Glutamine enrichment curves (n=5), observed vs. theoretical 15N 
enrichment (APE). 
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Glutan1ine concentrations were measured by reverse isotope dilution using [U- 13C5J 
glutamine as the internal standard. Standards containing 0.1 /--lmol internal standard 
and concentrations of unlabelled glutamine in the range 0-0.5 /--lmol were analysed. 
To confirn1 a linear response for concentration measurements graphs of the theoretical 
against the observed glutamine/internal standard ratio were plotted (Figure 3.9). 
A correlation of 0.999 was achieved with a slope close to unity (1.07). Graphs of the 
observed ratio (glutamine/internal standard) against the concentration were then plotted 
and used to calculate the concentrations in the samples. Figure 3.10 shows the average 
of fiye concentration curves. The plasma glutamine concentrations were also recorded 
in plasma amino acid profiles measured on an automated amino acid analyser 
(Amersham Pharmacia Biotech, Bucks., UK). We were able to compare the glutamine 
concentrations measured on the GCMS with those measured using a different 
technique (Figure 3.11). A correlation of 0.8 was achieved with a slope close to 
unity (0.91) across a wide range of glutamine concentrations (200-800 /-tmol rl). 
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Figure 3.11. Glutamine concentration (f.lmol rl) measured by GeMS and the amino 
acid analyser. 
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Preparation of plasnla samples 
As the glutanline and glutamate standards were chromatographically separated on the 
GC there was no need for an additional separation step in the sample preparation 
procedure. A rapid cation-exchange chromatography step was chosen to isolate the 
anlino acids from plasma samples. The final protocol (Table 3.1) was adapted from 
the methods of Wolfe (1992) and Nissim et al (1984). Enrichment quality control 
samples were made by spiking pooled plasma samples with [2_1SN] glutamine to give 
baseline and enriched (3 APE) samples. The quality controls were aliquoted and stored 
at -70°C until used for assay development or with each batch of samples. 
Cation exchange columns were prepared, 1.5 inches of an aqueous slurry of 
AG 50W -X8 resin were placed in plastic chromatography columns (Bioconnections, 
Leeds, UK). The columns were pre-washed with 1 M HCL to ensure that all the resin 
\"as in the H+ form. 1 M HCL was added to the columns until pH paper indicated the 
eluate was pH 1 (~lml). The columns were washed with H20 until the eluate was 
neutral and were then capped to keep the resin moist until the samples were ready. 
The internal standard (100nmol [V_l3Cs] glutamine) was added to 500 ~l plasma 
aliquots during the study, before the samples were frozen. On the day of the assay the 
plasma samples were thawed and acidified with 500 ~l, 50 % e/v) glacial acetic acid. 
The acidified plasma was applied to the cation exchange column, the sample tube was 
washed with 1 ml H20 and the wash transferred to the columns. The columns were 
washed with a further 5 ml H20. The amino acids were eluted by washing the column 
with 3M NH40H (4 ml), followed by 1 ml H20. The samples were collected once the 
column eluate had turned basic (as indicated by litmus paper), frozen and lyophilised 
overnight. 
The samples were dried azeotropically with dichloromethane prior to derivatisation to 
remove any traces of water, as TBDMS derivatives are hydrolytic ally unstable. 
The samples were then dissolved in 1 00 ~l acetonitrile and derivatised with 1 00 ~l 
MTBSTF A at 120°C for 2 hours. After cooling, the excess reagent was removed 
under N2 at room temperature. The residue was dissolved in 600-800 ~l decane 
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Table 3.1. Preparation ofTBDMS derivative of plasma glutamine for GCMS analysis. 
COlUllI1l preparation 
1. Prepare slurry of cation resin (AG-50W-X, H+, 200-400 mesh) in H20 
2. Add resin to plastic chromatography columns (~1.5 inches of settled resin). 
3. Add 1 M HCL (~1 ml) until pH paper indicates eluate is pH 1. 
-L Wash column with H20 (~1 0 ml) until pH paper indicates eluate is neutral. 
5. Cap columns until samples are ready. 
Procedure 
1. Add 500 J.lI, cold 50 % acetic acid to thawed plasma sample and vortex. 
2. Load sample onto columns. Allow all fluid above resin to elute before 
loading sample, but do not allow columns to run dry. 
3. Wash sample tube with 1 ml H20 and transfer to column. 
-+. Wash columns with 5 ml H20. 
5. Elute glutamine with 4 mI3MNH40H, followed by 1 ml H20. 
6. Freeze samples and lyophilize. 
Derivatisation 
1. Add 500 J.lI dichloromethane, mix and dry sample under N2• 
2. Add 100 J.lI acetonitrile, 100 J.lI MTBSTF A, cap and mix. 
3. Heat in block at 120°C for 2 hours. 
4. Remove excess reagents under N2• 
5. Add 600-800 J.lI decane, cap and mix. 
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containing 5 % MTBSTF A for GCMS analysis. Typical ion chromatograms of 
mlz 431, 432 and 436 from a plasma sample are shown in Figure 3.12. 
To check for possible sample contamination from this sample preparation procedure 
saline blanks were taken through the above protocol. There were no peaks in these 
samples corresponding with the glutamine peak from plasma samples. In addition the 
area ratio measurement for unenriched plasma samples (0.376 ± 0.003, n=10) was 
close to the theoretical ratio (0.3748) calculated by mass spectrometer software. 
Glutamine recovery from cation exchange columns was checked with eH] glutamine 
(250 j..tCi 250 J..lrl; Amersham Pharmacia Biotech, Bucks., UK). Ten plasma samples 
\"ere spiked \vith tracer and taken through the above protocol. The column elutate was 
collected, frozen and lyophilised. The lyophilised samples were reconstituted in 
1 ml H20, mixed with 15 mls Picofluor and counted on a liquid scintillation ~ counter 
(Rackbeta 1219, LKBlWallac, Notts., UK). The mean value for the recovery of counts 
\vas 92 + 0.4 % (n=10). 
Using the protocol shown in Table 3.1 all the samples from each subject and the 
plasma quality controls were extracted in a single assay «1 hour). A set of enrichment 
and concentration calibration curves were also prepared and lyophilised with the 
plasma samples. Each sample series (samples, quality controls and standards) was 
derivatised the following day and run as a single batch on the GCMS. The standards 
and quality controls were re-injected at the end of each sample run to check for 
instrument drift. 
The intra-assay coefficient of variation (CV) was calculated from 10 replicates of the 
baseline quality control sample measured within one assay. The intra-assay CVs were 
0.34 % for enrichment and 2 % for concentration (700 J..lmol rl). The inter-assay CV 
was determined for the baseline and enriched quality control samples measured in 
14 separate assays over a 1 year period. The inter-assay CV s were 3 % for enrichment, 
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Figure 3.12. Typical selected ion chromatograms at m/z 431, 432, and 436 of the tri-TBDMS derivative of glutamine from a plasma sample 
representing unenriched glutamine, enriched glutamine and the internal standard. 
~ leasurement of KIC enrichment. 
Plasn1a KIC enrichment was used as a measure of intracellular leucine enrichment for 
the calculation of leucine appearance rate (see page 67) (Matthews et al 1982). 
The O-tertiary-butyldimethylsilyl quinoxalinol derivative of KIC was prepared by a 
modification of the method described by Ford et al 1985. The proteins were 
precipitated from a 1 00 ~tl plasma aliquot with 1 ml ethyl alcohol. After centrifugation 
the supernatant was evaporated to dryness under N2 at 50°C. The residue was 
dissolved in water (200~1) and reacted with 1 00 ~l freshly prepared 
orthophenylenediamine solution (2 % in 4M HCL) at 90°C for 1 hour. The solution 
\yas extracted t\yice with 1 ml ethyl acetate and the combined extracts were dried over 
anhydrous sodium sulphate. The solvent was evaporated at room temperature under 
N~, the residue \yas dissolved in 1 00 ~l acetonitrile and reacted with 1 00 ~l MTBSTF A 
at 120°C for.+5 minutes. The quinoxalinol-TBDMS derivatives of the keto acids were 
kept in the final reaction mixture until just before analysis when the excess reagent was 
removed under N2 at room temperature, and the residue dissolved in 100 ~l decane 
containing 5 % MTBSTFA. 
The derivatised keto acids were analysed on the same GCMS system described for the 
glutamine assay. The column temperature was held at 120°C for 1 minute then 
programmed at 20°C min-1 to 300°C and held at 300 °c for 1 minute. Selected ions at 
mlz 259 and 260 were monitored for KIC and [l-l3C] KIC respectively using a dwell 
time of 25 msec, giving 10.64 cycles per sec. Typical ion chromatographs of 
mlz 259 and 260 from a plasma sample are shown in Figure 3.13. KIC enrichment was 
calculated using the APE equation previously described for glutamine (page 53). 
Stock solutions (lmg mrl) ofKIC and [1_13C] KIC (98.5 %; UnivarPlc., Croydon, 
UK) were prepared and aliquots were stored at -20°C. On the day of the assay an 
enrichment calibration curve was prepared (range 0-10 APE). Ethyl alcohol (1 ml) was 
added to the standards which were subsequently treated the same as the plasma 
samples. A typical calibration curve for [l-l3C] KIC enrichment is shown in Figure 
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Figure 3.13. Typical selected ion chromatograms at m/z 259 and 260 of the quinoxalinol-TBDMS derivative ofKIC from a plasma sample 
representing unenriched and enriched KIC (peak at 8.42 minutes). 
0-10 APE with a slope almost equal to unity (0.9977). The enrichment standard curve 
was run at the beginning and end of each sample run to check for instrumental drift 
across the sample run. Enrichment quality controls were prepared by spiking plasma 
with [I-l3C] KIC to give baseline, medium (----3 APE) and high (----6.5 APE) enriched 
samples. The inter-assay coefficient of variations were 1.86, 1.15 and 1.21 % 
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Plasma glucose concentrations were measured on a Clandon model 23AM Glucose 
analyser (Yellow Springs Instruments, Ramps, UK). This instrument utilises glucose 
oxidase, immobilised between two membranes, coupled with a hydrogen peroxide 
sensor. A constant volume of standard or plasma (25 J.ll) is introduced a reaction 
chamber using a syringe-pipette. The glucose diffuses through a membrane into 
contact with the enzyme glucose oxidase which catalyses the reaction: 
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D-glucose + O2 ~ gluconic acid + H20 2 
The H20 2 generated diffuses through a second membrane which excludes glucose, to a 
platinum anode and a constant proportion is oxidised. The current created is directly 
proportional the glucose concentration in the sample: 
H20 2 ~ 2H+ + O2 + 2e-
A silver cathode at which O2 is reduced to water completes the circuit: 
4H+ + O2 ~ H20 + 2e-
At the start of each analysis the instrument was calibrated using 0,5.6, 10, and 
25 mmol rl glucose standard solutions. During analysis the calibration was checked 
\yith the 10 mmol rl standard every 10 samples. If the results differed by more than 
0.2 mmol the calibration was repeated. 
Amino acids 
Plasma amino acids concentrations were measured using an Alpha plus series II 
automated amino acid analyser (Amersham Pharmacia Biotech, Bucks., UK) which 
uses cation-exchange chromatography and post-column derivatisation with ninhydrin 
to separate and detect the amino acids. 
The stored amino acid samples were thawed, the pH adjusted to 2.2 if necessary and 
filtered (0.2 11m). The amino acids are separated on a sulphonated polystyrene resin 
(Ultropac 8) using a system of 5 lithium based buffers of varying pH and ionic 
strength. Controlling the column temperature enhances the chromatography. The 
post-column ninhydrin reaction proceeds in the reaction coil at 135°C where the amino 
acids react to form chromophores with maximum absorption at 570 or 440 nm. The 
light absorption is measured at these two wavelengths in the photometer unit which is 
connected to an integrator (Spectra-physics SP4270: Thermo Separation Products, 
Staffs, UK). All buffers and reagents for the amino acid analyser were purchased from 
Amersham Pharmacia Biotech. 
The amino acid is identified by its retention time relative to a standard and the area 
under the peak indicates concentration when compared to the internal standard (nor-
leucine). An amino acid standard solution, with added glutamine and ornithine, was 
prepared at 0.1 I1mol rl (A-2908; Sigma-Aldrich, Dorset, UK) and standards were run 
every 6-8 samples. To correct for differences in the "colour yields" for the reactions of 
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the different amino acids with ninhydrin, a colour index for each amino acid is 
calculated from the standard as follows: 
Colour Index (CI) area nor-leucine peak 
area amino acid peak 
The average CI was calculated for a set of samples between two standards, the amino 
acid concentrations were then calculated as follows: 
[an1ino acid] - area nor-leucine peak * CI * dilution factors 
(~n10l rl) area amino acid peak 
Infusate glutamine and leucine concentrations were also measured on the amino acid 
analyser. An aliquot of the infusate was diluted (x 250) with lithium citrate buffer 
(PH 2.2) and then mixed with an equal volume of 10 % sulphosalicylic acid containing 
the internal standard nor-leucine (100 nm mrl). The pH was adjusted to 2.2 and the 
sample filtered through 0.2 ~m syringe filters before transferring the sample to the 
analyser. Inter and intra assay CVs for amino acid concentrations are shown in 
Table 3.2. 
Hormone assays 
Serum insulin concentrations were measured in duplicate, using an in-house double 
antibody radioimmunoassay described by S6nksen (1976). Briefly, 50 /-11 aliquots of 
serum were incubated overnight, at room temperature with the first antibody, guinea 
pig anti-insulin serum (GP8) and the tracer, 1251_A 14-tyr-monoiodo-insulin (Amersham 
Pharmacia Biotech, Bucks., UK). 100 /-11 of the second antibody, a solid phase 
sheep-anti-guinea pig serum antibody (Pharmacia Decanting Suspension 1) was added 
and the samples were incubated for a further 2 hours. 1 ml of water was added to the 
sample immediately prior to centrifugation (1500 g, 4°C, 45 minutes), the supernatant 
immediately decanted and the precipitate counted on the gamma counter 
(Gammamaster 1277, LKB/Wallac). The RiaCalc programme (Amersham Pharmacia 
Biotech) was used to determine the sample concentrations from the standard curve. 
The standard curve range was 0-1000 mU rl and the assay gave a normal fasting range 
of < 12 mU rl. The intra and inter assay CVs were 6 and 9 % respectively. 
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Table 3.2. Intra and inter assay CVs for plasma amino acid concentrations 

























































C-peptide concentrations were measured using a similar in-house double antibody 
radioimmunoassay. The first antibody, guinea pig anti-C-peptide serum, was 
purchased from Biogenesis Ltd. (Poole, UK). The tracer 1251_ Tryosyl-C-peptide was 
donated by Dr A. Lindsey (Hammersmith Hospital). The second antibody was 
Phannacia Decanting Suspension as above. The standard curve range was 
0-3.3 nmol rl and the assay gave a normal fasting range of 0.25-0.33 nmol rl 
(20-30 years). The intra and inter CVs were 9 and 11 % respectively. 
Glucagon levels were also determined using similar methodology, but using a 
comn1ercially available radioimmunoassay kit (Biogenesis Ltd, Poole, UK). All the 
samples from this study were assayed using a single kit. The ICU patients' samples 
\,"ere diluted according to expectation. The standard curve range was 0-100 pg mr1, 
and the assay gave a normal fasting range of 50-150 pg mrl. The intra assay CV was 
<10%. 
GH levels ,vere measured using a commercially available immunoradiometric assay kit 
(Skybio Ltd., Beds, UK). The GH assay is a two-site immunoradiometric assay. The 
first antibody is C25IJ-labelled for detection, the second is coupled to solid phase for 
separation. Unbound materials are removed by centifugation and washing the tubes. 
The standard curve range was 0-200 mU rl. Undetectably low values were considered 
as concentrations at the detection limit of the assay. All the samples from this study 
were assayed using a single kit, the intra assay CV was <2 %. 
IGFBP-l and 3 concentrations were measured using coated-tube immunoradiometric 
assay kits (Diagnostic Systems Laboratories, Texas, USA). These kits employ a 
two-site immunoradiometric assay in which the IGFBP-l (or 3) is sandwiched between 
two antibodies. The first antibody is immobilised to the inside walls of the assay tubes, 
the second is radiolabelled for detection. Unbound materials are removed by decanting 
and washing the tubes. The standard curve range for the IGFBP-l assay was 
0-160 ng mrl, samples outside the standard curve range were diluted with the 
appropriate buffer and reassayed. The standard curve range for the IGFBP-3 assay was 
0-100 ng mr1 , all samples were diluted 1: 100 with the appropriate buffer before 
analysis. The intra and inter assay CV s were <1 and <6 % for IGFBP-l and <4 and 
<1 % for IGFBP-3 respectively. 
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Cortisol, thyroid honnones, and IGF-I concentrations were all measured by 
illllllunoassay in the Chemical Pathology Department at St Thomas' Hospital. Cortisol 
was llleasured by an enzyme linked immunosorbent assay using the Enzymun-Test 
cortisol kit (Boehringer Mannheim, Sussex, UK). Free T4 and T3 were measured by 
solid phase competitive immunoassays using chemiluminesence (Chiron Diagnostics, 
Essex, UK). Total IGF-I was measured by an in-house radioimmunoassay after acid 
ethanol precipitation of the IGFBPs. 
Calculations 
Calculation of glutamine kinetics 
Measurements of glutamine metabolism were calculated using standard isotope 
dilution equations. Glutamine appearance rate (RagIn; /-lmol min-I kg-I) was calculated 
as: 
RagIn F (l / (APEgln * 0.01) -1) 
where F is the isotope infusion rate (/-lmol min-I kg-I) and APEgln is the steady state 
plasma [2- I5N]glutamine enrichment. In the post-absorptive state the endogenous rate 
of glutamine appearance in plasma (Endo RagIn) is equal to the calculated RagIn. At 
steady state, the rate of glutamine disappearance from plasma (glutamine uptake: Rdgln) 
\vas assumed to be equal to RagIn. Glutamine metabolic clearance rate 
(MCRgln ; ml min-I kg-I) was calculated as: 
MCRgln Rdgln / [gIn] 
where [gIn] is the steady state plasma concentration of glutamine (/-lmol rI). 
Leucine Ra was calculated in a similar manner using the plasma enrichment of KIC as 
an estimate of the intracellular leucine enrichment (Matthews et al 1982). Whole body 
leucine kinetics can be determined by a short, continuous infusion of 
[I-13C] leucine and measurement of plasma 13C leucine enrichment (Matthews et al 
1980). The plasma leucine enrichment is higher than the intracellular leucine 
enrichment because 1) the leucine tracer is infused directly into the extracellular, 
plasma compartment and 2) unlabelled leucine from protein breakdown dilutes the 
leucine enrichment in the intracellular compartment (Matthews et aI1982). KIC is 
fonned intracellularly from the transamination of intracellular leucine and is released 
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into the systen1ic circulation. Plasma KIC enrichment is therefore assumed to be a 
n10re valid indicator of the intracellular leucine enrichment. 
Estimation of glutamine de novo synthesis 
The whole body turnover (equal to Ra at steady state) of an essential amino acid such 
as leucine (Qleu) can be described by the following equation 
Qleu = Sku + Cleu = Bleu + lIeu 
where Sku is the incorporation of leucine into body proteins (protein synthesis), Cleu is 
leucine catabolisn1, Bleu is the release of leucine from body protein (proteolysis) and lIeu 
is the dietary intake of leucine. In the post absorptive state lIeu is negligible and so 
Qleu = Bleu 
For a non-essential amino acid (glutamine) an additional term is added to the above 
modeL Dgln which represents the de novo synthesis of glutamine 
Qgln = Sgln + Cgln = Bgln + Dgln + Igln 
In the post absorptive state there are only two inflow components to the turnover of a 
non-essential amino acid 
Qgln = Bgln + Dgln 
Assuming amino acids are released from protein at rates proportional to their 
concentration in body protein, Bgln can be estimated as follows 
Bgln = k * Bleu 
where k is the assumed molar ratio of glutamine to leucine content of body protein. 
Body protein contains 13.9 g of glutamine and glutamate per 100g, but the exact 
glutamine content of body protein is not known so glutamine is assumed to contribute 
half the total content (7 g or 47.9 mmol). 100g of body protein contains 8 g or 
61.1 mmolleucine. This gives a k value of 0.78 (i.e. 47.9/61.1) for the molar ratio of 
glutamine to leucine in body protein (Darmaun et aI1998). The rate of de novo 
glutamine synthesis can then be estimated as 
Dgln = RagIn - Bgln 
Nutritional support was maintained throughout the second study in the critically ill 
patients. The above equations were corrected for the known exogenous rates of leucine 
and glutamine infusion. In all three treatment groups the leucine turnover has two 
inflow components: exogenous leucine intake (lIeu) from the TPN and protein 
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breakdown (Bleu). lIeu can be calculated from the TPN regime and therefore Bleu can be 
estinlated as 
B leu = Qleu - lIeu 
In the patients recieving TPN the fraction of glutamine turnover (Qgln - Bgln) not 
accounted for by proteolysis arises from de novo synthesis. In the patients recieving 
TPNGLN this fraction can arise either from de novo synthesis or from the exogenous 
glutamine intake 
Qgln = Bgln + Dg1n + 19ln 
19ln can be calculated from the TPNGLN regime and therefore Dg1n can be estimated. 
Statistics 
Results are presented as means + standard error of means (SE). Steady state for plasma 
glutamine and KIC enrichment was confirmed as an insignificant correlation with time 
(p>O.05) by repeated-measures ANOV A (NeSS 6.0, Dr J. Hintze, Utah, USA). 
Comparisons between Study 1 and Study 2 in the critically ill patients were made by 
paired t tests. All other comparisons between groups were made by unpaired t tests 
using equal or unequal variance as necessary. The insulin, GH, cortisol and glucagon 
data \vere log transformed before analysis due to non-normal distribution. 
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Chapter 4 
GLUTAMINE METABOLISM IN NORMAL SUBJECTS 
Introduction 
Stable isotope tracers have been used to investigate the kinetics of a number of amino 
acids in healthy humans. The amino acid glutamine has attracted considerable interest 
as it is an in1portant intermediate in a number of metabolic pathways and plays a key 
role in nitrogen homeostasis. However, to date there have been no published reports of 
studies using stable isotope tracer techniques to investigate the effect of age on 
glutan1ine metabolism in normal adults. 
Aim 
The aim of this study was to establish a method using L_[2_15N] glutamine as a tracer 
to investigate whole body glutamine metabolism in normal adult subj ects and to 
compare glutamine metabolism in young and elderly healthy subjects. 
SUbjects 
Twelye healthy volunteers were recruited from staff and their relatives of the 
Department of Diabetes, Endocrinology and Internal Medicine, St Thomas' campus. 
All were in good general health. There was no recent relevant medical history and 
none were on any regular medication. The study protocol is described in Chapter 2. 
Results 
The physical characteristics of the normal subjects are shown in Table 4.1. The 
twelve normal subjects studied were divided into two groups based on their ages, both 
groups contained three males and three females. The elderly (>60 years) group had a 
mean age of 68 ± 2 years, whereas the young «35 years) group had a mean age of 
28 ± 2 years. The mean weights of the groups were 80.3 ± 4.2 and 69.8 ± 3.0 kg, 
respectively (p=0.068). Body mass index (BMI) and fat mass were significantly higher 
in the elderly group 28.1 ± 1.6 vs. 23.2 ± 0.4 kg m-2 (p<0.05) and 28.8 ± 4.7 vs. 
17.1 ± 2.2 kg (p<0.05), respectively. LBM was not significantly different between the 
two groups 51.5 ± 6.3 vs. 52.7 ± 4.6 kg. 
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Table 4.1. Physical characteristics of normal subjects. 
Subject Gender Age Weight Height BMI LBM Fat Mass 
No. (yrs) (kg) (cm) (kg m-2) (kg) (kg) 
young (<35 years) 
1 F 31 65.4 167 23.5 47.2 18.2 
2 M 27 80.7 184 23.8 68.5 11.9 
3 M 23 76.7 183 22.9 65.8 10.9 
4 F 25 66.0 166 24.0 45.7 20.3 
5 F 29 62.0 171 21.2 44.8 17.2 
6 M 34 68.0 170 23.5 44.1 23.9 
mean + SE 3M:3F 28 + 2 69.8 + 3.0 174 +3 23.2 + 0.4 52.7 + 4.6 17.1 + 2.2 
elderly (>60 years) 
7 F 65 78.9 158 31.8 41.5 37.4 
8 M 70 91.5 174 30.2 62.8 28.7 
9 F 67 76.2 156 31.3 29.5 46.7 
10 M 65 86.6 185 25.3 69.2 17.4 
11 M 77 85.5 174 28.2 62.0 23.5 
12 F 62 62.8 170 21.7 44.0 18.8 
mean + SE 3M:3F 68 + 2 80.3 + 4.2 169 + 5 28.1 + 1.6 51.5 + 6.3 28.8 + 4.7 
BMI, body mass index; LBM, lean body mass. 
-...l 
...... 
Metabolite and homl0ne profiles are shown in Table 4.2. Plasma glucose levels were 
significantly higher in the elderly volunteers (p<0.05). There was no difference in 
insulin, C -peptide or GH levels between the two groups. IGF-I levels were 
significantly lower (p<0.05) in the elderly group, but there were no differences in 
IGFBP-1 or 3 levels. Cortisol levels were significantly higher (p<0.05) in the elderly 
group, but there were no differences in glucagon or thyroid hormone levels. 
Table 4.3 shows that plasnla amino acid profiles were similar in both groups of normal 
Yolunteers, with the exception of decreased serine (p<O.Ol) and histidine (p<0.05) and 
increased cystine (p<O.Ol) concentrations in the elderly subjects. 
Table 4.2. Hormone and metabolite concentrations of young «35) and elderly (>60) 
nOffilals. Values are means + SE, n =6. 
Units 
Glucose -1 mmoll 
Insulin -1 mUI 
C-peptide nmol r1 
GH -1 mUI 
IGF-I -1 nmoll 
IGFBP-l -1 ngml 
IGFBP-3 -1 ngml 
Cortisol -1 nmoll 
Glucagon pgmr1 
-1 Free Thyroxine pmoll 




7.0 ± 1.2 
0.28 ± 0.03 
5.96 ± 2.49 
22.3 ± 1.1 
42± 5 
2889 ± 310 
205 ± 16 
61 ± 5 
14.8 ± 0.4 
4.0 ± 0.4 
Elderly 
Normals 
5.8 ± 0.2 
11.9 ± 2.7 
0.48 ± 0.13 
4.44 ± 1.21 
16.5 ± 1.7 
35 ± 4 
3254 ± 325 
342 ± 40 
64± 6 
14.7 ± 0.6 














Table 4.3. Plasma amino acid profiles of young «35) and elderly (>60) normals. 
Values are means + SE, 11=6. 
























121 + 7 
115 + 6 
44+ 6 
581 + 35 
204+9 
216 + 20 
198 + 17 
50 + 1 
18 + 1 
42 +4 
125 + 12 
38 + 4 
41 + 3 
42 +4 
144 + 10 
83 + 8 
365 + 31 
2150 + 72 




120 + 21 
91 + 5 
61 + 10 
534 + 23 
202 + 22 
283 + 25 
215 + 18 
68 +4 
33 + 11 
36 + 6 
134 + 9 
39 + 9 
44 + 5 
46+4 
166 + 17 
63 +4 
385 + 32 






















In five of the young normals we took extra blood samples to monitor the rise in plasma 
glutamine enrichment to steady state and the fall in enrichment once the tracer infusion 
had been stopped. This allowed us to determine that a 4 hour infusion protocol 
achieved a "'steady state" of plasma glutamine enrichment and to calculate the 
distribution volume of the infused glutamine. The time course of the plasma glutamine 
enrichments in the young normals shows a "steady state" was achieved at 4 hours 
(Figure 4.1). An unprimed, four hour constant infusion protocol was therefore used for 
the remainder of the studies. Using this data and a single pool compartmental model 
(SAAM II, University of Washington, 1994) we estimated a tracer miscible pool of256 
+ 15 Jlmol kg-I. 
Figure 4.2 shows the plasma glutamine enrichments and concentrations for the two 
groups of normal subjects during the final 30 minutes of tracer infusion indicating that 
"steady state" \vas achieved. There was no difference in plasma glutamine 
concentration between the two groups ofnonnals (534 ± 23 vs. 581 ± 35 Jlmol rl, 
elderly vs. young) (Figure 4.3). RagIn was significantly lower in the elderly group 
(4.15 ± 0.33 vs. 5.20 ± 0.22 Jlmol min-1 kg-I; p<0.05), but although MCRgln was lower 
in the elderly group this did not reach statistical significance (7.77 + 0.55 vs. 9.03 + 0.4 
ml min-1 kg-I; p=0.09) (Figure 4.3). The estimated rate of release of glutamine from 
protein breakdown was similar in both groups of control subjects (1.47 + 0.13 vs. 
1.34 + 0.09 Jlmol min-1 kg-I), but the rate of glutamine appearance from de novo 
synthesis was significantly lower in the elderly group (3.57 + 0.09 vs. 2.81 + 0.28 
Jlmol min-I kg-I, p<0.05). There was no difference in the proportion of RagIn arising 
from de novo glutamine synthesis (67 + 2 vs. 71 + 2 %) or protein breakdown (33 + 2 
vs. 29 + 2 %) in the two groups (Figure 4.4). 
However, when the results were expressed per kg lean body mass (Figure 4.5), the 
difference in RagIn (6.96 ± 0.37 vs. 6.69 ± 0.51 Jlmol min-I kg LBM-1) and the 
difference in the rate of glutamine appearance from de novo synthesis were no longer 
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Figure 4.1. Time course of the plasma glutamine enrichments (APE) in young 
nonnals. Values are mean + SE, n=5. 
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Figure 4.2. Plasma glutamine enrichment (APE) and concentration (j.lmol rl) for 
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Figure 4.3. Plasma glutamine concentration, glutamine appearance rate and metabolic 
clearance rate for normal volunteers, young (0) and elderly (.). Values are means 
+ SE; n=6 in each group. 
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De novo glutamine synthesis Protein derived glutamine 
Figure '+.4. Percentage of glutamine appearance rate arising from de novo synthesis 
and proteolysis for normal volunteers, young (D) and elderly (.). Values are means 
+ SE; n=6 in each group. 
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Figure 4.5. Glutamine appearance rate and metabolic clearance rate calculated per kg 
lean body mass for normal volunteers, young (D) and elderly (.). Values are means 
+ SE; n=6 in each group. 
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Discussion 
In the present study the RagIn value in the young normal subj ects was similar to 
previously published values for healthy adults in the same age range (e.g. Darmaun et 
al 1988. Matthews et al 1990, Brillon et al 1995). In contrast the RagIn value for the 
elderly group of normals was significantly lower than in the young group, and lower 
than previously published values for healthy adults using the same tracer (Table 4.4). 
Ho\yeyer. the increase in body weight in the elderly group resulted from an increase in 
fat mass not a decrease in LBM. When the results were expressed per kg LBM there 
was no age associated decrease in RagIn, suggesting that the apparent difference in RagIn 
is related to age associated changes in body composition rather than altered glutamine 
n1etabolism. There is no previously published data reporting RagIn measurement in 
elderly normal SUbjects. In elderly patients (62 + 3 years) with gastrointestinal cancer, 
the average RagIn following 2 hours of [5_15N] glutamine infusion was 4.4 ~mol min-1 
kg-1 (\T an Acker et al 1998). 
Different tracers can give different values for plasma appearance rate depending on the 
metabolic fate of the portion of the molecule labelled. This has been previously shown 
for the non-essential amino acid alanine where the turnover rates measured using 
[15N] labels are slower than those obtained using [13C] labels (Yang et a11984). This 
is because the flux of unlabelled carbon through the pyruvate pool is considerably 
greater than the flux of amino nitrogen through the transamination pool and hence the 
nitrogen label is more likely to be conserved after transamination and returned to an 
alanine molecule. The various parts of the glutamine molecule can enter a variety of 
different metabolic pathways at different rates. Glutamine is predominantly 
metabolised to glutamate with the loss of the amide nitrogen, glutamate is further 
metabolised to a-ketoglutarate with the loss of amino nitrogen and hydrogens (Kreider 
et al 1997). The carbons are lost when a-ketoglutarate enters the citric acid cycle. 
RagIn has been measured in several studies in healthy adult subjects using a range of 
tracers (Table 4.4). Most of the early studies used nitrogen labelled tracers, in 
particular [2_15N] glutamine, but recently investigators have begun to use carbon and 
hydrogen labelled tracers. Hankard and co-workers gave simultaneous infusions of 
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[I-DC], [U_ 14C], [3,4}H] glutamine to six healthy men (Hankard et alI995). The 
Ragin values obtained (5.9, 6.2 and 6.6 !-tmol min- l kg-I, respectively) were not 
significantly different and were similar to the value previously reported by Darmaun et 
al 1986 using [2_15N] glutamine (Hankard et al 1995). However, in a slightly larger 
study group (n=10), simultaneous infusions of [2_15N], [U_ 14C], and [3,4}H] glutamine 
gave significantly different Ragin values (Krieder et al 1997). The hydrogen labelled 
tracer gave RagIn estimates which were slightly, but significantly higher (7 %; p< 0.05) 
than those obtained with the carbon labelled tracer, which were in tum higher than the 
values obtained with the nitrogen labelled tracer (22 0/0; p<O.Ol). The authors suggest 
the difference in the hydrogen and carbon tracers could be due to recycling of 
glutamine carbon via a glucose-glutamine cycle (Perriello et al 1995) which would 
increase plasma glutamine specific activity and lower the apparent RagIn. The lower 
RagIn obtained with the nitrogen labelled tracer could also be partly due to recycling of 
the nitrogen label (Kreider et al 1997). 
In 1986 Darmaun et al measured RagIn in post absorptive healthy adults using both 
[5_ 15N] and [2_15N] glutamine tracers. The RagIn value obtained with the amide tracer 
(-L 7 !-tmol min- l kg-I) was ~80 % of the value given by the amino tracer 
(5.8 !-tmol min- l kg-I, p<O.Ol). The lower RagIn value obtained with the amide 15N 
tracer could be explained if recycling of the label occurred, with reincorporation of 15N 
ammonia released by glutaminase action back into glutamine via glutamine synthetase. 
This would increase the apparent [5_15N] glutamine enrichment and lower the 
calculated Ragin. Darmaun considered this an unlikely explanation (as different 
enzymes add and remove the amide group) and instead proposed that the differences in 
RagIn values were due to loss of the amino label by reversible transamination. In rat 
tissues it has been shown that glutamine transaminates with a nunber of a-keto acids 
forming the corresponding amino acid and a-ketoglutaramate (Meister 1984). This 
would decrease the [2_15N] glutamine enrichment resulting in a higher measure of RagIn 




Table 4.4. Glutamine production rates (~llnolmin-I kg-I) measured in healthy adults during i.v. glutamine tracer infusions. 
Isotopic tracer No. of Age Source of information 
[2_15N] [S)5N] [l_J3C] [3,4-/3C] [U)4C] [3,4-3H] subjects 
5.8 + 0.6 4.7 + 0.5 5 23-26 Darmaun et al 1986 
5.4 + 0.5 6 23-30 Darmaun et al 1988 
5.3 + 0.2 5 25 ± 1 Matthews et al 1990 
5.7 + 0.4 5 24± 1 Matthews & Campbell 1992 
4.9 + 0.2 6 23-39 Matthews et al 1993 
5.6 + 0.3 6 33 ± 3 Darmaun et al1994 
4.5 + 0.3 5 28 ± 1 Gore & J ahoor 1994 
5.6 + 0.5 6 32± 2 Carbonnel et al1995 
5.9 + 0.4 6.2 + 0.3 6.6 + 0.4 6 24±2 Hankard et al 1995 
5.8 + 0.3 11 49±2 Nurjhan et al1995 
4.7 + 0.2 8 29±2 Hankard et al 1997 
4.7 + 0.4 5.7 + 0.5 6.1 + 0.5 10 28 ± 2 Kreider et al 1997 
5.1 + 0.4 11 29± 3 Darmaun et al1998 
For a tracer to measure the overall rate of production of a substrate it should equilibrate 
fully \vith the entire whole body pool of the tracee. Darmaun et al 1986 showed that 
the infused [2_15N] or [5_ 15N] glutamine tracer equilibrates with a tracer miscible pool 
of only 207 ~mol kg-I, suggesting there is little mixing between plasma glutamine and 
the intracellular-muscle glutamine (5200 ~mol kg-I) and that the labelled glutamine 
does not trace intracellular metabolism. In our young normals we estimated a tracer 
nliscible pool of 256 ± 15 ~mol kg-I close to the value reported by Darmaun. Darmaun 
concluded that the Ragin measured between 2-4 hours of tracer infusion represents 
inter-organ flux of glutamine rather than whole body glutamine production. However, 
inter-organ glutamine transport is considered to equate to glutamine metabolism, 
because the enzymes for its production are typically located in tissues (e.g. muscle) 
different from the tissues containing enzymes for glutamine degradation (e.g. gut) 
(Hankard et al 1995). 
The model used to calculate Ragin assumes the whole body pool is a single, 
homogeneous instantly mixing compartment, and requires isotopic steady state. In a 
study in patients with gastrointestinal cancer in which [5_15 N] and [1_13 C] glutamine 
\vere infused for 11 hours both the plasma glutamine and muscle free glutamine 
enrichments increased, indicating isotopic steady state had not been achieved (Van 
Acker et al 1998). The authors suggest this is due to incomplete equilibration of the 
tracer with the large intramuscular free glutamine pool. This may lead to a 
considerable overestimation of whole body RagIn as there was a ~20 % decrease in the 
RagIn calculated after 11 hours of tracer infusion compared with the RagIn calculated 
after 2 hours. However, this data has not been reproduced by any other group. In the 
present study we sampled the steady state over the final 30 minutes of the tracer 
infusion, the plasma glutamine enrichments for the two groups of control subjects are 
shown in Figure 4.2. Repeated-measures ANOV A did not show a significant 
correlation with time, but this sampling period may have been too short to detect an 
increase in the plasma glutamine enrichment. In five of the normals we took earlier 
blood samples, the results shown in Figure 4.1 indicate an isotopic steady state 
between 3 and 4 hours. Using both [2_I5N] and [5_15N] glutamine tracers with 
conventional GCMS sample analysis Darmaun and co-workers (1986) demonstrated 
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that the isotopic steady state in plasma was maintained between 2 and 4 hours of tracer 
infusion. 
In the VanAcker study the glutamine isotopes were infused at a much lower rate than 
in the present study (0.12 vs. 2.5 mg h-I kg-I) and the 15N and 13C enrichments of 
glutamine were measured by gas chromatography-combustion-isotope ratio mass 
spectron1etry (GC-C -IRMS). GC-C-IRMS is a much more sensitive technique than 
conventional GCMS and is capable of measuring much lower enrichments. Van Acker 
et al 1998 suggested that traditional GCMS methodology might not be precise enough 
to detect the sn1all increases in plasma glutamine enrichment over this sampling period. 
It could be argued that RagIn was overestimated in the present study. However, in all 
our tracer infusion studies the tracer was infused for four hours and the isotopic "steady 
state" was sampled over the same period, thus the same errors will be incurred in each 
study. 
As glutamine is a non-essential amino acid in the post-absorptive state RagIn is derived 
from protein breakdown (BgIn) and de novo synthesis (Dgln). If it is assumed that the 
release of an amino acid from proteolysis is proportional to its abundance in body 
protein, the rate of release of a non-essential amino acid from proteolysis can be 
estimated from the appearance rate of an essential amino acid (e.g. leucine) when 
tracers are infused simultaneously into the same subjects (Robert et al 1982). Although 
body protein is known to contain 13.9 g of glutamine plus glutamate per 100 g, the 
exact glutamine content is not known. During in vitro acid hydrolysis of protein the 
glutamine residues are degraded to glutamate, therefore most protein composition 
tables only provide the total glutamine plus glutamate levels (Hankard et al 1995). 
This total glutamine plus glutamate value has been used to calculate the proportion of 
RagIn derived from protein synthesis, but this leads to underestimation of the calculated 
de novo glutamine synthesis rate (Darmaun et al 1988, Nurjhan et a1 1995). 
Researchers have estimated that glutamine contributes half the total glutamine plus 
glutamate value i.e. 7 g per 100 g protein (Matthews and Campbell 1992, Hankard et al 
1997, Darmaun et al 1998). Regardless of the glutamine content chosen it must be 
emphasised that the calculated values ofBgIn or Dgln are only estimates, but since, the 
true glutamine content of whole body protein is likely to be constant the direction of 
changes in BgIn or DgIn should be valid (Hankard et aI1995). The proportions of the 
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RagIn estimated as arising from de novo glutamine synthesis (71 %) and from 
proteolysis (29 0/0) in the young normals were similar to previously reported values for 
young healthy volunteers of a similar age (68 % and 32-36 %, respectively) (Hankard 
et al 1997, Darmaun et al 1998). Dgln (67 %) and Bgln (33 %) for the elderly normals 
\vere also close to these values. This probably reflects the fact that muscle tissue is the 
main site of glutamine production in the post-absorptive state (Van Acker et al 1998) 
and the measured lean body mass was similar in the two groups of normals in our 
study. 
There \vas a wide range ofGH levels in both the young (0.63-16.99 mD rl) and elderly 
(0.68-9.53 mD rl) normals. The values we have quoted are for samples taken during 
the metabolic tracer study and not an average for 24 hour profiles. Because of the 
pulsatile nature of GH secretion it is difficult to report a normal range. The average 
GH levels in our controls are similar to the mean GH value (4.0 + 0.98 mD rl) 
reported following a 24 hour profile in six elderly fasting normals (64 + 4 years) (Ross 
et al 1991a). IGF-I levels were lower in the elderly normal; decreasing IGF-I levels 
with age is well known and may be linked to reduced GH secretion. The IGF-I levels 
for the elderly normals were all within the normal range for >60 year olds (3.7-32.9 
nmol rl). Insulin and C-peptide levels tended to be higher in the elderly normals, 
although this increase was not significant. However, the plasma glucose levels were 
significantly increased. This suggests increased insulin resistance probably due to their 
increased fat mass. The young normals were recruited from members of the 
department and so were within their normal working environment and also had 
previous experience of metabolic tracer studies. The elderly normals may have been 
stressed by their visit to the hospital and by the study protocol, this may explain the 
higher cortisol levels found in this group. Although the cortisol levels were higher in 
the elderly normals they were still within the normal range (120-500 nmol rl, 9:00 a.m. 
sample). 
It is well recognised that LBM decreases with age, so it was surprising to find similar 
LBM measurements for the two groups of normals. Body composition measurements 
vary in sophistication from reference methods (e.g. measurement of total body 
potassium), which are only available in research centres, to simple bedside 
measurements (e. g. bioelectric impedance) (Manning and Shenkin 1995, Enzi et al 
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1997). Bioelectric impedance is the most accessible method to measure body 
composition and was therefore used in the controls in the present study. This 
technique uses prediction equations which take into account body weight, height and 
gender to convert the impedance measurement into an estimate of total water volume, 
from which LBM is estimated (assuming a constant hydration of lean tissue). 
However, a large variation in the hydration of lean tissue has been reported for healthy 
subjects (69-76 %; Streat et al 1985) which increases with age (64-80 %: Sergi et al 
1993). A recently published study has questioned the accuracy of bioelectric 
inlpedance analysis in the elderly (due to the variability in lean tissue hydration) and 
suggests that further validaion studies are necessary (Bussolotto et al 1999). In the 
present study the elderly normals tended to be heavier than the young normals although 
the difference was not statistically significant. lfwe had been able to match two 
groups of normal subj ects for weight it is likely that LBM would have been lower in 
the elderly group. 
As LBM is normally lower in older subjects it is clearly important to match for LBM 
\vhen comparing glutamine metabolism in critically ill patients with normal subjects. 
Many of the techniques used to estimate body composition (measurement of total body 
potassium, in vivo neutron activation analysis, and dual energy x-ray absorptiometry) 
require the subj ects to be moved to whole body scanners or counters. This makes them 
impractical for use in critically ill patients who may be attached to ventilators and/or 
hemodialysis machines (Manning and Shenkin 1995). In addition, there is some doubt 
about the practicality and validity of bioelectrical impedance measurements of body 
composition in critically ill patients as the results may be affected by the hydration 
status of the patient (Manning and Shenkin 1995, Jacobs 1996). Fluid retention 
(overestimate) or dehydration (underestimate) will affect the estimation ofLBM. As 
most methods of measuring body composition appear to have severe limitations in the 
critically ill these results suggest it is important to match the controls for age and BMl 
when measuring glutamine metabolism in leU patients. 
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Chapter 5 
GLUTAMINE METABOLISM IN THE CRITICALLY ILL 
Introduction 
Glutan1ine is the most abundant amino acid in both plasma and the free intracellular 
amino acid pool in skeletal muscle (Bergst6m et aI1974). Because most tissues have 
the ability to synthesise glutamine it is defined as a non-essential amino acid. 
However. free glutamine concentrations are extremely labile and marked decreases 
have been reported in a variety of catabolic states (Askanazi et a11980, Vinnars et al 
1975). This suggests that during serious illness a deficiency in glutamine availability 
may develop and has led to the idea that glutamine is a conditionally essential amino 
acid (Lacey and Wilmore 1990). 
The measurement of whole body plasma glutamine metabolism using glutamine 
labelled \vith 15N has been developed, allowing experimental and clinical 
investigations of glutamine metabolism. Healthy subjects and the effects of various 
catabolic hormones on glutamine metabolism have been studied (Darmaun et a11986, 
Darmaun et a11988, Brillon et a11995, Matthews et a11990, Gore and Jahoor 1994). 
However, despite the current clinical interest in the benefits of glutamine 
supplementation there have been very few tracer studies investigating glutamine 
metabolism in patient groups, particularly critically ill patients. To our knowledge 
there have been no published reports of studies using stable isotope tracer techniques to 
measure glutamine metabolism in critically ill patients soon after the onset of illness in 
a general lCU. 
Aim 
The aim of the present study was to use L_[2_15N] glutamine to investigate whole body 
glutamine metabolism in a group of critically ill patients and a group of matched 
healthy controls. 
Subjects 
Seven severely ill patients (age range 32-76 years) in the lCU of St Thomas' Hospital 
were studied, details of their clinical and metabolic characteristics are given in Table 
5.1. Five of the patients had undergone emergency abdominal surgery within 24 hours 
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of the start of the study. A continuous insulin infusion (Actrapid; Novo Nordisk, 
Copenhagen, Denmark) was provided if necessary, as part of the clinical care, to 
maintain plasma glucose concentration at or below 7 mmol rI. Seven of the normal 
subjects from Chapter 4, matched for gender, age, weight and BMI, were selected as 
healthy controls for comparison; their physical characteristics are also shown in Table 
5.1. The study protocol is described in Chapter 2. 
Results 
Table 5.1 shows the details of the seven critically ill patients studied. The severity of 
the illness is indicated by the TISS and APACHE II scores (Cullen et al1974, Knaus et 
al 1985). These indices identified the patients as being severely ill and dependent on 
cardiorespiratory and nutritional support. None of the patients were acidaemic 
(PH 7.4.+ ± 0.02). Only two of the patients were given exogenous insulin infusions 
during the study, patients 1 and 6 received 2 and 1 U hr- I respectively. 
Metabolite and hormone profiles are shown in Table 5.2. There was no difference in 
the plasma glucose between the two groups. Although plasma insulin levels tended to 
be higher in the critically ill patients, this did not reach statistical significance 
(p=0.062, range 8.5-29 mU rI). C-peptide levels were significantly increased in the 
patients (P<0.01). GH levels were similar in both groups. Total IGF-I and IGFBP-3 
were significantly lower in the patient group (p<0.05 and p<O.OOl). Although the 
mean IGFBP-1 levels were more than doubled in the patients this increase was not 
statisically significant (P=0.14, range 22-238 ng mrl). Cortisol levels were higher in 
the patients, but again this increase did not reach statistical significance (p=0.069, 
range 242-2393 nmol rI). Glucagon levels were significantly higher in the patient 
group (p<0.001). Thyroid hormone levels were significantly lower (p<0.05) in the 
patients. 
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Table 5.1. Characteristics of critically ill patients and matched healthy controls 
Subject Gender Age Weight Height BMI APACHE TISS Plasma Plasma Main Diagnosis 
No. (yrs) (kg) (cm) (kg m-2) II Albumin CRP 
(g(l) (mg (I) 
leU patients 
1 F 68 64.0 171 22.2 15 34 19 157 Bowel resection 
2 M 76 73.6 182 22.2 23 49 27 68 GI bleed/laparotomy 
3 M 72 82.0 187 23.4 15 37 23 161 GI obstruction 
4 F 65 75.0 170 26.0 9 50 34 82 Bowel resection 
5 F 75 85.0 168 30.1 19 38 25 329 Bowel obstruction 
6 M 75 103.7 183 3l.0 24 47 19 248 AAA 
7 F 32 58.5 170 20.2 18 62 17 145 Bowel resection 
mean 3M:4F 66+6 77.4 + 5.6 176 ± 3 25.0 + 1.6 18 + 2 45 +4 23 +2 170 + 35 
±SE 
Matched controls 
1 F 62 62.8 170 2l.7 
2 M 77 85.5 174 28.2 
3 M 65 86.6 185 25.3 
4 F 67 76.2 156 3l.3 
5 F 65 78.9 158 3l.8 
6 M 70 9l.5 174 30.2 
7 F 29 62.0 171 2l.2 
mean 3M:4F 62 + 6 77.6 + 4.4 170±4 27.1 + 1.7 Reference 35 - 46 <7 
±SE ranges: 
BMI, body mass index; APACHE II, acute physiology and chronic health evaluation; TISS, therapeutic intervention scoring system; 
CRP, C-reactive protein; GI, gastrointestinal; AAA, aortic abdominal aneurysm. 
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Table 5.2. Honnone and metabolite concentrations of critically ill patients and 
matched healthy controls. Values are means + SE, n=7. 
Units 
Glucose -1 mmoll 
Insulin -1 mUI 
C-peptide -1 nmoll 
GH -1 mUI 
IGF-I -1 nmoll 
IGFBP-l -1 ngml 
IGFBP-3 -1 ngml 
Cortisol -1 nmoll 
Glucagon pgmr1 
Free Thyroxine -1 pmoll 
Free Tri-iodothyronine -1 pmoll 
Healthy 
Controls 
5.7 ± 0.2 
10.9 ± 2.5 
0.44 + 0.11 
4.42 ± 1.03 
17.0 ± 1.5 
38 ± 5 
2218 ± 282 
318±41 
61 + 6 
14.5 ± 0.6 




17.5 ± 2.6 
1.63 ± 0.36 
3.75± 1.10 
12.4 ± 0.7 
103 ± 36 
1219 ± 142 
784 ± 288 
302 + 52 















The plasma amino acid profiles are listed in Table 5.3. The plasma glutamine 
concentration was significantly lower in the critically ill patients (p<O.OOl). Plasma 
threonine (p<0.01), serine (p<O.OOl), glycine (p<O.Ol) alanine (p<O.OOl), leucine 
(p<0.05). lysine, (p<O.Ol), histidine (p<O.Ol) and arginine (p<O.Ol) concentrations 
were significantly lower in the patients, whereas phenylalanine (p<O.Ol) and aspartate 
(p<O.Ol) levels were significantly higher. There was no significant difference in 
BCAA, but total amino acids were significantly lower (p<O.OOl) in the patients. 
Figure 5.1 shows the plasma glutamine enrichments and concentrations for the 
critically ill patients and their matched controls during the final 30 minutes of the tracer 
infusion. The glutamine turnover data for the patients and their matched controls are 
summarised in Figure 5.2. MCRgIn was significantly higher in the critically ill patients 
compared \yith the matched controls (14.92 + 0.68 vs. 7.85 + 0.47 ml min-I kg-I; 
p<O.OOl). There was no difference in whole body RagIn (or RdgIn) between the two 
groups (-+.89 + 0.31 vs. 4.24 + 0.33 J.lmol min-I kg-I). BgIn was significantly higher in 
the patients compared to the matched controls (2.06 + 0.13 vs. 1.32 + 0.08 J.lmol min-I 
kg-I; p<O.OOl). When expressed as a percentage of RagIn there was a significant 
increase in the proportion of RagIn arising from protein breakdown in the patients 
(43 + 3 vs. 32 + 2 %; p<0.05) (Figure 5.3). DgIn was similar in both groups 
(2.83 + 0.28 vs. 2.92 + 0.26 J.lmol min-I kg-I), but when expressed as a percentage of 
RagIn there was a significant decrease in the proportion of RagIn arising from de novo 
synthesis in the critically ill patients (57 + 3 vs. 68 + 2 %; p<0.05) (Figure 5.3). 
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Table 5.3. Plasma amino acid profiles of critically ill patients and matched healthy 
controls. Values are means + SE, n = 7. 
AliI ill 0 acid Matched Controls 
(jonol (1) 
Aspartate 5 + 0.5 
Threonine 122 + 18 
Serine 98 + 8 
Glutamate 59 + 9 
Glutamine 540 + 53 
Glycine 204 + 18 
Alanine 276 + 23 
,TaHne 205 + 18 
Cystine 65 + 5 
~ Iethionine 30 + 9 
Isoleucine 34 + 5 
Leucine 129 + 9 
Tyrosine 39 + 7 
Phenylalanine 42 +4 
Ornithine 44+4 
Lysine 159 + 16 
Histidine 63 + 3 
BCAA 368 + 32 
Total 2214 + 100 
Critically III 
Patients 
17 + 6 
48 + 6 
50 + 6 
34 + 8 
329 + 21 
129 + 13 
139 + 15 
151 + 20 
56 + 13 
12 + 2 
33 + 13 
95 + 12 
40 + 6 
72 + 7 
34 + 3 
88 + 6 
39 +4 
274 + 37 
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Figure 5.1. Plasma glutamine enrichment (APE) and concentration ().lmol rl) for 
critically ill patients (e) and matched controls (0). Values are means + SE; n=7. 
93 
700 













Plasma glutamine concentration 
20 





































Figure 5.2. Plasma glutamine concentration, glutamine appearance rate and metabolic 
clearance rate for critically ill patients (.) and matched healthy controls (D). Values 
are means + SE; n=7 in each group. 
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Healthy Critically Healthy Critically 
controls ill controls ill 
De novo glutamine synthesis Protein derived glutamine 
Figure 5.3. Percentage of glutamine appearance rate arising from de novo synthesis 
and proteolysis for critically ill patients (.) and matched healthy controls (D). Values 
are means + SE; n=7 in each group. 
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Discussion 
There is currently intense clinical interest in glutamine metabolism in critical illness. 
Previous studies have reported whole body glutamine turnover measurements in bums 
patients (Gore and J ahoor 1994), enterectomized patients (Darmaun et al 1991 a), 
patients with nonneoplastic gastrointestinal disease (Carbonnel et al 1998), patients 
with active coeliac disease (Messing et al 1998) and in type 1 diabetics (Darmaun et al 
1991 b). There have been no previous studies using isotopic tracers to investigate 
glutamine nletabolism in acute critical illness. In this study we have shown that 
despite a marked decrease in plasma glutamine concentration, whole body RagIn was 
unchanged in critically ill patients. Whole body RagIn reflects inter-organ glutamine 
transport rates through plasma (Darmaun et alI986). However, the percentage of 
RagIn arising from protein breakdown was increased and the percentage from de novo 
glutamine synthesis was decreased in this patient group. The observed decrease in 
plasma glutamine concentration suggests that this increase in protein derived glutamine 
\"as insufficient to meet the increased demand for glutamine. 
MCRgln was increased in the critically ill patients suggesting that this may be the 
primary mechanism for the fall in glutamine concentration. MCRgln reflects the rate at 
which glutamine is cleared from the plasma pool. Since amino acids are removed from 
blood by a transporter we would expect this removal to exhibit Michaelis-Menten 
kinetics (i.e. non-linear kinetics). There will thus be an inverse relationship between 
clearance and concentration. Thus if RagIn decreases concentration would be expected 
to fall and clearance to rise. However glutamine RagIn and Rdgln were unchanged in the 
critically ill patients despite a fall in glutamine concentration. The increase in MCRgln 
in the patients is therefore likely to be due to a change in the transport process e.g. an 
increase in efficiency. 
There were marked differences in the levels of plasma amino acids between the 
patients and their matched controls. The decreased glutamine concentrations seen in 
the patients in the present study were similar to previously published values for 
critically ill patients (365 + 126 !J.mol rl; Gamrin et alI996). It has been suggested 
that the decrease in glutamine levels may indicate an inability of glutamine synthetic 
mechanisms to meet the increased metabolic demand of critical illness. Thus 
glutamine may behave as a "conditionally essential" amino acid. The concentrations of 
96 
the essential amino acids, leucine, lysine, threonine and histidine were also lower in the 
patients. This has been reported in previous studies of critically ill patients (Gamrin et 
al 1996, Roth et al 1982). The decrease in plasma amino acid concentrations may be 
due to increased splanchnic amino acid uptake as a result of the elevated levels of 
stress hormones (Wemerman et al 1985). In contrast there was an increase in the 
plasma phenylalanine concentration. This response has also been observed in previous 
studies of critically ill patients and it has been shown that with continuing illness 
phenylalanine concentrations continue to rise (Gamrin et al 1996, Roth et al 1982). As 
liver is the major organ of phenylalanine hydroxylation and oxidation, the increasing 
phenylalanine levels may be an indicator of liver damage in these patients or may 
simply reflect the increased phenylalanine release from muscle exceeding its 
utilization. 
It has been shown that there is an integtrated metabolic response to critical illness 
increased concentrations of the "catabolic" hormones (catecholamines, glucocorticoids 
and glucagon) and with elevated levels of cytokines and inflammatory mediators (Van 
den Berghe et al 1998). In the patients in the present study free thyroid hormone 
concentrations were decreased. Low serum T 3 and T 4 levels are typical of the thyroid 
status in critically ill patients which has been called "sick euthyroid syndrome" (Docter 
et al 1993). Glucagon levels were increased in the patients and although cortisol levels 
also tended to be higher, the increase did not reach statistical significance. Ross et al 
1991 (b) reported elevated mean 24 hour cortisol levels with loss of the normal 
circadian rhythm in critically ill patients. C-peptide levels were increased in the 
patients indicating increased endogenous insulin secretion, although the increase in 
insulin levels was not significant. 
Critical illness is associated with changes in the GH/IGF-I axis which include low 
circulating IGF-I, IGFBP-3 and ALS levels with normal or high IGFBP-11evels 
(Ross et a11991a, Ross et aI1991b). In our study the IGF-I and IGFBP-3 levels were 
lower in the critically ill patients, and IGFBP-l levels tended to be higher although this 
increase was not significant. These changes are characteristic of the "acquired GH 
resistance" of critically ill patients and are thought to reduce the indirect protein 
anabolic effects of GH which are mediated by IGF -I (Ross et al 1991 a, Ross et al 
1991 b). Unfortunately, we were unable to take sufficient samples to establish GH 
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profiles, and the GH values reported are from samples taken during the metabolic 
tracer study. Because of the pulsatile nature of GH secretion, these samples do not 
provide very useful information regarding GH status. Despite the "acquired GH 
resistance" of leu patients the GH levels in our patients were similar to the matched 
controls. However. Ross and co-workers compared the 24 hour GH profiles in six 
critically ill patients with matched healthy controls and showed that although the 
baseline GH levels were higher in the critically ill (3.1 + 0.8 vs. 0.8 + 0.3 mU rl) the 
mean GH levels were similar (4.5 + 0.8 vs. 4.0 + 1.0 mU rl) in both groups (Ross et al 
1991 a). 
Animal studies suggest that glucocorticoids are important mediators of the altered 
glutamine metabolism that occurs during stress. Seven days of dexamethasone 
treatment in dogs (0.44 mg kg-I dail) increased glutamine release from hindquarter 
skeletal muscle resulting in a decreased intracellular free glutamine concentration 
(Muhlbacher et al 1984). Despite the increased glutamine release, plasma levels of 
glutamine also fell (--26 %) suggesting increased uptake by other tissues. 
Dexamethasone treatment has also been shown to stimulate the uptake and utilisation 
of glutamine by the kidneys in the dog (Souba et al 1985) and the intestine in the dog 
(Souba et al 1985) and in the rat (Ardawi et al 1988). 
Previous studies have investigated the effects of catabolic hormone infusions on 
glutamine metabolism in healthy volunteers. Using [2_15N] glutamine as a tracer, 
Darmaun and colleagues infused hydrocortisone (140 /-lg h-1 kg-1 for 64 hours) into 
healthy volunteers to raise plasma cortisol levels into the range normally seen in 
critically ill patients (Darmaun et al 1988). The modest hypercortisolemia (35 /-lg drl) 
increased whole body RagIn by 40 %. The increase in RagIn was primarily due to a 55 % 
increase in de novo glutamine synthesis, and resulted in a significant increase in the 
plasma glutamine concentration. This cortisol mediated increase in RagIn has been 
shown to be dose dependent (Brillon et al 1995). In this experiment, 17 hour infusions 
of hydrocortisone at 80 or 200 /-lg h-1 kg-I, increased plasma cortisol levels to 34 and 
65 /-lg drI and increased RagIn by --23 and --40 % respectively. The majority (--80 %) of 
this increase was accounted for by increased de novo glutamine synthesis. A short 
term increase in RagIn could occur by contraction of the muscle intracellular free 
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glutanline pool, and the tracer methodology used to estimate de novo glutamine 
synthesis does not distinguish between increased glutamine release from the 
intracellular muscle free glutamine pool or increased glutamine synthesis and release 
by muscle (Brillion et al 1995). 
An infusion of epinephrine (2 f.!g min-I for 8.5 hours) caused only a modest increase in 
whole body RagIn (7 %) in healthy adults (Matthews et al 1990). This infusion rate 
resulted in plasma epinephrine levels of ~ 750 pg mrI which are typical of the levels 
seen in trauma and sepsis. In contrast, a triple hormone infusion of epinephrine, 
cortisol and glucagon increased whole body RagIn and MCRgIn, and decreased plasma 
glutamine concentration (Gore and Jahoor 1994). The plasma cortisol (2538 ± 248 
nmol rI) and glucagon (498 ± 102 ng rI) levels achieved in these volunteers were 
much higher than the levels seen in our critically ill patients. These studies suggest 
that these counter regulatory hormones may regulate the rate of glutamine metabolism, 
possibly through effects on glutamine transporters (McGivan and Pastor-Anglada 
1994), however they cannot fully mimic the complex changes occurring in critically ill 
patients. 
Although there are no comparable studies in critically ill patients, whole body RagIn has 
been measured in patients following bum injury using a similar stable isotope 
technique (Gore and Jahoor 1994). RagIn was higher in bum patients (7.2 ± 0.6 J.lmol 
min-I kg-I), in comparison with the values we obtained for critically ill patients 
(4.9 ± 0.3 J.lmol min-I kg-I) in the current studies. Although the decreases in plasma 
glutamine concentration were similar in the two studies, a significant increase (60 0/0) 
in RagIn was reported in the bums patients compared to a control group, in contrast to 
the unchanged value in the present study. These changes were associated with a 
marked increase in glutamine MCRgln in the bums patients (~200 %) compared with 
control subjects, in contrast to the 92 % increase recorded in our patient group. 
However, these measurements were made 2 weeks after the bum injury whereas the 
patients in the present study were studied within 24 hours of admission to the lCU, and 
often within hours of emergency surgery. Although the plasma glucagon levels in the 
bums patients were similar to our lCU patients, the cortisol levels were much higher 
(1848 ± 579 nmol rI). The bums patients had been receiving enteral nutrition which 
was withdrawn 8 hours prior to the study. An increase in whole body RagIn (28 %) has 
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also been shown in chronically malnourished, nonstressed adults with noncancer 
gastric diseases (BMl --16 kg m-2) (Carbonnel et al 1995). 
Phenylbutyrate treatment (0.36 g kg-1 dail) has been used to create a "stress-free 
moder' of glutamine depletion in healthy adults by "trapping" glutamine (Darmaun et 
al 1998). The proposed mechanism involves the conversion of phenylbutyrate to 
phenylacetate by p-oxidation which in tum reacts with glutamine in the liver and 
kidneys to form phenyl acetyl glutamine, which is excreted by the kidneys. The acute 
glutamine depletion (--26 % fall in plasma glutamine levels) induced by 1 day of 
phenylbutyrate treatment, did not affect whole body RagIn but increased MCRgIn by 
-34 %. There \vere no compensatory increases in the rates of de novo glutamine 
synthesis and/or release from protein breakdown, (Darmaun et al 1998). This suggests 
hormone changes and increased glutamine requirements play an important role in 
mediating the increased RagIn previously reported for bums patients (Gore and Jahoor 
1994). 
Critically ill patients are a difficult group to study in large numbers for two main 
reasons; 1) the difficulties of conducting studies in severely ill patients and 2) the 
heterogeneity of patients treated in an intensive care unit in terms of severity of illness, 
nutritional status, and timing of studies, make it difficult to classify and compare 
individuals. Consequently much of the research investigating the effects of glutamine 
supplementation has used metabolically healthy patients with stable circulation and 
minimal preoperative blood loss undergoing planned operative intervention 
(standardised surgical procedures: e.g. elective cholecystectomy). 
In this study the patients recruited in the lCU were those in whom the clinical decision 
had been made to use TPN. Although these patients were a heterogeneous group, in 
contrast to previous studies of glutamine metabolism, they represent the group in 
whom glutamine supplementation may have potential benefit. The study demonstrates 
that the increased glutamine clearance associated with a normal RagIn resulted in a 
decrease in glutamine concentration, suggesting that the increase in protein breakdown 
was insufficient to meet the demand for glutamine in these catabolic patients. 
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Chapter 6 
EFFFECT OF NUTRITIONAL SUPPORT ON GLUTAMINE METABOLISM 
IN CRITICAL ILLNESS 
Introduction 
During critical illness amino acids are mobilised from peripheral tissue, such as 
muscle, and are used by organs in the splanchnic area for gluconeogenesis, oxidation, 
ureagenesis, protein synthesis and also as substrates for the immune system and wound 
healing (Gamrin at al 1996). This is thought to lead to the wasting of lean body mass 
characteristic of critical illness which often persists despite nutritional support. 
Because maintenance of body protein stores may have an impact on morbidity and 
mortality several strategies are currently being investigated to prevent the loss of lean 
tissue, including the use of specialised nutrition. 
At present glutamine is not routinely added to TPN, but recent clinical trials suggest 
that glutamine supplementation improves both nitrogen balance and gut mucosal 
integrity and decreases the number of infections, length of hospital stay, and 6 month 
mortality in critically ill patients (Van der Hulst et al 1993, Ziegler et al 1992, Griffiths 
et al 1997). Despite the current clinical interest in the potential benefits of glutamine 
supplementation there have been no tracer studies investigating the effects of 
glutamine supplementation on glutamine metabolism in critically ill patients. 
Aim 
The aim of the present study was to use L_[2_15N] glutamine to investigate the effects 
of standard TPN and TPN supplemented with glutamine (TPNGLN) on whole body 
glutamine metabolism in critically ill patients. 
Subjects 
Twelve severely ill patients (age range 32-76 years) in the lCU of St Thomas' Hospital 
were studied. Further details of their clinical and metabolic characteristics are 
summarised in Table 6.1. The majority of the patients had undergone emergency 
abdominal surgery within 24 hours of the start of the study. The study protocol is 





Table 6.1. Characteristics of critically ill patients receiving TPN or TPNGLN 
Subject Gender Age Weight Height BMI APACHE TISS Plasma Plasma Main Diagnosis 
No. (yrs) (kg) (cm) (kg m-2) II Albumin CRP 
(g [1) (mg [1) 
TPN 
1 F 68 64.0 171 22.2 15 34 34 82 Bowel Resection 
2 F 55 42.0 158 16.8 20 47 28 191 Bowel Resection 
3 M 76 73.6 182 22.2 23 49 27 68 GI Bleed/laparotomy 
4 M 74 66.0 175 21.6 20 48 18 217 AAA 
5 F 69 60.5 162 23.1 18 42 25 185 AAA 
6 M 73 63.0 170 21.8 19 49 22 212 AAA 
mean ± SE 69 +3 61.5 + 4.3 170 +4 21.2 + 0.9 19 + 1 45 +2 
TPNGLN 
1 M 72 82.0 187 23.4 15 37 23 161 GI Obstruction 
2 F 65 75.0 170 26.0 9 50 19 557 Bowel Resection 
3 M 75 103.7 183 31.0 24 47 27 203 AAA 
4 F 75 85.0 168 30.1 19 38 23 329 Bowel Obstruction 
5 M 59 98.0 181 29.9 14 47 20 247 Bowel Resection 
6 F 32 58.5 170 20.2 18 62 17 145 Bowel Resection 
mean ± SE 63 +7 83.7 + 6.6 177+3 23.8 + 4.1 17 +2 46+3 
BMI, body mass index; APACHE II, acute physiology and chronic health evaluation; TISS, therapeutic intervention scoring system; 















randomised to receive either standard TPN, or TPN with additional intravenous 
glutanline (TPNGLN: 0.4 g kg-1 dai1, Oxford Nutrition, Oxford, UK). The standard 
TPN consisted of 50 % dextrose, Intralipid 20 % (Kabivitrum Inc., Stockholm, 
S\yeden) and a nlixed amino acid solution (Yamin 14; Pharmacia & Upjohn, Milton 
Keynes, UK). The composition of Intralipid 20 % and Yamin 14 are shown in Tables 
6.2 and 6.3 respectively. This TPN combination provided 30 kCal kg-1 dai1 and 
0.2 gN kg- 1 dail. The patients randomised to TPNGLN received additional nitrogen in 
the fonn of the glutamine infusion (-- 0.06 gN kg-1 dail). The nutritional support was 
not made isonitrogenous as this could have limited the availability of other amino 
acids. A continuous insulin infusion (Actrapid; Novo Nordisk, Copenhagen, 
Denmark) ",as provided if necessary, as part of the clinical care, to maintain plasma 
glucose concentration at or below 7 mmol ri. Following 72 hours of nutritional 
support a second turnover study (Study 2) was performed, the TPN was maintained 
throughout this second study. 
Table 6.2. Composition of Intralipid 20 %. 
Ingredients Concentration 
per 500 ml 
Purified soybean oil 100 g 
Fractionated egg phospholipids 6 g 
Glycerol 11 g 
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Table 6.3. Composition of Va min 14. 
Ingredients Concentration 
per 1,000 ml 
L-Alanine 12.0 g 
L-Arginine S.4 g 
L-Aspartic acid 2.5 g 
L-Cysteinel cystine 420mg 
L-Glutamic acid 4.2 g 
Glycine 5.9 g 
L-Histidine 5.1 g 
L-Isoleucine 4.2 g 
L-Leucine 5.9 g 
L-Lysine 6.S g 
L-Methionine 4.2 g 
L-Phenylalanine 5.9 g 
L-Proline 5.1 g 
L-Serine 3.4mg 
L-Threonine 4.2 g 
L-Tryptophan 1.4 g 
L-Tyrosine 170mg 
L-Valine 5.5 g 
Sodium 100 mmol 
Potassium 50 mmol 
Calcium 5mmol 
Magnesium Smmol 
Chloride 100 mmol 
Sulphate Smmol 
Acetate 135 mmol 
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Results 
Table 6.1 shows the details of the twelve critically ill patients studied. There were no 
significant differences in age, weight, height or BMI between the two treatment groups. 
The severity of illness is indicated by the APACHE II and TISS scores which identify 
the patients as being severely ill and dependent on cardiorespiratory and nutritional 
support (Cullen et a11974, Knaus et aI198S). There were no significant differences in 
the APACHE II and TISS scores between the two groups of patients at the start of the 
study. None of the patients were acidaemic, there were no significant differences in 
the arterial pH values between the treatment groups in Study 1 (TPN 7.43 ± 0.03; 
TPNGLN 7 . ..+4 ± 0.02). In addition bicarbonate concentrations indicated no depletion 
of alkaline reserves (TPN 26 ± 2 mmol rl; TPNGLN 26 ± 1.S mmol rl). There were 
no significant changes in blood gas analysis results between Study 1 and Study 2 for 
both patient groups. Plasma urea concentrations were elevated in both groups 
indicating high rates of protein catabolism (TPN 13 ± 2 mmol rl; TPNGLN 13 ± 2.S 
mmol rl; normal reference range 4-7 mmol rl). The exogenous insulin infusion rates 
are sho\\'n in Table 6.4 
The hormone and metabolite data for the patients receiving TPN and TPNGLN is 
summarised in Table 6.S. Plasma glucose levels increased significantly with treatment 
in the TPN group (p<O.OS), but not in the TPNGLN group. Insulin levels increased 
significantly in Study 2 for both treatment groups (TPN, p<O.Ol; TPNLGLN, p<O.OS). 
C-peptide levels were significantly increased in the second study in the TPNGLN 
group (p<O.OS), but not in the TPN group. There were no significant changes in GH 
levels between Study 1 and 2 for both treatment groups. Total IGF-I was unchanged 
following both TPN and TPNGLN, however IGFBP-1 was significantly decreased in 
Study 2 in the TPN group (p<O.OS). There were no significant changes in cortisol, 
glucagon, free thyroxine or free tri-iodothyroxine levels between Study 1 and 2 for 
both treatment groups. 
Plasma amino acid profiles are shown in Table 6.6. Total amino acids were 
significantly increased in the second study in the patients receiving TPNGLN (p<O.Ol), 
but not in the patients receiving standard TPN. BCAA levels were unchanged by both 
treatments. In the group receiving TPN there were significant increases in plasma 
serine (p<O.OS), glycine (p<O.OS), alanine (p<O.OS), methionine (p<0.01) and ornithine 
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(p<O.OS) levels in Study 2. Plasma serine (p<O.OS), glutamate (p<O.OS), glycine 
(p<O.OS). alanine (p<O.OOI), methionine (p<O.OS), and histidine (p<O.OI) were all 
significantly increased in the second study in the patients receiving TPNGLN. Plasma 
glutan1ine concentrations were significantly increased by treatment with TPNGLN 
(p<O.OOI), but not by treatment with TPN (Figure 6.3). 
Table 6"+. Exogenous insulin infusion rates for patients receiving TPN or TPNGLN. 
Subject Insulin Infusion rate 
No. (U hr-1) 
Study 1 Study 2 
TPN 
1 2 2 
2 O.S 2 
3 0 0 
4 0 1 
S 1 1 
6 0 0 
TPNGLN 
1 0 1 
2 0 3 
3 1 3 
4 0 0 
5 2 2 





Table 6.5. Honnone and metabolite concentrations of critically ill patients receiving TPN or TPNGLN. Values are means + SE, 
11=6. 
Units TPN TPNGLN 
Study 1 Study 2 p Study 1 Study 2 p 
Glucose -1 6.6 ± 0.5 7.8 ± 0.3 <0.05 6.3 ± 0.5 7.7 ± 0.5 NS mmoll 
Insulin -1 17.0±2.9 53.8 ± lOA <0.01 18.5 ± 3.0 88.7 ± 36.0 <0.05 mUI 
C-peptide nmol r1 1.83 ± 0049 2.11 ± 0.61 NS 1045 ± 0.32 2.09 ± 0041 <0.05 
GH -1 5.28 ± 1.81 6.98 ± 2.57 NS 2.81 ± 0.66 2.78±1.13 NS mUI 
IGF-I -1 13.6 ± 1.8 11.0 ± 204 NS 12.1 ± 0.9 10.8 ± 1.0 NS nmoll 
IGFBP-l -1 231 ± 79 39 ± 12 <0.05 87 ± 35 132 ± 86 NS ngml 
IGFBP-3 -1 1116±334 1250 ± 412 NS 1256 ± 153 1270 ± 108 NS ngml 
Cortisol -1 469 ± 53 486 ± 69 NS 872 ± 325 1231 ± 765 NS nmoll 
Glucagon pgmr1 383 ± 67 360 ± 145 NS 256 ± 47 304 ± 44 NS 
Free Thyroxine -1 14.0 ± 1.9 13.6 ± 1.8 NS 10.8 ± 1.3 9.7 ± 1.6 NS pmoll 



























Study 1 Study 2 
34 ± 10 38 ± 9 
49 ± 8 91 ± 15 
46 ±4 105 ± 16 
30 ± 8 94± 29 
376 ± 34 426 ± 58 
153 ± 29 318 ± 68 
200 ± 35 414 ± 72 
191 ± 29 222 ± 28 
50 ± 9 70 ± 17 
11 ± 2 27 ± 2 
36 ± 8 32 ± 4 
116 ± 19 112 ± 18 
41 ± 9 38 ± 7 
80 ± 8 105 ± 9 
32 ± 3 95 ± 22 
99 ± 12 144 ± 18 
41 ± 4 52 ±4 
337 ± 54 365 ± 49 
1546 ± 149 2324 ± 309 
TPNGLN 
p Study 1 Study 2 p 
NS 14 ± 6 20 ± 6 NS 
NS 57 ± 6 73 ± 8 NS 
<0.05 54± 6 84 ± 13 <0.05 
NS 36 ± 7 61 ± 14 <0.05 
NS 338 ± 22 461 ± 24 <0.001 
<0.05 145 ± 13 220 ± 23 <0.05 
<0.05 170 ± 20 278 ± 26 <0.001 
NS 158 ± 13 174 ± 17 NS 
NS 55 ± 14 50 ±4 NS 
<0.01 17 ± 2 31 ± 6 <0.05 
NS 41 ± 6 42 ± 8 NS 
NS 98 ± 8 86 ± 9 NS 
NS 49 ± 7 36 ± 12 NS 
NS 82 ± 10 105 ± 20 NS 
<0.05 40 ± 5 72 ± 16 NS 
NS 105 ± 12 125 ± 11 NS 
NS 38 ± 5 61 ± 8 <0.01 
NS 290 ± 29 302 ± 31 NS 
NS 1463 ± 94 1967 ± 108 <0.01 
The plasn1a glutamine enrichments and concentrations from both studies for the TPN 
patient group are shown in Figure 6.1 and for the TPNGLN in Figure 6.2. These 
figures show that a "steady state" was achieved during the final 30 minutes of tracer 
infusion. The glutamine turnover data for both groups of patients is summarised in 
Figure 6.3. The glutamine production rate was not affected by treatment with TPN 
(5.77 + 0.49 vs. 5.50 + 0.56 /-lmol min-I kg-I) or TPNGLN (5.06 + 0.50 vs. 5.42 + 0.67 
/-lmol min-I kg-I). Glutamine uptake was unchanged in the TPN group (6.01 + 0.51 vs. 
5.70 + 0.57 /-lmol min-I kg-I) but was significantly increased in the second study in the 
TPNGLN group (5.23 + 0.50 vs. 7.41 + 0.69 /-lmol min-I kg-I; p<0.05). MCRgln was 
not affected by treatment with TPN (15.65 + 1.02 vs. 14.23 + 2.22 ml min-I kg-I) or 
TPNGLN (14.97 + 1.06 vs. 15.55 + 0.84 ml min-1 kg-I). 
Bgln \"as significantly decreased in Study 2 in the TPN group (2.48 + 0.15 vs. 2.15 + 
0.19 /-lmol min-I kg-I; p<O.OI) and although a similar trend was observed in the 
TPNGLN group this failed to reach significance (1.96 + 0.11 vs. 1.66 + 0.18 /-lmol min-
I kg-I; p=0.08). When expressed as a percentage of the endogenous RagIn, protein 
derived glutamine release was decreased following treatment with both TPN (44 + 4 
vs. 40 + 3 %; p<0.05) and TPNGLN (40 + 3 vs. 32 + 3 %; p<0.05) (Figure 6. 4). DGIn 
was not significantly altered by treatment with TPN (3.29 + 0.45 vs. 3.34 + 0.46 /-lmol 
min-I kg-I) or TPNGLN (3.10 + 0.45 vs. 3.76 + 0.54 /-lmol min-I kg-I). However, the 
percentage of RagIn arising from de novo synthesis was significantly increased 
following treatment with TPN (56 + 4 vs. 60 + 3 %; p<0.05) and TPNGLN (60 + 3 vs. 
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Figure 6.1. Plasma glutamine enrichment (APE) and concentration (J.lmol rl) for 
critically ill patients receiving standard TPN, Study 1 (0) and Study 2 (.). Values are 
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Figure 6.2. Plasma glutamine enrichment (APE) and concentration (Jlmol rl) for 
critically ill patients receiving TPNGLN, Study 1 (0) and Study 2 (e). Values are 
means + SE; n=6. 
111 
700 9 










...- "7~ 5 0 ..... 







TPN TPNGLN TPN TPNGLN 
Plasma glutamine concentration Endogenous glutamine Ra 
9 20 










1= 5 ~ 
,... "7~ 10 
c ..... 
-
-+ S c ...... 8 ,... S c 
..... 




TPN TPNGLN TPN TPNGLN 
Glutamine uptake Glutamine MeR 
Figure 6.3. Plasma glutamine concentration, glutamine appearance rate, uptake and 
metabolic clearance rate in critically ill patients receiving TPN or TPNGLN, Study 1 
(D) and Study 2 (.). Values are means + SE; n=6 in each group. 
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Figure 6.4. Percentage of endogenous glutamine appearance rate arising from de novo 
synthesis and proteolysis in critically ill patients receiving TPN or TPNGLN, Study 1 
(D) and Study 2 (.). Values are means + SE; n=6 in each group. 
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Discussion 
Glutamine is considered to be a "conditionally" essential amino acid as during 
situations of severe stress both the circulating and intracellular free glutamine 
concentrations fall. Several studies have shown that the addition of glutamine or its 
analogues to TPN improves nitrogen balance, and reduces the fall in muscle glutamine 
concentration and protein synthesis in post-operative patients (Stehle et al 1989, 
Hammarqvist et a11989, Wemerman et al 1990, Petersson et a11994, Blomqvist et al 
1995). In the present study we found glutamine supplementation to TPN increased 
plasma glutamine concentration. By using an isotopic tracer of glutamine to measure 
glutamine metabolism we were also able to demonstrate that whole body glutamine 
uptake \yas increased. This increased uptake may be for use by tissues with high 
metabolic den1ands for glutamine or to replenish the muscle free pools. TPN without 
glutamine failed to normalise glutamine concentration and had no effect on glutamine 
uptake suggesting that glutamine supplementation may be important to meet the 
increased metabolic demands of glutamine requiring tissues in the catabolic state. 
In Chapter 5 it was shown that despite a marked decrease in plasma glutamine 
concentration, Ragln was unchanged in critically ill patients compared with matched 
healthy controls. It was also found that MCRg1n was increased in these patients, 
suggesting the primary mechanism for the reduced concentration may be an increased 
efficiency of glutamine transport. In the present study when nutritional support was 
provided, with or without glutamine supplementation, the glutamine production rate 
was unchanged and MCRgln remained elevated. The increased glutamine uptake would 
thus have been facilitated by the increased efficiency of glutamine transport. 
As glutamine is a non-essential amino acid the measured Ragln is derived from de novo 
glutamine synthesis and glutamine release from protein breakdown. In the present 
study there was a decrease in the proportion of endogenous glutamine production 
derived from protein breakdown (and an increase in de novo synthesis) when the 
patients were receiving nutritional support. Since glutamine production rate was 
unchanged in the present study this suggests that there was a shift to de novo synthesis 
of glutamine from the exogenous supply of amino acids. This may be related to the 
provision of substrates and energy for de novo synthesis or to the changes in the 
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patients' insulin levels. Exogenous insulin was given when necessary to maintain the 
patients' blood glucose at or below 7 mmol rl, a standard procedure in the rcu at 
St Thomas' Hospital. Plasma glucose levels increased to a similar extent in both 
patient groups when nutritional support was provided, however this increase only 
reached significance in the TPN group. C-peptide levels, a measure of endogenous 
insulin secretion, were higher in both groups of patients in Study 1 compared to the 
elderly nomlals described in Chapter 4 (0.48 + 0.13 nmol rl). C-peptide levels 
increased in Study 2 in both groups indicating increased insulin secretion in response 
to feeding, but this increase was only significant in the TPNGLN treated patients. 
Insulin levels also tended to be higher in the critically ill patients compared to the 
elderly normals and were increased in Study 2 in both groups of patients. As can be 
seen from Table 6.2 the patients were receiving a wide range of exogenous insulin 
infusion rates (0-3 U hr-I). This treatment contributed to the observed increase in 
plasma insulin levels in both treatment groups. Since insulin plays a central role in the 
control of protein metabolism by reducing protein breakdown (Gelfand and Barrett 
1987) this may account for some of the decrease in glutamine production derived from 
protein breakdown. Similarly the insulin deficiency of type 1 diabetes has been shown 
to increase the proportion of the glutamine appearance from protein breakdown 
(Darmaun et al 1991 b). 
Marked decreases in free glutamine concentrations have been reported in catabolic 
states associated with protein wasting. In addition experiments using animal models 
had indicated a positive relationship between protein synthesis and glutamine 
concentration (MacLennan et al 1987, Jepson et aI1988). This led to interest in the 
use of glutamine supplementation in critically ill patients with the original hypothesis 
that glutamine supplementation would help counteract the muscle protein catabolism 
seen in these patients. Several groups have investigated the effects of supplementing 
TPN with glutamine, or its analogues on protein metabolism in post-operative patients. 
Glutamine solutions with long term stability are now available and in the present study 
we used a glutamine solution (20 g in 800 mls) prepared by aseptic filtration from 
Oxford Nutrition which had a shelf life of 1 year when stored at -20°C. However, two 
different approaches were previously taken to overcome the pharmaceutical difficulties 
of including glutamine in TPN. Firstly the glutamine solution was prepared, sterilised 
115 
by filtration and added to the TPN immediately before administration to the patients. 
U sing this approach, Hammarqvist and co-workers evaluated the impact of 3 days of 
standard TPN and glutamine enriched TPN (0.285 g kg-1 dail) on protein metabolism 
in patients undergoing elective abdominal surgery (cholecystectomy) (Hammarqvist et 
al 1989). The cumulative nitrogen balance was less negative in the patients receiving 
glutamine supplementation. In the same study muscle biopsy samples were taken 
before and three days after the operation to measure the intracellular amino acids and 
also the concentration and size distribution of ribosomes (as a measure of muscle 
protein synthesis). In the patients receiving glutamine the decrease in intracellular free 
glutamine concentration was less severe, and the ribosomal analysis indicated that 
protein synthesis was maintained at pre-operative levels. While suitable for research 
purposes this method of glutamine administration is not practical for routine clinical 
use. 
The second approach to include glutamine in TPN was to utilise more stable glutamine 
analogues such as the glutamine containing dipeptides (Stehle et al 1989, Hammarqvist 
et al 1990). Stehle et al 1989 reported an improved nitrogen balance, which was 
associated with maintenance of the intracellular glutamine pools, in post-operative 
patients receiving TPN supplemented with the dipeptide L-alanyl-L-glutamine. 
Hammarqvists group reported similar results to their earlier study (preservation of 
muscle free glutamine and muscle protein synthesis and improved nitrogen balance) 
when the TPN was supplemented with L-alanyl-L-glutamine instead of glutamine 
(Hammarqvist et al 1990). A reduction in the loss of muscle free glutamine has also 
been reported in studies using omithine-a-ketoglutarate, or a-ketoglutarate as 
precursors of glutamine to supplement TPN (Wemerman et al1989, 1990). Peters son 
and co-workers looked at the longer-term effects of glutamine supplementation in 
patients undergoing elective abdominal surgery (Petersson et al 1994). Patients were 
randomised to receive either standard TPN or TPN supplemented with the dipeptide 
glycyl-glutamine for the first three days following surgery. Oral food was started on 
the third day post operatively. In the patients receiving TPN the muscle free glutamine 
levels were decreased by day 3, this decrease was delayed until day lOin the patients 
receiving glutamine supplementation. These results suggest that glutamine 
supplementation maintains intracellular glutamine concentrations but if the glutamine 
supplementation is discontinued the muscle free glutamine content falls. 
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These early studies on the possible benefits of glutamine supplementation measured 
nitrogen balance and protein synthesis using ribosomal analysis, for example, a 
co-variation in the change in muscle glutamine concentration and polyribosome 
content was reported in post-operative patients (Wemerman et al 1990). The use of 
ribosomal analysis as a measure of protein synthesis has been questioned and this 
technique is now considered a less robust index of protein synthesis than a change in 
protein synthesis measured directly (Smith and Rennie 1996). The improvement in 
nitrogen balance with glutamine supplementation led to the assumption that some of 
the benefits associated with glutamine supplementation were mediated through 
alterations in protein metabolism and the preservation of muscle mass. However, it 
has been suggested that the interpretation of the improvement in nitrogen balance 
needs caution as a significant proportion of this balance may be due to replenishment 
of the muscle glutamine pool rather than increased protein synthesis (Walser 1991). In 
the present study (results not reported) glutamine supplementation had no additional 
effects on whole body protein breakdown, synthesis or balance (Carroll et al 1999). 
Using [1_14C] leucine to measure in vivo protein metabolism Hankard et al (1996) 
investigated the acute effects of a 5 hour enteral infusion of glutamine 
(800 J.lmol ki1 h-1) on whole body protein metabolism in healthy adults. Doubling the 
plasma glutamine concentration (582 + 13 vs. 1,184 + 37 J.lmol r1) decreased leucine 
oxidation (~42 %) and increased non-oxidative leucine disposal, a measure of whole 
body protein synthesis (~7 %). In contrast phenylbutyrate induced short-term (24 hour) 
plasma glutamine depletion in normal subjects (380 + 15 vs. 514 + 24 J.lmol r1) 
increased leucine oxidation (~22 %) and decreased protein synthesis (~11 %) 
(Darmaun et al 1998). These studies suggest glutamine may playa role in the 
regulation of whole body protein synthesis in healthy adults (Darmaun et al 1998). 
However, there is no direct evidence from studies in humans that increased muscle 
glutamine concentration enhances protein synthesis in catabolic states. In a study using 
[1_13C] leucine to measure protein metabolism in children with Duchenne Muscular 
Dystrophy, an acute (5 hour) oral load of glutamine (800 J.lmol kg-1 h-1) which doubled 
the plasma glutamine concentration (481 + 16 vs. 804 + 85 J.lmol r1) decreased protein 
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breakdown (--8 %), but did not alter protein synthesis (Hankard et al 1998). Long and 
co-workers investigated the effects of 3 days of glutamine supplementation 
(0.35 g kg- 1 dafl) of enteral nutrition on vivo protein metabolism in trauma patients 
and could not demonstrate any differences in protein synthesis, breakdown or nitrogen 
balance con1pared to patients receiving unsupplemented enteral nutrition. (Long et al 
1995). 
Therefore, it has not been firmly established whether the fall in free muscle glutamine 
concentration observed in catabolic states is a reflection of the protein catabolic state or 
a causatiye factor. The relationship between muscle glutamine concentration and 
protein synthesis could be co-incidental, with variables being linked by a common 
third factor such as insulin, or thyroid hormones (Jepson et a11988). 
The benefits of glutamine supplementation may be mediated through other tissues and 
pathways rather than a direct effect on muscle and protein. Glutamine is an important 
energy substrate for enterocytes (Powell-Tuck 1993). Supplementation of TPN with 
glutamine containing dipeptides has been shown to prevent the mucosal atrophy and 
increased intestinal permeability associated with long-term TPN (Van der Hulst et al 
1993, Tremel et al 1994). The integrity of the gastrointestinal tract normally provides 
an important barrier to the entry of bacteria or toxins (Griffiths et al 1997). This effect 
of glutamine supplementation may partly explain the decrease in the number of 
infections, reduced hospital stay and costs which have been reported in bone marrow 
transplant patients receiving TPN supplemented with glutamine (Ziegler et al 1992, 
MacBumeyet aI1994). 
Glutamine is used at a high rate by immunocytes, and the low plasma glutamine levels 
seen in critically ill patients may contribute to immunosuppression (Parry-Billings et al 
1990). In bone marrow transplant patients glutamine supplementation has been shown 
to increase the percentage of lymphocytes and improve the T lymphocyte population 
(Ziegler et al 1998). Glutamine is also an important precursor of the antioxidant 
glutathione. Intravenous glutamine has been shown to preserve plasma, liver and 
intestinal mucosal glutathione stores in animal models (Cao et al 1998, Hong et al 
1992, Harward et al 1994). 
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Many of the early clinical studies of glutamine supplementation have studied patients 
undergoing elective surgery. These are homogenous groups of patients undergoing 
standard operative traumas, and are generally less severely ill than patients admitted to 
the ICU. In a more recent study in severely ill patients Palmer and colleagues found 
supplenlenting TPN with 25 g dafl glutamine for 5 days did not produce a consistent 
pattern of change in either plasma or muscle free glutamine levels(Palmer et al 1996). 
Although we used a similar level of glutamine supplementation and the patients had a 
similar initial plasma glutamine concentration in the present study (~28 g dafl) we 
\vere able to show a significant increase in plasma glutamine levels. In the study 
reported by Palmer and colleagues TPN was commenced ~3 days after the patients 
admission to the ICU, therefore these patients may have been more severely glutamine 
depleted than the patients in the present study where TPN was started within 1-2 days 
of admission 
The nutritional support in the present study was not isonitrogenous since the patients 
receiving TPNGLN were given extra nitrogen in the glutamine supplementation 
(-0.06 gN kg-1 dafl). We decided not to make the nutritional support isonitrogenous 
as we were concerned that to do so could have limited the availability of other amino 
acids. However, the changes in plasma amino acid profiles were similar in both groups 
and many of the amino acids were restored to near normal levels. The patients we have 
studied were recruited in the ICU from patients in whom the clinical decision had been 
made to use TPN. We chose to study these patients as they represent the group in 
whom there is considerable clinical interest in the potential benefits of glutamine 
supplementation, but they are a very heterogeneous group as can be seen from the 
patient details in Table 6.1. The changes in amino acid levels did not reach the same 
degree of statistical significance in the two treatment groups due to the wide variation 
in amino acid levels between the patients and the small patient numbers. 
It was shown in the previous chapter that glutamine uptake is maintained in the 
critically ill, despite low glutamine concentrations, by an increase in the efficiency of 
glutamine transport as demonstrated by the increase in MCRg1n (Chapter 5). This is 
probably due to the increased metabolic demand for glutamine by tissues such as the 
immune system and the gastrointestinal tract in the catabolic state. In the present study 
we have shown that following glutamine supplementation glutamine concentration was 
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restored to normal but glutamine uptake was increased providing further evidence that 
glutamine nlay be a conditionally essential amino acid. Since MCRgln remained 
elevated this suggests that an increased efficiency of glutamine transport facilitates the 
increased uptake of glutamine. 
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Chapter 7 
EFFFECT OF GH/IGF-I THERAPY ON GLUTAMINE METABOLISM IN 
CRITICAL ILLNESS 
Introduction 
The availability of recombinant human GH and IGF-I has led to considerable interest 
in their use, either alone or in combination, to reduce protein catabolism, in a variety of 
catabolic states. However, as glutamine is mobilised from protein stores (skeletal 
muscle) during periods of illness, an increase in protein synthesis may lead to further 
glutamine depletion in critically ill patients (Hinds 1999). 
A.inl 
The aim of the present study was to use L_[2_ 15N] glutamine to investigate the effects 
of the addition of combined treatment with GH and IGF -I to TPN supplemented with 
glutamine (TPNGLN+GHlIGF-I) on whole body glutamine metabolism in critically ill 
patients. 
Subjects 
Five severely ill patients (age range 50-78 years) in the ICU of St Thomas' Hospital 
\yere studied, details of their clinical and metabolic characteristics are summarised in 
Table 7.1. Three of the patients had undergone emergency abdominal surgery within 
24 hours of the start of the study, one patient had suffered a cardiac arrest and one had 
been admitted with a bowel obstruction. The study protocol is described in Chapter 2. 
At the end of the baseline study (Study 1) the patients received TPN with additional 
intravenous glutamine (OA g kg- l dafl) and combined rhGH (0.2 IU kg- l dafl) and 
rhIGF-I (160 ~g kg-1 dafl) therapy (TPNGLN+GH/IGF-I). The GH was administered 
as a single subcutaneous injection at 12:00 hours. The IGF-I dose was split into two 
equal twice daily subcutaneous injections at 12:00 and 22:00 hours. A continuous 
insulin infusion (Actrapid; Novo Nordisk, Copenhagen, Denmark) was provided if 
necessary, as part of the clinical care, to maintain plasma glucose concentration at or 
below 7 mmol rl. Following 72 hours of nutrition all hormonal support a second 
turnover study (Study 2) was performed, the TPN was maintained throughout this 
second study. 
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The control group for this study was a group of six critically ill patients who received 
TPNGLN (results presented in Chapter 6). 
Results 
Table 7.1 shows the details of the five critically ill patients receiving 
TPNGLN+GH/IGF-I. There were no significant differences in age, weight, height or 
BMI between the patients receiving TPNGLN+GH/IGF-I or the patients receiving 
TPNGLN described in Chapter 6. The severity of illness is indicated by the APACHE 
II and TISS scores which identify the patients as being severely ill and dependent on 
cardiorespiratory and nutritional support (Cullen et al 1974, Knaus et aI1985). There 
\yere no significant differences in the APACHE II and TISS scores between the two 
groups of critically ill patients at the start of the study. None of the patients in the 
TPNGLN+GHlIGF-I group were acidaemic (arterial pH values 7.39 ± 0.02) and 
bicarbonate concentrations indicated no depletion of alkaline reserves 
(25 ± l.2 mmol rl). There were no significant changes in blood gas analysis results 
behveen Study 1 and Study 2. Plasma urea concentrations were elevated in Study 1 
indicating high rates of protein catabolism (TPNGLN+GH/IGF-I 9.3 ± l.4 mmol rl; 
normal reference range 4-7 mmol rl). None of the patients in the TPNGLN+GH/IGF-I 
group were given exogenous insulin during Study 1, and only 1 patient (patient 5) 
received 2 U hr- I during Study 2. 
The hormone and metabolite data for the patients receiving TPNGLN+GH/IGF-I is 
summarised in Table 7.2. Plasma glucose levels increased significantly in the second 
study (p<0.05). There were no significant changes in the plasma insulin or C-peptide 
levels between the two studies. Although there was a marked increase in GH levels in 
Study 2 this did not achieve statistical significance (p=0.084). As anticipated there was 
a significant increase in total IGF-I levels in Study 2 (p<0.05) to just above the normal 
range (41- >60 years: 3.7-43.9 nmol rl). IGFBP-3 levels were also significantly 
increased in Study 2 (p<0.05). There were no significant changes in IGFBP-l, cortisol, 
glucagon, or thyroid hormone levels between Study 1 and 2. 
Plasma amino acid profiles are shown in Table 7.3. The plasma amino acid profiles 
were similar in Study 1 and 2, apart from significant increases in glutamine (p<0.05) 
and phenylalanine (p<0.05) concentrations. 
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Figure 7.1 shows the plasma glutamine enrichments and concentrations from Study 1 
and 2 for the TPNGLN+GH/IGF-I patient group, during the final 30 minutes of tracer 
infusion indicating "'steady state" was achieved. The glutamine turnover data is 
sUlllnlarised in Figures 7.2 and 7.3. The glutamine turnover data from the TPNGLN 
group has been included in these figures for reference. Glutamine production rate and 
MCRg1n were not altered by treatment with TPNGLN+GH/IGF-I (5.08 + 1.10 vs. 
5.78 + 0.82 /-lmol min-1 kg-1 and 16.92 + 2.00 vs. 14.90 + 1.58 ml min-I kg-I). 
Glutamine uptake was significantly increased in the second study in the 
TPNGLN+GH/IGF-I treated patients (5.2 + 1.1 vs. 7.6 + 0.8 /-lmol min-I kg-I; p<0.05). 
Bg1n and Dg1n were not significantly altered by treatment with TPNGLN+GHlIGF -I 
(2.11 + 0.25 vs. 1.91 + 0.15 /-lmol min-I kg-I and 2.97 + 1.00 vs. 3.86 + 0.72 /-lmol 
min-I kg-I, respectively). When expressed as a percentage of the endogenous RagIn, the 
decrease in Bgln (46 + 6 vs. 35 + 4 %; p=0.08) and the increase in DgIn (54 + 6 vs 





Table 7.1. Characteristics of critically ill patients receiving TPNGLN +GH/IGF-I. 
Subject Gender Age Weight Height BMI APACHE TISS Plasma Plasma Main Diagnosis 
No. (yrs) (kg) (cm) (kg m-2) II Albumin CRP 
(g(l) (mg (I) 
1 M 65 65.0 182 19.7 19 50 15 378 Bowel Resection 
2 F 54 61.0 171 20.9 20 52 11 105 Bowel Resection 
3 M 50 60.0 179 18.7 9 38 26 38 GI Obstruction 
4 M 62 115.0 179 35.9 16 42 20 249 Cardiac Arrest 
5 M 78 76.0 175 24.8 14 47 24 361 AAA 
mean ± SE 62 +5 75.4 + 10.3 177+2 24.0 + 3.1 16 + 2 46+3 
BMI, body mass index; APACHE II, acute physiology and chronic health evaluation; TISS, therapeutic intervention scoring system; 








Table 7.2. Hormone and metabolite concentrations of critically ill patients receiving 
TPNGLN+GH/IGF-I. Values are means + SE, n=5. 
Units Study 1 Study 2 p 
Glucose -1 6.3 ± 1.0 8.3 ± 1.5 <0.05 mmoll 
Insulin -1 18.4 ± 5.0 58.5 ± 32.2 NS mUI 
C-peptide nmol r1 1.33 ± 0.49 1.64 ± 0.52 NS 
GH -1 8.75 ± 4.34 29.58 ± 9.71 NS mUI 
IGF-I -1 10.3 ± 0.8 48.1±9.1 < 0.05 nmoll 
IGFBP-l -1 134 ± 59 58 ± 15 NS ngml 
IGFBP-3 -1 1466 ± 145 2749 ± 447 <0.05 ngml 
Cortisol -1 411 ± 95 775 ± 341 NS nmoll 
Glucagon pgmr1 247 ± 82 316 ± 81 NS 
Free Thyroxine -1 12.2 ± 2.8 15.3 ± 3.8 NS pmoll 
Free Tri-iodothyronine -1 3.0 ± 0.3 4.2 ± 0.6 NS pmoll 
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Table 7.3. Plasma amino acid profiles of critically ill patients receiving 























18 + 5 
57 + 7 
57 + 9 
43 + 26 
307 + 65 
162 + 29 
183 + 42 
148 + 24 
37 + 5 
14 + 2 
27 +4 
84 + 15 
62 + 22 
65 + 7 
35 + 9 
115 + 15 
46 + 7 
260 + 40 
1434 + 161 
Study 2 p 
28 + 12 NS 
67 + 10 NS 
73 + 14 NS 
48 + 10 NS 
524 + 71 <0.05 
265 + 63 NS 
286 + 83 NS 
165 + 23 NS 
49 + 8 NS 
22 + 6 NS 
30 + 3 NS 
79 + 12 NS 
36 + 4 NS 
82 + 8 <0.05 
36 + 7 NS 
113 + 16 NS 
54 + 8 NS 
274 + 33 NS 
1894 + 270 NS 
126 
6 






s I i t -1 Y 1 ..c 3 u .-I-< ~ (1) 
t'j .., 







200 210 220 230 240 250 
700 
600 ! f-I ! ! 1 500 
- 400 
-




200 210 220 230 240 250 
Infusion time (min) 
Figure 7.1. Plasma glutamine enrichment (APE) and concentration (J.lmol rl) for 
critically ill patients receiving standard TPNGLN+GH/IGF-I, Study 1 (0) and Study 2 
(e). Values are means + SE; n = 5. 
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Figure 7.2. Plasma glutamine concentration, glutamine appearance rate, uptake and 
metabolic clearance rate in critically ill patients receiving TPNGLN (n=6) or 
TPNGLN+GH/IGF-I (n=5), Study 1 (D) and Study 2 (.). Values are means + SE. 
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Figure 7.3. Percentage of endogenous glutamine appearance rate arising from de novo 
synthesis and proteolysis in critically ill patients receiving TPNGLN (n=6) or 
TPNGLN+GHlIGF-I (n=5), Study 1 (D) and Study 2 (.). Values are means + SE. 
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Discussion 
This study demonstrates that addition of combined GH/IGF-I therapy to nutritional 
support with glutamine supplementation in critically ill patients did not affect the 
increase in who Ie body glutamine uptake or the restoration of plasma glutamine 
concentration. GH treatment may reduce the availabity of glutamine for immunocytes, 
enterocytes and hepatic glutathione synthesis by preventing the moblization of 
glutamine from muscle (Takala et al 1999, Hinds 1999). The results of the present 
study suggest that combined GH/IGF -I therapy does not have adverse effects on 
glutan1ine n1etabolism these patients. 
The continued loss of lean tissue in the critically ill despite enteral or parenteral 
nutritional support has led to interest in the use of anabolic hormones such as insulin, 
GH and IGF-I in these patients. The changes in the GH/IGF-I axis in critically ill 
patients are characterised as acquired GH resistance. Basal GH levels are increased, 
but pulsatile GH secretion is reduced, GH binding activity is reduced, IGF-I levels are 
lo\\' and IGFBP-l levels are high (Ross et al 1991 a, Ross et al 1991 b). Both low and 
high affinity GH binding proteins (GHBP) have been identified, the high affinity 
GHBP represents the extracellular domain of the GH receptor and is thought to reflect 
GH receptor expression or abundance (Baumann 1999). The low levels oflGF-1 
reported in critically ill patients may be related to reduced GH receptor activity, 
reflected by the low GH binding activity (Ross et al 1991 b). These changes may 
represent an adaptive change in critically ill patients reducing both any direct and the 
indirect effects ofGH (anabolism and protein synthesis mediated by IGF-I) however 
this may be inappropriate in modem ICU s where nutritional support is available (Hinds 
1999). 
The effects of GH on protein metabolism have been demonstrated in GH deficient 
adults. GH replacement therapy increases lean body mass, and computerised 
topographic analysis of thigh cross sections suggest this increase is partly due to 
increased muscle content (Cuneo et aI1991). Whole body protein synthesis, measured 
by [1_13C] leucine kinetics, was increased by ~ 24 % following two months of 
treatment (Russell-Jones et aI1993). However days or weeks ofGH treatment 
increases the circulating IGF-I and insulin levels making it difficult to assess the direct 
action of GH on protein metabolism (Fryburg and Barrett 1995). In healthy adults a 
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6 hour infusion of GH (0.014 /-lg kg- I min-I) into the brachial artery stimulated forearm 
n1uscle protein synthesis by"" 70 %, based upon the measurement of eH] phenylalanine 
extraction (Fryberg et al1991). The systemic levels ofGH, IGF-I or insulin were not 
affected by the local GH infusion indicating that GH itself was responsible for these 
changes. Copeland and Nair (1994) have also investigated the acute effects ofGH on 
protein metabolism in healthy subjects in protocol designed to control for confounding 
perturbations in other hormones by using a simultaneous somatostatin infusion. 
Control subjects received replacement doses of insulin, glucagon, and GH. In the GH 
group the GH dose was increased to raise the GH levels to the high physiological range 
(12-20 ng n1rl) for the final 3.5 hours of the protocol. GH treatment reduced leucine 
oxidation (p=0.04) and increased whole body protein synthesis (p=0.07), but there was 
no stimulation of muscle protein synthesis. This lack of stimulation of muscle protein 
synthesis by GH may have been due to the fact that the GH treatment period was too 
short to stimulate local production oflGF-1 in muscle (Copeland and Nair 1994). 
GH treatment has been shown to improve nitrogen balance in healthy volunteers 
receiving hypocaloric parenteral nutrition (Manson and Wilmore 1986), in patients (GI 
surgery, GI obstruction, fistulas or acute pancreatitis) established on parenteral 
nutrition (Ziegler et al 1988, Ponting et al 1990) and parenterally or enterally fed ICU 
patients (Ziegler et al 1990b). Improvement of nitrogen balance is assumed to result in 
a preservation of muscle mass, but these improvements can be brought about by an 
increase in whole body protein synthesis, a decrease in protein breakdown or a 
combination of the two. A number of studies have used isotope tracer studies to assess 
the effects of combining GH treatment with parenteral nutrition on protein metabolism 
in catabolic patients. Douglas et al (1990) suggested that the improved nitrogen 
balance following 3 days of GH treatment (20 IU dail, subcutaneous) in patients with 
sepsis and/or trauma resulted from increased protein synthesis rather than reduced 
breakdown. In severe trauma patients 7 days of treatment with GH (0.15 mg kg-I dai\ 
intramuscular) improved N balance and increased protein synthesis (Jeevandam et al 
1996). In elderly patients (70 + 4 years) 6 days of GH treatment (0.15 IU kg-I dafl, 
subcutaneous) following elective abdominal surgery, reduced leucine oxidation and 
increased whole body protein synthesis as assessed by an infusion of [l-13C] leucine 
(Carli et a11997). More recently Berman et al1999 used [1)4C] leucine and [2,6)H] 
phenylalanine to assess the effects ofGH treatment (0.1 mg kg-l dail) on whole body 
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and foreann skeletal muscle protein kinetics in patients who had undergone surgery for 
upper gastrointestinal malignancies. Combined treatment with TPN and GH 
significantly increased whole body net protein balance compared to TPN alone, but 
there \vas no significant effect on either whole body protein synthesis or breakdown. 
GH treatment tended to increase skeletal muscle protein synthesis and decrease protein 
breakdown resulting in a positive net protein balance, but these changes did not 
achieve significance. 
The demonstration that GH had protein anabolic effects in catabolic patients led to 
t\\"o European nlulti-centre, trials being conducted in lCU patients to investigate the 
effects of GH treatment on the length of stay in the lCU and hospital, duration of 
nlechanical ventilation, and outcome (Takala et al 1999). The patients studied had 
been in the lCU for 5-7 days and were expected to require intensive care for at least 
10 more days. A total of 532 patients were given GH at a mean daily dose of 
0.10 + 0.02 mg kg-1 dai1 (0.3 + 0.06 IU kg-1 dail) or placebo. However, rather than 
improving mortality as was expected, GH was found to significantly increase the in-
hospital mortality rate in both studies (p < 0.001). In the patients who survived the 
duration of mechanical ventilation, intensive care and hospitalisation were prolonged 
by GH treatment. The precise mechanism( s) for the increased mortality and morbidity 
in these patients remain(s) unclear. Possible explanations include impaired immune 
function, glutamine deficiency and insulin resistance (Takala et aI1999). 
While GH treatment may reduce protein loss one of the side effects associated with GH 
therapy is insulin resistance which worsens the glucose intolerance associated with 
severe stress (Sherwin et al 1983). In the European trials the blood glucose 
concentrations (p<0.001) and insulin requirements (p<O.OOl) were higher in the GH 
treated patients compared with the patients receiving placebo, but there were no 
differences between the survivors and non-survivors in the GH treated groups 
(Takala et al 1999). In our study GH treatment was given in combination with lGF-l 
therapy to overcome this potential complication of GH treatment. Anabolic doses of 
lGF-l have a tendency to cause hypoglycaemia (Clemmons et al 1992). In the present 
study the plasma glucose concentration increased in the patients when nutritional 
+ honnonal support was provided although this increase only reached significance for 
the TPN and TPNGLN+GH/lGF -I treated patients. C-peptide levels, a reflection of 
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endogenous insulin secretion, were higher in Study 1 in the critically ill patients 
compared to the elderly normals (Chapter 4: 0.48 + 0.13 nmol rl) indicating increased 
insulin secretion and remained high following treatment with TPNGLN+GHlIGF-I. 
Insulin levels also tended to be higher in Study 1 in the patients compared to the 
elderly normals (11.9 + 2.7 mU rl) but the increase following TPNGLN+GH/IGF-I 
was not significant. 
The multi-centre European studies also differed from the present study in that the 
patients were given a variety of nutritional supports excluding glutamine 
supplementation. An increase in protein anabolism as a result of GH treatment may 
result in a decrease in glutamine availability, exacerbating the glutamine depletion seen 
in the critically ill (Hinds 1999). It is possible that decreased glutamine availability 
may have contributed to the increased morbidity and mortality in the multi-centre ICU 
trials however gluamine levels were not recorded (Takala et al 1999). 
\\nen GH treatment (24 IU dai1, subcutaneous) was given to patients receiving TPN 
following gastrointestinal surgery the glutamine release from the forearm muscle, 
measured by the arterio-venous balance technique, was abolished (Mjaaland et al 
1993). Muscle biopsy studies in post-operative patients have shown that GH treatment 
reduces the fall in muscle free glutamine concentrations normally seen following 
surgery (Hammarqvist et al 1992). Biolo and colleagues have evaluated the acute 
effects (24 hour) of GH on muscle glutamine metabolism in severely traumatised 
patients after 1-2 weeks in an ICU. A local infusion of GH into the femoral artery 
(0.1 ~g kg min-I) reduced glutamine release from leg muscle by ~60 % and decreased 
the rate of de novo glutamine synthesis (Biolo et al 1997 and 1999). These results 
suggest that GH administration may have a potentially harmful affect on glutamine 
availability in the critically ill by suppressing muscle glutamine production. 
In a porcine model of surgical trauma both chronic (3 days) and acute (1 dose on the 
morning of surgery) GH pre-treatment increased intestinal glutamine uptake decreased 
hind limb (skeletal muscle) net glutamine release and tended to reduce net glutamine 
uptake in the liver (Mjaaland et al 1995). In the same model GH pre-treatment (3 days) 
combined with a post-operative exogenous glutamine infusion also increased intestinal 
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glutamine uptake and reduced peripheral (muscle) glutamine release, but switched 
hepatic glutamine exchange from uptake to release (Unneberg et al 1996). In a similar 
model both GH and IGF-I (given independently, without exogenous glutamine) 
increased whole body RagIn, intestinal uptake and hepatic release of glutamine in the 
early stages of sepsis (Balteskard et al 1998). These experiments suggest that in the 
early stages of trauma GH pre-treatment induces an equilibrium in glutamine 
metabolism as the increased hepatic glutamine production may compensate for any 
reduction in muscle glutamine production. 
Since the protein anabolic actions of growth hormone are primarily mediated by IGF-I 
there is also interest in the use of this hormone in the treatment of catabolic patients 
(Clemmons et al 1992, Lieberman et a11994, Goeters et aI1995). In healthy adults 
rendered catabolic by a hypocaloric diet, 6 days ofIGF-I treatment attenuated the 
negatiye nitrogen balance (Clemmons et al 1992). A significant, but transient 
improvement in N balance was reported in cachetic patients with acquired 
immunodeficiency syndrome receiving a low dose IGF-I infusion, 4 ~g h- l kg- l for 
12 hours for 10 days (Lieberman et aI1994). However, there was no effect on whole 
body protein metabolism measured by [1-13C] leucine following 10 days ofIGF-I 
treatment. In a recent study of patients following gastric surgery (receiving TPN), the 
anabolic actions ofIGF-I treatment (80 ~g kg-I, subcutaneous injection, twice a day for 
6 days) on protein metabolism could not be shown when assessed by nitrogen balance 
or 3-methyl histidine excretion (Goeters et aI1995). 
In their study of IGF -I in calorically restricted healthy adults Clemmons and colleagues 
reported that the IGF-I treatment tended to cause hypoglycaemia despite the fact that 
insulin levels were suppressed 3 to 4 fold (Clemmons et al 1992). The potency ratio of 
insulin to IGF-I to achieve similar reductions in plasma glucose levels in humans is 
1: 13 (GuIer et aI1987). Using this conversion factor the IGF-I dose given in our study 
is equivalent to 0.23 mU kg- l dai l of insulin. Kupfer and colleagues reported the 
addition of GH to the IGF-I treatment attenuated the hypoglycaemia (Kupfer et al 
1993). A possible explanation for this is that the tendency of GH to cause insulin 
resistance counteracts the hypoglycaemic effects ofIGF-I. As IGF-I treatment 
counteracts GH induced glucose intolerance, combined GH/IGF -I treatment may be a 
more appropriate treatment than either hormone alone. Furthermore in calorically 
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restricted normal adults combined IGF-I1GH treatment was also shown to have a 
greater anabolic effect than either hormone alone (Clemmons et a11992, Kupfer et al 
1993). Combined GH/IGF-I treatment has also been demonstrated to additively 
increase anabolism in parenterally fed rats SUbjected to surgical stress (Lo et al 1995). 
In the present studies although there was a marked increase in GH levels in Study 2, 
this increase was not significant, however the final GH injection was given at 12:00 
hours on the previous day. As anticipated the total IGF -I levels were significantly 
increased in Study 2 in the TPNGLN+GH/IGF-I treated patients, however the 
availability ofIGF-I depends on its interaction with the IGF binding proteins. It has 
been reported that several days ofIGF-I treatment causes increased IGFBP-1 and 
decreased IGFBP-3 levels (Young et al 1992, Kupfer et al 1993, Goeters et al 1995). 
In the present study IGFBP-l levels in the critically ill patients in Study 1 tended to be 
higher than those reported for the elderly normals in Chapter 4 (35 + 4 ng mrl). 
IGFBP-l is found at higher levels in conditions of stress and is regulated by insulin and 
glucose levels (Baxter 1999). The liver is the major source ofIGFBP-1 and it has been 
suggested that increased levels of this binding protein indicates hepatic insulin 
insensitivity (Baxter 1999). 
IGFBP-3 is the main carrier protein for IGF-I and its levels are regulated by growth 
hormone. In critically ill patients IGFBP-3 levels have been shown to be decreased 
due to increased levels of a circulating protease that acts specifically on IGFBP-3 
(Timmins et al 1996). This protease-induced increase in IGF-I availability could mean 
increased IGF-I delivery to target tissues or increased delivery to sites for disposal 
(Ross and Wilmore 1996). In the present study IGFBP-3 levels were initially lower in 
the critically ill patients compared with the elderly normals (Chapter 4: 3254 + 325 
ng mrl). GH induces IGFBP-3, whereas administration ofIGF-I causes a down 
regulation ofGH release which in tum causes the down regulation ofIGFBP-3. In the 
present study IGFBP-3 levels were increased by nutritional support with combined 
GH/IGF-I therapy to near normal levels. Kupfer and co-workers also reported 
increased IGFBP-3 and ALS levels following combined GH/IGF-I treatment in 
calorically restricted normals (Kupfer et al 1993). 
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The patients receiving TPNGLN and TPNGLN+GH/lGF-l were given isonitrogenous 
nutritional support and the changes in plasma amino acid profiles were similar in both 
groups. Many of the amino acids were restored to near normal levels. However the 
changes in amino acid levels did not reach the same degree of statistical significance in 
the patients receiving TPNGLN+GH/lGF-l with significant increases only in the 
glutaIlline and phenylalanine levels. This is possibly due to the smaller patient number 
in this group. 
The patients for the present study were recruited in the leU from patients in whom the 
clinical decision had been made to use TPN. Unfortunately the study was terminated 
due to the withdrawal of GH from use in leus following the increased mortality in the 
GH multi-centre trials (Takala et al 1999). leU patients are very heterogeneous and 
some of the trends between studies, for example the changes in insulin and amino acid 
concentrations, may have reached significance if we had been able to study more 
patients. The results show combined GH and lGF-I treatment did not decrease 
glutamine production rate in these critically ill patients. The addition of combined 
GHtIGF-l therapy to nutritional support with glutamine supplementation did not affect 
the increase in whole body glutamine uptake or the restoration of plasma glutamine 
concentration suggesting that in the presence of glutamine supplementation, this 




Glutmnine is considered to be a "conditionally essential" amino acid during critical 
illness as it appears the metabolic demands for glutamine exceed endogenous 
production resulting in a decrease in free glutamine concentrations. To date it has not 
been clearly established whether this represents a true deficiency or an alteration in 
glutmnine homeostasis related to severe illness (Darmaun et al 1998). The present 
studies have used isotopic tracer studies to assist in understanding the mechanisms for 
the changes in glutmnine metabolism. As current parenteral amino acid regimes do not 
contain glutmnine, there is considerable experimental and clinical interest in the use of 
glutmnine supplementation in critically ill patients (Wemerman and Hammarqvist 
1999. Griffiths 1999, Van Acker et aI1999). The current study was designed to be 
consistent \\'ith the clinical practice in leU at St Thomas' where TPN is started as soon 
as possible if enteral nutrition is considered impractical. 
Skeletal muscle is quantitatively the most important source of glutamine in the human 
body (Griffiths 1999, Van Acker et al 1999). Almost half the admissions to a general 
leU are of patients over 60 years old (Griffiths 1997), and this is reflected in the fact 
that only five of the 17 patients in the present studies were younger than 60 years of 
age. It is well recognised that LBM declines with age. It was surprising that in our 
study there was no difference in LBM between the young and elderly healthy 
volunteers. In elderly leU patients, especially those suffering from extensive or 
prolonged disease, the supply of glutamine may become limited due to depleted free 
pools or reduced capacity to produce glutamine caused by decreased muscle mass 
(Soeters and Olde Damink 1996, Griffiths 1997). Inability to meet the metabolic 
demands for glutamine could have severe consequences for tissues which consume 
glutamine at high rates such as the gastrointestinal tract and the immune system (Van 
Acker et al 1997). 
The studies described in this thesis show that despite the fall in plasma glutamine 
levels there was no difference in RagIn between the critically ill patients and the 
matched healthy controls. However the tracer technique we have used measures whole 
body RagIn which reflects the average whole body RagIn from all tissues. Any increased 
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glutanline release from skeletal muscle may have been off set by decreased release 
from other tissues such as the liver (Van Acker et al 1999). Future studies may benefit 
fronl conlbining these tracer techniques with organ balance measurements to provide 
nlore specific information about glutamine metabolism in specific tissues. In the 
present studies glutamine uptake was increased in the ICU patients when exogenous 
glutanline was provided. This increased uptake may be for use by tissues with a high 
metabolic demand for glutamine or to replenish the muscle free pools. Unfortunately 
for ethical reasons we were unable to take muscle biopsy samples from the patients to 
monitor the intracellular muscle glutamine levels. 
The patients in the current study were studied within 24 hours of admission to the ICU; 
at this stage the fall in plasma glutamine concentrations may represent use of an 
available amino acid pool rather than a true glutamine deficiency. It could be argued 
that in previously well-nourished, healthy individuals the initial metabolic responses 
seen during the first hours or days following acute trauma or illness are adaptive 
changes and do not require nutritional intervention (Van den Berghe et al 1998). 
Ho\vever, the last three decades have seen considerable technical and therapeutic 
advances in intensive care medicine which can keep severely ill patients alive for 
weeks and months (Griffiths et a11995, Van den Berghe et al 1998). Although a 
nutritional intervention is unlikely to alter early mortality in ICU patients it may speed 
recovery and reduce the length of stay in the ICU (Jones et al 1999). It would be 
interesting to investigate glutamine metabolism in a group of longer stay ICU patients 
to compare with the patients from the current study. Griffiths and colleagues reported 
a reduction in 6 month mortality in ICU patients who were treated with TPN 
supplemented with glutamine compared to those receiving standard TPN (Griffiths et 
al 1997). The excess deaths in the group not receiving glutamine supplementation 
occurred after 21 days which supports the argument that with progressive skeletal 
muscle loss endogenous glutamine supply becomes critical to survival (Griffiths 1997). 
Supplementation of parenteral nutrition with glutamine could be considered correction 
of a nutritional deficiency rather than additional treatment however enteral nutrition 
does contain glutamine (Jones et a11999, Wemerman and Hammarqvist 1999). 
Current ICU practice is to introduce enteral nutrition as soon as possible and only 
introduce parenteral nutrition if enteral nutrition fails or is impractical. When enteral 
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nutrition in leU patients was supplemented with additional glutamine there was no 
difference in mortality rates between the patients receiving standard or supplemented 
nutrition, but there was a significant reduction in hospital patient costs in the glutamine 
treated patients (30 % per survivor) (Jones et al 1999). The difference in hospital costs 
was partly due to shorter leU stays, decreased need for supplemental parenteral 
feeding, and shorter post-leU stays in the glutamine supplemented patients. It would 
therefore be of interest to investigate glutamine metabolism using isotopic tracers in 
patients receiving enteral nutrition. 
It has been estimated that leU patients lose 2 % of skeletal muscle per day, despite 
nutritional support (Griffiths 1997). This continued loss has led to interest in the 
potential of GH to preserve muscle mass in these patients. However, since the first 
major trial in leU patients revealed a doubling of mortality in GH-treated patients 
compared \"ith placebo treated patients, further use of GH in leUs will not be 
permitted for some time (Takala et al 1999). The precise mechanism(s) for this finding 
remain speculative, but it is important to determine why GH treatment had such an 
effect. 
Although the study described in this thesis is in only a small group of leU patients the 
administration of GHllGF -I with glutamine supplementation did not appear to have 
deleterious effects. The decision to include glutamine supplementation in the GHllGF-
I treated patients was made before the results of the multi-centre leU trials became 
apparent. As GH is known to be protein anabolic we were concerned that GH 
treatment could exacerbate the glutamine depletion in these catabolic patients. 
Although it would have been interesting to study the effects of the combined hormonal 
treatment on patients receiving standard TPN, we felt it would be unethical to give this 
treatment without glutamine supplementation. In addition, unlike the multi-centre 
trial, we gave combined GH/lGF -I treatment to overcome the potential hyperglycaemic 
complications associated with GH therapy 
The decision by the pharmaceutical industry to withdraw GH from use in the leU is 
understandable, but may be premature. There have been numerous small studies 
investigating the use of GH treatment in catabolic patients where GH was shown to be 
either beneficial or not harmful. The differences in outcome between the previous GH 
139 
studies and the multi-centre trial may reflect differences in the patient populations and 
their respective neuroendocrine states (Van den Berghe 1999, Demling 1999). Many 
of the earlier studies involved non-lCU patients such as patients with AIDS wasting or 
patients recovering from bums (including children) or patients in the first days 
following elective surgery, trauma or sepsis. In the major multi-centre trial patients 
\\'ere included 5-7 days after life threatening insult if it was anticipated that their 
intensive care dependency would be prolonged. Furthermore the high doses of GH 
used (16-24 IU daft) in the multi-centre trial may have been a contributing factor to 
the negative outcome (lsaksson 1999). High GH doses are used in lCU studies as 
critically ill patients are considered to be GH resistant. This may be true in acute 
critical illness but more recent data published while the GH trial was ongoing suggests 
that in prolonged critical illness patients are not necessarily GH resistant (Van den 
Berghe 1999). It is possible that GH treatment may be beneficial at a later stage in the 
patients' recovery, with lower doses adjusted individually to achieve a defined degree 
of clinicaVmetabolic response (Isaksson 1999). 
In conclusion, the findings of this study support the use of glutamine supplementation 
\vith parenteral nutrition. The protein turnover studies performed in conjunction with 
the studies presented in this thesis indicated that GH/lGF -I treatment improved whole 
body protein balance (Carroll et al 1999). Together with the lack of effect on 
glutamine metabolism these findings suggest that GH/lGF-l treatment may be of 
benefit to critically ill patients when glutamine supplementation is provided. It is 
important that more clinical research is undertaken to investigate further the roles of 
both glutamine supplementation and GH/lGF -I treatment in lCU patients. 
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The metabolic consequences of critical illness: 
acute effects on glutamine and protein metabolism 
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Jackson, N. C., P. V. Carroll, D. L. Russell-Jones, P. H. 
Sonksen, D. F. Treacher, and A. M. Umpleby. The meta-
bolic consequences of critical illness: acute effects on gluta-
mine and protein metabolism. Am. J. Physiol. 276 (Endocri-
nolo Metab. 39): E163-E170, 1999.-Net protein loss and 
large decreases in plasma glutamine concentration are char-
acteristics of critical illness. We have used [2_15Nlglutamine 
and [1-13Clleucine to investigate whole body glutamine and 
leucine kinetics in a group of critically ill patients and 
matched healthy controls. Glutamine appearance rate (Ra,Gln) 
was similar in both groups. However, in the patients, the 
proportion of Ra,Gln arising from protein breakdown was 
higher than in the control group (43 ± 3 vS. 32 ± 2%, P < 
0.05). Glutamine metabolic clearance rate (MCR) was 92 ± 
8% higher (P < 0.001), whereas plasma glutamine concentra-
tion was 38 ± 5% lower (P < 0.001) than in the control group. 
Leucine appearance rate (whole body proteolysis) and nonoxi-
dative leucine disposal (whole body protein synthesis) were 
59 ± 14 and 49 ± 15% higher in the patients (P < 0.001). 
Leucine oxidation and MCR were increased in the patients by 
104 ± 37 and 129 ± 39%, respectively (P < 0.05). These 
results demonstrate that critical illness is associated with a 
major increase in protein turnover. The acute decrease in plasma 
glutamine concentration and the unaltered plasma Ra,Gln 
suggest that the increase in proteolysis is insufficient to meet 
increased demand for glutamine in this severe catabolic state. 
stable isotopes; leucine; age 
CRITICAL ILLNESS resulting from trauma, surgery, or 
sepsis is associated with altered metabolism character-
ized by an increased catabolic rate, negative nitrogen 
balance, wasting of lean body mass, immunosuppres-
sion, and compromised wound healing. The muscle loss 
is thought to be due to the mobilization of amino acids 
for high priority use by organs in the splanchnic area 
for gluconeogenesis, oxidation, ureagenesis, and pro-
tein synthesis and also as substrates for the immune 
system and wound healing (18). 
Glutamine is the most abundant amino acid in both 
plasma and the free intracellular amino acid pool in 
skeletal muscle (4). Because most tissues have the 
ability to synthesize glutamine, it is defined as a 
nonessential amino acid. However, free glutamine con-
centrations are extremely labile, and marked decreases 
have been reported in a variety of catabolic states (3, 
37). This suggests that during serious illness a defi-
ciency in glutamine availability may develop and has 
The costs of publication of this article were defrayed in part by the 
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marked "advertisement" in accordance with 18 U.S.C. Section 1734 
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led to the idea that glutamine is a conditionally essen-
tial amino acid (24). At present, glutamine is not 
routinely added to parenteral nutrition solutions, but 
recent clinical trials suggest that glutamine supplemen-
tation improves both nitrogen balance and gut mucosal 
integrity and decreases the number of infections and 
length of hospital stay (36, 42). 
The use of [1-13CHeucine as a tracer to measure rates 
of whole body protein breakdown and synthesis is a 
well-established technique that has been applied to a 
variety of clinical conditions (19). The measurement of 
whole body plasma glutamine flux by use of glutamine 
labeled with 15N has also been developed, allowing 
experimental and clinical investigations of glutamine 
metabolism. Healthy subjects and the effects of various 
catabolic hormones on glutamine metabolism have 
been studied (7, 10, 11, 20, 28). However, despite the 
current clinical interest in the benefits of glutamine 
supplementation, there have been very few tracer 
studies investigating glutamine metabolism in patient 
groups, particularly critically ill patients. To our knowl-
edge there have been no published reports of studies 
using stable isotope tracer techniques to measure gluta-
mine metabolism in critically ill patients soon after the 
onset of illness in a general intensive care unit (ICU). 
The aim of the present study was to use [2-15N]gluta-
mine and [1-13CHeucine to investigate whole body 
glutamine and leucine metabolism in a group of criti-
cally ill patients and a group of matched healthy 
controls. The importance of matching the critically ill 
group for age and weight was also studied by compar-
ing glutamine and leucine kinetics in a young and an 
elderly control group. 
METHODS 
Materials 
L-[2-15NJglutamine (99% AP), L-[P3Cl1eucine (99% AP), 
and NaH13C03 (99% AP) were purchased from Tracer Tech-
nologies (Somerville, MA). Sterile solutions of the tracers 
were prepared in 0.9% saline with an aseptic technique by the 
Pharmacy Department, Guy's and St. Thomas' Hospital (Lon-
don, UK). 
Subjects 
Seven severely ill patients (age range 32-76 yr) in the ICU 
of St. Thomas' Hospital were studied. Details of their clinical 
and metabolic characteristics are given in Table 1. The 
severity of illness was evaluated on the day of the study by 
use of the APACHE II and TISS score systems (Table 1). Five 
of the patients had undergone emergency abdominal surgery 
within 24 h before the study. Patients 3 and 5 had had 
previous infections, but none of the patients had evidence of 
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Table l. Clinical and metabolic characteristics of patients 
Duration Plasma Plasma 
Age, Weight, BMI, Postsurgery, * Albumin, CRP, 
Patient No. Gender yr kg kg/m2 Main Diagnosis APACHE II TISS h g/dl mg/dl 
1 F 68 65 22.2 GIobstruction/lapa- 15 34 24 19 157 
rotomy 
2 M 76 74 22.2 GI bleed/laparotomy, 23 49 24 27 68 
ARF 
3 M 72 82 23.4 Pneumonia, GI 15 37 NA 23 161 
obstruction 
4 F 65 75 26.0 GI infarction/lapa- 9 50 16 34 82 
rotomy 
5 F 75 85 30.1 ARDS/sepsis 19 38 NA 25 329 
6 M 75 104 31.0 AAArepair 24 47 20 19 248 
7 F 32 59 20.2 Tumor/colonic resec- 18 62 16 17 145 
tion 
Mean::':SE 3M/4F 66::':6 78::': 6 25.0::': 1.6 18::':2 45::':4 20::':2* 23::':2 170::':35 
Characteristics of 
matched controls 
Mean::':SE 3M/4F 62::':6 78::': 4 27.1::':1.7 
BMI, body mass index; CRP, C-reactive protein; GI, gastrointestinal; ARF, acute renal failure; ARDS, acute respiratory distress syndrome; 
AAA, aortic abdominal aneurysm; NA, not applicable. * Includes data from 5 patients who had undergone emergency surgery. 
active infection (negative blood, sputum, and urine culture) 
during the study period. All patients were studied after a 
fasting period of between 12 and 24 h. Six of the seven 
patients were admitted acutely and had previously been self 
caring and independent, responsible for their own diet. The 
remaining patient (patient 5) had been receiving an oral 
hospital diet for 19 days before the study. 
A group of 12 control subjects were recruited for the study; 
their physical characteristics are shown in Table 2. All were 
in good general health. There was no recent relevant medical 
history, and none of the controls was on any regular medica-
tion. The healthy adults were divided into two groups on the 
basis of age, young «35 yr) and elderly (>60 yr). 
The protocol was approved by the Ethics Committee, Guy's 
and St. Thomas' National Health Service Trust. All control 
subjects provided informed written consent; written consent 
was obtained from relatives or friends ofICU patients. 
Study Protocol 
leU patients. All ICU patients were fasted for ~ 12 h before 
the start of the study. Indwelling arterial and central venous 
Table 2. Characteristics of the healthy volunteers 
Subject No. Gender Age,yr Weight, kg 
lines were used for blood sampling and for the tracer infusion, 
respectively. After baseline sampling, priming boluses of 
[1-13Clleucine (1 mglkg) and NaHI3C03 (0.2 mglkg) were 
injected, and 4-h constant infusions of [2_I5N]glutamine (2.5 
mg· kg-I. h- I) and [P3Clleucine (1 mg· kg-I. h-1) were started. 
Blood and breath samples were taken at 210, 215, 220, 225, 
230, and 240 min for steady-state measurement of plasma 
glutamine and u-ketoisocaproic acid enrichment, glutamine 
and leucine concentrations, and breath I3C02 enrichment. 
Blood samples were also taken at baseline and steady state 
for the measurement of metabolite and hormone levels [plasma 
albumin, C-reactive protein, glucose, insulin, insulin-like 
growth factor I (IGF -I), cortisol, thyroid hormones, and amino 
acidsl. For glutamine analysis, 0.5-mllithium heparin plasma 
aliquots were mixed with 100 pI of internal standard (100 
nmolll [U_13C5lglutamine). All samples were stored at -70°C 
until analysis. 
The ICU patients were all sedated and mechanically 
ventilated (Servo 900; Siemens, Berlin, Germany). Continu-
ous measurements of expired volume, CO2 production, and 
oxygen consumption were made using an on-line mass spec-
Height, em BMI,kglm2 LBM,kg Fat Mass, kg 
Young «35 yr) 
1 F 31 65.4 167 23.5 47.2 18.2 
2 M 27 80.7 184 23.8 68.5 11.9 
3 M 23 76.7 183 22.9 65.8 lO.9 
4 F 25 66 166 24.0 45.7 20.3 
5 F 29 62 171 21.2 44.8 17.2 
6 M 34 68 170 23.5 44.1 23.9 
Mean::':SE 28::':2 69.8::':3.0 173.5::':3.3 23.2::':0.4 52.7::':4.6 17.1::':2.2 
Elderly (>60 yr) 
7 F 65 78.9 157.5 31.8 41.5 37.4 
8 M 70 91.5 174 30.2 62.8 28.7 
9 F 67 76.2 156 31.3 29.5 46.7 
10 M 65 86.6 185 25.3 69.2 17.4 
11 M 77 85.5 174 28.2 62.0 23.5 
12 F 62 62.8 170 21.7 44.0 18.8 
Mean::':SE 68::':2 80.3::': 4.2 169.4::':4.5 28.1::': 1.6 51.5::':6.3 28.8::':4.7 
LBM, measured lean body mass. 
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trometer (Airspec 2200; Airspec, Kent, UK). Five measure-
ments were averaged at steady state for each patient. 
Healthy subjects. After an overnight fast, the healthy 
subjects were admitted to the research area of the Diabetes 
and Endocrine Day Centre (St. Thomas' Hospital). Height 
and weight were recorded and body composition was mea-
sured using the technique of bioelectrical impedance (Tanita, 
Tokyo, Japan) (25). Cannulas were inserted into an antecubi-
tal vein for isotope infusion and a superficial vein of the 
contralateral hand for blood sampling. During the sampling 
period, the hand was placed in a heated box (air temperature 
60°C) to produce arterialized venous blood (1). An infusion 
protocol identical to that of the ICU patients was used. 
Total CO2 production, resting energy expenditure, and 
oxygen consumption were measured at steady state with 
indirect calorimetry (Medgraphics, Cardiokinetics, Sal-
ford, UK). 
Experimental Methods 
The isotopic enrichment and concentration of glutamine 
were determined from the tert-butyldimethylsilyl derivative 
by use of a method modified from Wolfe (41). Glutamine 
concentration was determined by reverse isotope dilution 
with L-[lJ-13C5]glutamine (Bioquote, North Yorkshire, UK) as 
the internal standard. Analysis by gas chromatography-mass 
spectrometry (GC-MS; MSD 5971A, Hewlett-Packard, Berk-
shire, UK) used electron impact ionization with selected ion 
monitoring ofthe [M-butyl]+ ions at mass-to-charge ratios of 
m I z 432, 433, and 436. The isotopic enrichment of ex-ketoiso-
caproate (ex-KIC) was measured as the quinoxalinol-tert-
butyldimethylsilyl derivative by use of a method modified 
from Ford et al. (16). GC-MS analysis used electron impact 
ionization with selected ion monitoring of the [M-butyl]+ ions 
at mlz 259 and 260. Plasma ex-KIC enrichment is used as a 
measure of intracellular leucine enrichment (29). 13C02 enrich-
ment was measured on a SIRA series II isotope ratio mass 
spectrometer (VG Isotech, Cheshire, UK) modified with a 
Roboprep G+ inlet system (Europa Scientific, Cheshire, UK). 
Plasma amino acid concentrations were measured on an 
Alpha II + automated amino acid analyzer (Pharmacia, Hert-
fordshire, UK). Plasma glucose concentrations were mea-
sured on a model 23AM glucose analyzer (YSI, Hampshire, 
UK). Serum insulin concentrations were measured by an 
in-house double-antibody radioimmunoassay (34). Total IGF-I 
was measured by radioimmunoassay after acid ethanol extrac-
tion. Free thyroid hormones were measured by a competitive 
immunoassay using chemiluminesence (Chiron Diagnostics, 
Essex, UK). Cortisol was measured by ELISA using the 
Enzymun-Test cortisol kit (Boehringer Mannheim, Sussex, 
UK). Plasma albumin and C-reactive protein were measured 
using an automated method (Kodak 250, Ortho Clinical 
Diagnostics, Amersham, UK). 
Calculations 
Measurements of leucine and glutamine metabolism were 
calculated using standard isotope dilution equations. Leucine 
appearance rate, a measure of whole body protein breakdown 
(RaLeu; in pmol·min-1·kg-1) was calculated as RaLeu = F[lI 
(APEKIC X 0.01) - 1], where F is the isotope infusi~n rate (in 
pmol·min-1.kg-l) and APEKIC is the plasma ex-KIC enrich-
ment. At steady state, leucine disappearance rate (Rd Leu) was 
assumed to be equal to Ra,Leu' Leucine oxidation rat~ (OXLeu; 
in pmol· min -1. kg-I) was calculated as OXLeu = (APE co X 
2 
Ra,co)/ APEKlC, where Ra,cQ, is the production rate of CO2 (in 
mmol/min), and APEco2 is the enrichment of expired CO2 • In 
all cases, leucine oxidation was corrected with the assump-
tion that 80% o[13C02 was expired (32). Nonoxidative leucine 
disposal (NOLD, a measure of whole body protein synthesis) 
was calculated as the difference between Rd,Leu and OXLeu' 
Leucine metabolic clearance rate (MCRLeu; in mI· min -1. kg-1 ) 
was calculated as MCRLeu = Rd Leu/[Leu], where [Leu] is the 
steady-state plasma leucine co~centration (in ).lmolll). Net 
protein balance was estimated using the net leucine balance 
(NOLD - Ra), with the assumption of 8 g of leucine for 100 g 
whole body protein (21). 
Glutamine Ra, Rd, and MCR values were calculated using 
analogous equations. Because glutamine is a nonessential 
amino acid, Ra,Gln is derived from both protein breakdown 
(BGln ) and de novo synthesis (DGln ). Glutamine release from 
protein breakdown was estimated as 0.78 X Ra,Leu (14), and 
DGin was calculated as DGin = Ra,Gln - BGln (21). 
Statistics 
All data are presented as means ± SE. Steady state for 
plasma glutamine enrichment and concentration was con-
firmed as an insignificant correlation with time (P > 0.05) by 
use of repeated-measures ANOVA (NCSS 6.0, Dr. J. Hintze, 
Kaysville, UT). Comparisons between groups were made by 
standard two-tailed unpaired t-tests with equal or unequal 
variance as necessary. The cortisol and insulin data were log 
transformed before analysis. 
RESULTS 
ICU Patients vs. Matched Controls 
Table 1 shows the details of the seven ICU patients 
studied. The severity of the illness is indicated by the 
TISS and APACHE II scores (9, 23). These indexes 
identified the patients as being severely ill and depen-
dent on cardiorespiratory and nutritional support. The 
seven healthy volunteers selected as controls were 
well-matched to the ICU patients for sex, age, weight, 
and body mass index (BMI, Table 1). Figure 1 shows the 
plasma glutamine enrichments and concentrations for 
the ICU patients and their matched controls during the 
final 30 min of the tracer infusion. The glutamine and 
leucine data for the ICU patients and their matched 
controls are summarized in Figs. 2 and 3. Glutamine 
MCR was significantly higher in ICU patients com-
pared with the matched controls (P < 0.001). There was 
no difference in whole body Ra,Gln (or Rd,Gln) between the 
two groups. However, there was a significant increase 
(P < 0.05) in the proportion of Ra,Gln arising from 
protein breakdown and a resulting decrease in the 
proportion arising from de novo synthesis in the criti-
cally ill patients (P < 0.05). 
Ra,Leu, OXLem MCRLem and NOLD were all signifi-
cantly higher in the critically ill patients (P < 0.001, 
P < 0.05, P < 0.05, and P < 0.001, respectively). Net 
24-h protein balance (Fig. 4) was significantly more 
negative in the critically ill subjects (P < 0.01). 
The plasma amino acid profiles are given in Table 3. 
Plasma threonine (P < 0.01), serine (P < 0.001), 
glutamine (P < 0.001), glycine (P < 0.01), alanine (P < 
0.001), leucine (P < 0.05), lysine, (P < 0.01), histidine 
(P < 0.01), and arginine (P < 0.01) concentrations were 
significantly lower in the patients, whereas phenylala-
nine (P < 0.01) and aspartate (P < 0.01) levels were 
significantly higher. Metabolite and hormone profiles 
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Fig. 1. Plasma glutamine enrichment (APE; A) and concentration 
(}lIDol/l; B) for intensive care unit (lCU) patients (.) and matched 
controls (0). Values are means::': SE; n = 7 in each group. 
are shown in Table 4. Thyroid hormone and IGF-I 
levels were significantly lower (P < 0~05) in the pa-
tients. There was no difference in the plasma glucose or 
insulin levels between the two groups. Cortisol levels 
were higher in the !CD patients (P = 0.069, range 
242-2,393 nmol/l). 
Control Subjects 
The characteristics of the control subjects are shown 
in Table 2. They were divided into two groups on the 
basis of age; both groups contained three males and 
three females. The elderly (>60) group had a mean age 
of68 ± 2 yr, whereas the young «35) group had a mean 
age of 28 ± 2 yr. The mean weights ofthe groups were 
80.3 ± 4.2 and 69.8 ± 3.0 kg, respectively (P = 0.068). 
BMI and fat mass were significantly higher in the 
elderly group, 28.1 ± 1.60 vs. 23.2 ± 0.42 kg/m2 (P < 
0.05) and 28.8 ± 4.7 vs. 17.1 ± 2.2 kg (P < 0.05), 
respectively. Lean body mass (LBM) was not signifi-
cantly different between the two groups (51.5 ± 6.3 vs. 
52.7 ± 4.6 kg). 
Table 5 summarizes the glutamine and leucine data 
from the healthy volunteers. Whole body plasma gluta-
mine flux (RaGIn) was significantly lower in the elderly 
group (4.15 ± 0.33 vs. 5.20 ± 0.22 j.lmol·min-1·kg-1, 
P < 0.05), but there was no difference in the proportion 
of Ra GIn arising from de novo glutamine synthesis or 
protein breakdown in the two groups. However, when 
the results were expressed per kilogram LBM, the 
difference in RaGin was no longer evident (6.96 ± 0.37 
vs. 6.69 ± 0.51 }Imol·min-1.kgLBM-l). There were no 
significant differences in glutamine MCR or in any of 
the measurements ofleucine metabolism (Ra Leu. OXLeu. 
MCRLeu, and NOLD) in the two groups of v~lunteers, 
whether the results were expressed per kilogram body 
weight or per kg LBM. 
Table 3 shows that plasma amino acid profiles were 
similar in both groups of healthy volunteers, with the 
exception of decreased circulating serine (P < 0.05) and 
histidine (P < 0.05) and increased plasma cystine 
concentrations in the elderly subjects. Metabolite and 
hormone profiles are shown in Table 4. Plasma glucose 
levels were significantly higher (P < 0.05) in the elderly 
volunteers. Cortisol levels were significantly higher 
(P < 0.05), and IGF-I levels were significantly lower 
(P < 0.05) in the elderly group, but there were no 
differences in insulin or thyroid hormone levels. 
DISCUSSION 
There is currently intense clinical interest in gluta-
mine metabolism in critical illness. Previous studies 
have reported whole body glutamine turnover measure-
ments in healthy controls, burn patients (20), enterecto-
mized patients (12), and patients with insulin-depen-
dent diabetes (13), but there have been no studies 
investigating glutamine metabolism in acute critical 
illness. In this study we have shown that, despite a 
marked decrease in plasma glutamine concentration, 
whole body plasma glutamine flux was unchanged 








































Fig. 2. Leucine appearance rate (Ra, A), oxidation rate (Ox, B), 
nonoxidative leucine disposal (NOLD, C), and metabolic clearance 
rate (MCR, D) for ICU patients (solid bars) and matched controls 
(open bars). Values are means::': SE; n = 7 in each group. 













Protein derived GIn 
Fig. 3. Glutamine appearance rate (Ra , A), %glutamine flux arising 
from de novo synthesis (B), %glutamine flux arising from proteolysis 
(C), and MCR (D) for ICU patients (solid bars) and matched controls 
(open bars). Values are means ::': SE; n = 7 in each group. NS, not 
significant. 
mine flux reflects interorgan glutamine transport rates 
through plasma (10). 
Glutamine MeR was increased in the patients, sug-
gesting that this may be the primary mechanism for 
the fall in glutamine concentration. Because amino 
acids are removed from blood by a transporter, we 
would expect this removal to exhibit Michaelis-Menten 
kinetics (i.e., nonlinear kinetics). There will thus be an 
inverse relationship between clearance and concentra-
tion. Thus, if Ra decreases, concentration will fall and 












Fig. 4. Net 24-h protein balance in ICU patients (solid bar) and 
matched controls (open bar). Values are means::': SE; n = 7 in each 
group. 
clearance will rise. However, glutamine Ra-to-Rd ratio 
was unchanged in the leU patients despite a fall in 
glutamine concentration. The increase in glutamine 
MeR in the leU patients must therefore be due to a 
change in the transport process, e.g., an increase in 
efficiency. 
The percentage of the glutamine flux arising from 
protein breakdown was increased in this patient group, 
but the observed decrease in plasma glutamine concen-
tration indicates that this increase was insufficient to 
meet the increased demand for glutamine. Marked 
alterations were also observed in protein metabolism, 
as reflected by the increases in leucine Ra, NOLD, 
MeR, and oxidation. These changes resulted in an 
increased net negative protein balance in the critically 
ill patients. 
Marked differences were observed in the circulating 
levels of amino acids between the patients and their 
matched controls. In addition to the decreased plasma 
glutamine concentration, the levels of the essential 
amino acids leucine, lysine, threonine, and histidine 
were lower in the patients. Similar changes have been 
observed in previous studies (18, 33), and it has been 
suggested that elevated levels of stress hormones, by 
increasing splanchnic amino acid uptake, may be re-
sponsible for the decreased plasma amino acid concen-
trations (39). The decrease in glutamine levels may 
indicate an inability of glutamine synthetic mecha-
nisms to meet the increased metabolic demand of 
critical illness. These findings have led to the sugges-
tion that glutamine may behave as a "conditionally 
essential" amino acid. In contrast, there was an in-
crease in the plasma phenylalanine concentration. This 
response has been observed in previous studies, and 
evidence suggests that levels of phenylalanine continue 
to rise with continuing illness (18, 33). 
The metabolic response to critical illness is an inte-
grated process, with elevated levels of cytokines and 
inflammatory mediators and increased concentrations 
of the "catabolic" hormones (catecholamines, glucocorti-
coids, and glucagon) (35). Changes observed in the patients 
in this study included elevated plasma cortisol concen-
tration and decreased levels of free thyroid hormones. 
Previous studies have investigated the effects of 
catabolic hormone infusions on glutamine metabolism 
in healthy volunteers. These have demonstrated that 
elevation of plasma cortisol to levels observed after 
trauma resulted in a 15% increase in whole body 
protein breakdown and a 40% increase in glutamine 
flux (11). This increase in flux was primarily due to a 
55% increase in de novo glutamine synthesis, and it 
resulted in a significant increase in the plasma gluta-
mine concentration. More recently, this cortisol-medi-
ated increase in flux was shown to be dose dependent 
(7). In contrast, a triple hormone infusion of epineph-
rine, cortisol, and glucagon increased whole body gluta-
mine flux and MeR and decreased plasma glutamine 
concentration (20). These studies suggest that these 
counterregulatory hormones may regulate the rate of 
glutamine metabolism, possibly through effects on glu-
tamine transporters (30); however, they cannot fully 
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Table 3. Plasma amino acid profiles 
Volunteers 
Amino Acid, 
=ol/l Young Elderly 
Aspartate 6:±:1 6:±:1 
Threonine 121 :±:7 120:±:21 
Serine 115:±:6 91:±:5 
Glutamate 44:±:6 61:±: 10 
Glutamine 581:±:35 534:±:23 
Glycine 204:±:9 202:±:22 
Alanine 216:±: 20 283:±:25 
Valine 198:±: 17 215:±: 18 
Cystine 50:±: 1 68:±:4 
Methionine 18:±: 1 33:±: 11 
Isoleucine 42:±:4 36:±:6 
Leucine 125:±: 12 134:±:9 
Tyrosine 38:±:4 39:±:9 
Phenylalanine 41:±:3 44:±:5 
Ornithine 42:±:4 46:±:4 
Lysine 144:±: 10 166:±: 17 
Histidine 83:±:8 63:±:4 
Arginine 74:±:6 64:±:6 
NS, not significant. 
mimic the complex changes occurring in critically ill 
patients. 
Although there are no comparable studies in ICU 
patients, whole body glutamine flux has been measured 
in patients after burn injury by use of a similar stable 
isotope technique (20). Whole body glutamine flux was 
higher in burns patients compared with the values we 
obtained (7.2 :::+::: 0.6 vs. 4.9 :::+::: 0.3 llmol·min-1·kg-1). 
Although the decreases in plasma glutamine concentra-
tion were similar in the two studies, a significant 
increase (60%) in glutamine flux was reported in the 
burns patients compared with a control group, in 
contrast to the unchanged value in the present study. 
These changes were associated with a marked eleva-
tion in glutamine MCR in the burns patients (200%) 
compared with control subjects, in contrast to the 92% 
increase recorded in our patient group. However, these 
measurements were made 2 wk after the burn injury, 
Table 4. Hormone and metabolite concentrations 
Volunteers 
Units of <35 >60 
Measure (n=6) (n=6) P 
Glucose mmolll 5.1:±:0.1 5.8:±:0.3 <0.05 
Insulin mun 7:±:1 12:±:3 NS 
IGF-I nmolll 22.3:±: 1.1 16.5:±: 1.7 <0.05 
Cortisol nmolll 205:±: 16 342:±:40 <0.05 
Free Thyroxine pmolll 14.8:±:0.4 14.7:±:0.6 NS 
Free Triiodothyronine pmolll 4.0:±:0.4 4.6:±:0.2 NS 
Healthy Critically 
Controls lllPatients 
(n=7) (n=7) p 
Glucose mmolll 5.7:±:0.2 6.0:±:0.5 NS 
Insulin mun 11:±:3 18:±:3 NS 
IGF-I nmolll 17.0:±: 1.5 12.4:±: 0.7 <0.05 
Cortisol nmolll 318:±:41 784:±:288 NS 
Free Thyroxine pmolll 14.5:±:0.6 11.4:±: 1.2 <0.05 
Free Triiodothyronine pmolll 4.6:±:0.2 3.0:±:0.5 <0.05 
IGF-I, insulin-like growth factor I. 
Matched Critically 
P Controls lllPatients P 
NS 5:±:0.5 17:±:6 <0.01 
NS 122:±: 18 48:±:6 <0.01 
<0.01 98:±:8 50:±:6 <0.001 
NS 59:±: 9 34:±:8 NS 
NS 540:±:53 329:±:21 <0.001 
NS 204:±: 18 129:±: 13 <0.01 
NS 276:±:23 139:±: 15 <0.001 
NS 205:±: 18 151:±:20 NS 
<0.01 65:±:5 56:±: 13 NS 
NS 30:±:9 12:±:2 NS 
NS 34:±:5 33:±: 13 NS 
NS 129:±:9 95:±: 12 <0.05 
NS 39:±:7 40:±:6 NS 
NS 42:±:4 72:±:7 <0.01 
NS 44:±:4 34:±:3 NS 
NS 159:±: 16 88:±:6 <0.01 
<0.05 63:±:3 39:±:4 <0.01 
NS 63:±:5 30:±:5 <0.01 
whereas the patients in the present study were studied 
within days of admission to the ICU. 
The leucine kinetic data in the critically ill indicated 
an increase in whole body protein synthesis and break-
down of 49 and 59%, respectively, and an increase in 
leucine oxidation (105%), indicating use of protein as 
an oxidative fuel. In addition, the plasma leucine 
concentration was decreased as a result of the in-
creased utilization ofleucine (indicated by the elevated 
leucine MCR). Isotope tracer methdology has been used 
to investigate whole body protein turnover in a variety 
of catabolic states, with conflicting results. A study in 
patients with multiple organ failure, using [1-13C]leu-
cine, demonstrated significant increases in protein 
Table 5. Whole body glutamine and leucine kinetics 
in healthy volunteers 
Volunteers 
Units of <35 >60 
Measure (n=6) (n=6) p 




thesis % 71:±:2 67:±:2 NS 
Glutamine 
derived from 
proteolysis % 29:±:2 33:±:2 NS 
Glutamine ml'min- 1 
MCR . kg-1 9.03:±:0.40 7.77:±:0.55 NS 
LeucineRa J.UIlol· min -1 
·kg-1 1.89:±: 0.17 1.71:±:O.11 NS 
Leucine Ox J.UIlol· min -1 
·kg-1 0.28:±:0.03 0.27:±:0.02 NS 
NOLD J.UIlol· min- 1 
·kg-1 1.74:±:0.16 1.58:±: 0.10 NS 
LeucineMCR ml·min- 1 
·kg-1 15.36:±: 1.52 13.98:±:0.94 NS 
Ra, appearance rate; MCR, metabolic clearance rate; Ox, oxidation; 
NOLD, nonoxidative leucine disposal. 
GLUTAMINE AND PROTEIN METABOLISM IN CRITICAL ILLNESS E169 
breakdown, synthesis, and leucine oxidation compared 
with control subjects (2). Plasma cortisol concentration 
was found to be the most significant predictor of protein 
breakdown and leucine oxidation in these patients. 
In contrast, studies of protein metabolism after elec-
tive hysterectomy have shown that both whole body 
protein synthesis and breakdown decrease compared 
with the preoperative state (8). Ribosomal analysis and 
tracer studies have also shown that muscle protein 
synthesis decreases after uncomplicated elective sur-
gery (15,31,40). With use of [15N] alanine as a tracer, a 
37% increase in protein synthesis and a 79% increase in 
protein breakdown have been reported in fed patients 
3-5 days after multiple skeletal trauma compared with 
controls receiving a similar diet (5). More recently, it 
has been shown that albumin and fibrinogen synthesis 
increased, whereas muscle protein synthesis decreased, 
in fed head-trauma patients (27). It is likely that the 
apparently conflicting data from these studies reflect 
the heterogeneity of the patient populations, the sever-
ity of illness, the nutritional status, the prior health of 
the patients, and the timing of the studies. 
The major limitation of the whole body protein 
measurement is that this approach reflects the average 
rates of protein turnover in all tissues. However, during 
times of severe stress, different tissues in the body may 
behave differently. The majority of the measured in-
creases in proteolysis may reflect increased muscle 
protein breakdown, as skeletal muscle is the largest 
protein pool in the human body. It is likely that, in part, 
the increase in protein synthesis reflects the increased 
synthesis of acute-phase proteins by the liver, tissue 
repair, and the immune response (leukocyte prolifera-
tion and cytokine production). This alteration of pro-
tein balance would account for the clinical observations 
oflean tissue loss in !CU patients. 
The importance of matching the critically ill group 
for age and weight was studied by comparing gluta-
mine and leucine kinetics in a young and an old control 
group. Leucine MeR, oxidation rate, incorporation into 
and release from body protein were similar in the 
control groups. This is in line with previously reported 
data suggesting that there is no independent effect of 
age on the measurements of leucine metabolism in 
postabsorptive adults, whether the results are ex-
pressed per kilogram body weight (17) or per kilogram 
LBM (6, 17, 38). The Ra,Gln value in the young control 
subjects was similar to previously published values for 
healthy adults in the same age range (e.g., 7, 11, 29). In 
contrast, the Ra,Gln value for the elderly group of 
controls was significantly lower than that in the young 
controls. However, the increase in body weight in the 
elderly group resulted from an increase in fat mass, not 
a decrease in LBM. When the results were expressed 
per kilogram LBM, there was no age-associated de-
crease in Ra,Gln, suggesting that the apparent difference 
in Ra is related to age-associated changes in body 
composition rather than altered glutamine metabo-
lism. 
It is difficult to measure body composition accurately 
in leU patients. Bioelectric impedance is the most 
accessible method, and this was used in the controls in 
the present study. However, as there is some doubt 
about the practicality and validity of bioelectrical imped-
ance measurements of body composition in critically ill 
patients (22, 26), these results suggest that matched 
controls are necessary when glutamine metabolism is 
measured in leU patients. 
The patients for our study were recruited in the leU 
from patients in whom the clinical decision had been 
made to use parenteral nutrition. Unlike previous 
studies reporting glutamine metabolism and most of 
the studies of leucine metabolism in catabolic patients, 
we have studied a heterogeneous group. We chose to 
study these patients because they represent a group in 
whom there is considerable clinical interest in the 
potential benefits of glutamine supplementation. The 
study demonstrates that critical illness is associated 
with marked alterations in protein metabolism. The 
increased glutamine clearance with a normal Ra Gin 
resulted in a decrease in glutamine concentrati~n, 
suggesting that the increase in protein breakdown was 
insufficient to meet the demand for glutamine in these 
catabolic patients. 
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Jackson, N. C., P. V. Carroll, D. L. Russell-Jones, P. H. 
Sonksen, D. F. Treacher, and A. M. Umpleby. Effects of 
glutamine supplementation. GH, and IGF-I on glutamine 
metabolism in critically ill patients. Am. J Physiol. Endocri-
nol. Metab. 278: E226-E233, 2000.-During critical illness 
glutamine deficiency may develop. Glutamine supplementa-
tion can restore plasma concentration to normal. but the 
effect on glutamine metabolism is unknown. The use of 
growth hormone (GH) and insulin-like growth factor I (IGF-I) 
to prevent protein catabolism in these patients may exacer-
bate the glutamine deficiency. We have investigated. in 
critically ill patients, the effects of 72 h of treatment with 
standard parenteral nutrition (TPN; n = 6). TPN supple-
mented with glutamine (TPNGLN; 0.4 g.kg-I·day-I. n = 6). 
or TPNGLN with combined GH (0.2 IU·kg-l·day-l) and 
IGF-I (160 pg·kg -I·day-I) (TPNGLN+GH/IGF-I; n = 5) on 
glutamine metabolism using [2_ I5N]glutamine. In patients 
receiving TPNGLN and TPNGLN+GH/IGF-I. plasma gluta-
mine concentration was increased (338 ± 22 vs. 461 ± 24 
}lffioll1. P< 0.001. and 307 ± 65 vs. 524 ± 71 pmol/l. P< 0.05. 
respectively) and glutamine uptake was increased (5.2 ± 0.5 
vs. 7.4 ± 0.7 pmol·kg-I·min- I. P< 0.05 and 5.2 ± 1.1 vs. 
7.6 ± 0.8 }lffi0l·kg-I.min- I. P< 0.05). Glutamine production 
and metabolic clearance rates were not altered by the three 
treatments. These results suggest that there is an increased 
requirement for glutamine in critically ill patients. Combined 
GHlIGF-I treatment with TPNGLN did not have adverse 
effects on glutamine metabolism. 
stable isotopes; nutritional support; catabolism; postopera-
tive care 
DURING CRITICAL ILLNESS amino acids are mobilized from 
peripheral tissue, such as muscle, and are used by 
organs in the splanchnic area for gluconeogenesis. 
oxidation. ureagenesis. protein synthesis. and also as 
substrates for the immune system and wound healing 
(9). This is thought to lead to the wasting of lean body 
mass characteristic of critical illness. which often per-
sists despite nutritional support. Because maintenance 
of body protein stores and the integrity of the gut 
mucosa may have an impact on morbidity and mortal-
ity, several strategies are currently being investigated 
The costs of publication of this article were defrayed in part by the 
payment of page charges. The article must therefore be hereby 
marked "advertisement' in accordance with 18 U.s.C. Section 1734 
solely to indicate this fact. 
to prevent the loss of lean tissue. These include the use 
of specialized nutrition and the use of anabolic hor-
mones. such as growth hormone (GH) and insulin-like 
growth factor I (IGF-I). 
Glutamine is the most abundant amino acid in the 
body and is traditionally classified as a nonessential 
amino acid because it is synthesized endogenously (2). 
However, marked decreases in free glutamine concen-
trations have been reported in a variety of catabolic 
states (1, 37). This suggests that during serious illness 
a defiCiency in glutamine availability may develop and 
has led to the idea that glutamine is a conditionally 
essential amino acid (22). 
At present, glutamine is not routinely added to 
parenteral nutrition solutions. but recent clinical trials 
suggest that glutamine supplementation improves both 
nitrogen balance and gut mucosal integrity and de-
creases the number of infections, length of hospital 
stay, and 6-mo mortality in critically ill patients (13, 36, 
41). In a previous study we showed that, despite a fall 
in plasma glutamine concentration and an increase in 
glutamine clearance, plasma glutamine flux was un-
changed in critically ill patients compared with matched 
healthy controls (18). Despite the current clinical inter-
est in the potential benefits of glutamine supplementa-
tion, there have been no tracer studies investigating 
the effects of glutamine supplementation on glutamine 
metabolism in critically ill patients. 
The availability of recombinant human GH (rhGH) 
and IGF-I (rhIGF-I) has led to considerable interest in 
their use, either alone or in combination. to reduce 
protein catabolism in a variety of catabolic states. 
However. evidence from recent multicenter trials has 
linked GH treatment with increased mortality in inten-
sive care unit (leU) patients (34). In these trials the 
patients did not receive routine glutamine supplemen-
tation. Because during periods of illness glutamine is 
mobilized from protein stores (sketetal muscle), an 
increase in protein anabolism may exacerbate the 
glutamine depletion seen in these patients. It is pos-
sible that this may have contributed to the increased 
mortality observed in these trials. 
The aim of the present study was to use [2_15N]gluta-
mine to investigate the effects of standard total paren-
teral nutrition (TPN) and parenteral nutrition supple-
mented with glutamine (TPNGLN) on whole body 
glutamine metabolism in critically ill patients. We also 
E226 0193-1849/00 $5.00 Copyright © 2000 the American Physiological Society http://www.ajpendo.org 
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studied the addition of combined treatment with GH 
plus IGF-I and TPNGLN (TPNGLN+GH/IGF-I) on 
glutamine metabolism. 
METHODS 
Materials. L-[2- ISN]glutamine [99 atom percent (AP)] and 
L-[ 1-13C]leucine (99 AP) wcre purchased from Tracer Technolo-
gies (Somerville. i\lA). Sterile solutions of the tracers were 
prepared in 0.90 0 saline with an aseptic technique by the 
Pharmacy Department of Guy's and St Thomas' Hospital 
(London. UK). The standard TPN consisted of SO% dextrose 
Intralipid 20% (Kabivitrum. Stockholm. Sweden). and ~ 
mixed amino acid solution (Yamin 14; Pharmacia & Upjohn. 
i\lilton Keynes. UK). L-Glutamine solution was purchased 
from Oxford Nutrition (Oxford. UK) and was stored at - 20°C 
until use. GH and IGF-I were supplied by Pharmacia & 
Upjohn. 
Subjects. Nineteen se\'erely ill patients in the ICU of St 
Thomas' Hospital were initially studied. Two patients died 
before completion of the second study; thus data are pre-
sented only from the 17 patients who survived to complete 
both studies. However. as indicated in Table 1. one patient 
later died in the lCU. The patients were all newly admitted to 
the ICU. and the majority had undergone emergency abdomi-
nal surgery. All required mechanical ventilation and intrave-
nous nutritional support. Further details of their clinical and 
metabolic characteristics are summarized in Table 1. The 
severity of illness was evaluated on the day of the study by 
use of the APACHE II and TlSS score systems (S. 21). 
The protocol was approved by the Ethics Committee. Guy's 
and St. Thomas' National Health Service Trust. Written 
informed consent was obtained from relatives of the patients. 
Study protocol. All of the patients were fasted for 2: 12 h 
before the start of the first study. Indwelling arterial and 
central venous lines were used for blood sampling and for the 
tracer infusion. respectively. After baseline sampling. a prim-
ing bolus of [1- 13C]leucine (1 mg/kg) was injected. and 4-h 
constant infusions of [2- ISN]glutamine (2.S mg· kg-I. h- I) and 
[1- 13C]leucine (1 mg·kg-I·h- I) were started. Blood samples 
were taken at 210. 21S. 220. 22S. 230. and 240 min for 
steady-state measurement of plasma glutamine and a-keto iso-
caproic acid (a-KIC) enrichment and glutamine concentra-
tion. Samples were also taken at steady state for the measure-
ment of routine biochemistry. metabolite. and hormone levels 
[glucose. insulin. IGF-I, lGF-binding protein-l (IGFBP-l), 
cortisol, glucagon, thyroid hormones, and amino acids]. For 
glutamine analYSiS, O.S-ml lithium heparin plasma ali-
quots were mixed with 100 pI internal standard (100 nmol 
L-[U-13Cs]glutamine). All samples were stored at -70oe until 
analysis. 
At the end of the baseline study, patients were randomized 
to receive either standard TPN, TPN with additional intrave-
Table 1. Clinical and metabolic characteristics of patients 
Plasma Plasma 
Age. Weight. Height. 8MI. APACHE Albumin. CRP. Main 28 Day 
Patient No. Gender yr kg em kg/m 2 II TISS g/dl mg/dl DiagnOSiS Mortality 
TPN 
1 F 68 64 171 22 15 34 34 82 Bowel Resec-
tion 
2 F 55 42 158 17 20 47 28 191 Bowel Resec-
tion 
3 M 76 74 182 22 23 49 27 68 GI Bleed/lapa-
rotomy 
4 M 74 66 175 21 20 48 18 217 AAA 
5 F 69 61 162 23 18 42 25 185 AAA 
6 M 73 63 170 22 19 49 22 212 AAA 
Mean::!::SE 69::!::3 62::!::4 170::!:: 4 21::!:: 1 19::!:: 1 45 ::!::2 
TPNCLN 
1 M 72 82 187 23 15 37 23 161 GIObstruction 
2 F 65 75 170 26 9 50 19 557 Bowel Resec-
tion 
3 M 75 104 183 31 24 47 27 203 AAA 
4 F 75 85 168 30 19 38 23 329 Bowel Obstruc-
tion 
5 M 59 98 181 30 14 47 20 247 Bowel Resec-
tion 
6 F 32 59 170 20 18 62 17 145 Bowel Resec-
tion 
Mean::!::SE 63::!:: 7 84::!:: 7 177±3 24::!::3 17::!:: 2 46::!::3 
TPNCLN + CH/JCF-J 
1 M 65 65 182 20 19 50 15 378 Bowel Resec-
tion 
2 F 54 61 171 21 20 52 11 105 Bowel Resec- + 
tion 
3 M 50 60 179 19 9 38 26 38 GIObstruction 
4 M 62 115 179 36 16 42 20 249 Cardiac Arrest 
5 M 78 76 175 25 14 47 361 AAA 
Mean+SE 62+5 75+ 10 177+ 2 24::!::3 16::!:: 2 46::!::3 
TPN. total parenteral nutrition; TPNGLN. TPN + supplemental GIn; TPNGLN + GH/IGF-I, TPNGLN +. growth ?o.rmone and insulin-like 
growth factor I; BMI. body mass index; GI, gastrointestinal; AAA. abdominal aortic aneurysm; CRP. C-reactive protem. APACHE II and TISS. 
scoring systems for disease severity classification. 
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nous glutamine (TPNGLN: 0.4 g.kg-I·day-I). or TPNGLN 
with rhGH (0.2 lU· kg-I. day-I) and rhIGF-I (160 
pg·kg-I·day-I). The patients randomized to TPNGLN re-
ceived additional nitrogen in the form of the glutamine 
infusion (-0.06 g N·kg-I·day-I). The nutritional support 
was not made isonitrogenous because this could have limited 
the availability of other amino acids. A continuous insulin 
infusion (Actrapid; Novo Nordisk. Copenhagen. Denmark) 
was pro\'ided if required to maintain plasma glucose concen-
tration at or below 7 mmol/1. The GH was administered as a 
single subcutaneous injection; the dose of IGF-I was split into 
two equal twice daily subcutaneous injections. 
After 72 h of treatment, a second turnover study was 
performed using the same tracers and infusion rates as the 
initial study. In this second study the patients were not 
fasted, as nutritional support was continued throughout the 
protocol (Fig. 1). The patients were all sedated and mechani-
cally ventilated (Servo 900; Siemens. Berlin. Germany) 
throughout both studies. 
Experimental methods. The isotopic enrichment and concen-
tration of glutamine were determined from the tert-butyldi-
methylsilyl derivatiYe by use of a method modified from Wolfe 
(40). Glutamine concentration was determined by reverse 
isotope dilution using L-[U-13Cs]glutamine (Bioquote, North 
Yorkshire, UK) as the internal standard. Analysis by gas 
chromatography-mass spectrometry (GC-MS; MSD 5971A. 
Hewlett-Packard. Berkshire. UK) used electron impact ioniza-
tion with selected ion monitoring of the [M-butyl] + ions at 
mass-to-charge ratios (m/z) 431. 432. and 436. The isotopic 
enrichment of o:-KIC was measured as the qUinoxalinol-
tert-butyldimethylsilyl derivative by use of a method modi-
fied from Ford and co-workers (8). GC-MS analysis used elec-
tron impact ionization with selected ion monitoring of the 
[~I-butyl] + ions at m/z 259 and 260. Plasma glucose concen-
trations were measured on a model 23AM glucose analyzer 
(ySI. Hampshire. UK). Serum insulin concentrations were 
measured by an in-house double-antibody RIA (32). Total 
IGF-I was measured by RIA after acid ethanol extraction. 
Total IGFBP-1 was measured by a coated-tube immunoradio-
metric assay (Diagnostic Systems Laboratories. Webster, TX). 
Cortisol was measured by ELISA using the Enzymun-Test 
cortisol kit (Boehringer Mannheim, Sussex, UK). Glucagon 
was measured using a commercially available RIA kit (Linco 
Research, St Louis. MO). Free thyroid hormones were mea-
sured by a competitive immunoassay using chemilumines-
cence (Chiron Diagnostics, Essex, UK). Plasma amino acid 
concentrations were measured on an Alpha II + automated 
amino acid analyzer (Pharmacia, Hertfordshire, UK). Plasma 
albumin and C-reactive protein were measured using an 
automated method (Kodak 250, Ortho Clinical Diagnostics, 
Amersham, UK). 
Calculations. Measurements of glutamine metabolism were 
calculated using standard isotope dilution equations. Gluta-
mine appearance rate (Racln; pmol·min-I·kg- I) was calcu-
lated as Racln = F[l/(APEcln ' 0.01) -1], where F is the isotope 
infusion rate (pmol. min -I . kg-I), and APEcln is the plasma 
glutamine enrichment. In the postabsorptive state, the endog-
enous glutamine rate of appearance in plasma (Endo RacIJ is 
equal to the calculated Racln. At steady state, the rate of 
disappearance of glutamine from plasma (glutamine uptake: 
RdclJ was assumed to be equal to Racln. Leucine appearance 
rate was calculated using an analogous equation but with use 
of the plasma enrichment of o:-KIC as a measure of intracellu-
lar leucine enrichment (27). Glutamine metabolic clearance 
rate (MCR; ml·min-I·kg- I) was calculated as MCR = Rdclnl 
[GIn], where [GIn] is the steady-state plasma glutamine 
concentration (pmol/mI). 
Because glutamine is a nonessential amino acid in the 
fasting state, Racln is derived from both protein breakdown 
(BcIJ and de novo glutamine syntheSiS (DcIJ. BCln was 
estimated as 0.78 x RaLeu (7), and DCln was calculated as 
DCln = Racln - BCln (15). 
Nutritional support was maintained throughout the sec-
ond study. Because the patients were not in the postabsorp-
tive state, the equations given above were corrected for the 
known exogenous rates of leucine and glutamine infusion. In 
all three treatment groups, the exogenous rate of infusion of 
leucine (I Leu) was calculated from the TPN regimen, and the 
endogenous leucine rate of appearance in plasma from pro-
tein breakdown (Endo RaLeu) was estimated as Endo RaLeu = 
RaLeu - ILeu ' In the group of patients receiving TPN without 
glutamine supplementation, BCln was estimated using Endo 
RaLeu' and DCln was calculated as shown above. 
For the two groups of patients receiving TPNGLN, the 
exogenous rate of glutamine infusion (IcIJ was calculated, 
and the endogenous glutamine rate of appearance in plasma 
(Endo RacIJ was estimated as Endo Racln = Racln - Icln. BCln 
was estimated using Endo RaLeuo and DCln was calculated 
using Endo Racln' 
Statistics. All data are presented as means ± SE. "Steady 
state" for plasma glutamine and o:-KIC enrichments was 
confirmed as an insignificant correlation with time (P> 0.05) 
by use of repeated-measures ANOYA (NCSS 6.0, Dr. 1. 
Hintze, Kaysville, UT). Comparisons between groups were 
Start of protocol 
9am 
Fig. 1. Schematic representation of study protocol. All 
patients were initially studied in the fasting state and 
were then randomized to receive either total parenteral 
nutrition (TPN. n = 6), TPN + GIn (TPNGLN, n = 6). or 
TPNGLN + growth hormone (GH) + insulin-like growth 
factor (IGF-I) (TPNGLN+GH/IGF-I. n = 5). After 72 h 
of nutritional ± hormonal treatment, a second tracer 
study was performed during which nutritional support 
was continued. Hatched areas represent tracer studies. 
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made using ANOYA. and comparisons between study 1 and 
study 2\\'ere made by standard two-tailed paired t-tests. The 
insulin, IGFBP-l, cortisol. and glucagon data were log trans-
formed before analysis. 
RESULTS 
Table 1 shows the details of the 17 ICU patients 
studied. There were no significant differences in age, 
weight, height, or body mass index among the three 
treatment groups. The severity of illness is indicated by 
the APACHE II and TISS scores, which identify the 
patients as being severely ill and dependent on cardio-
respiratory and nutritional support (5, 21). There were 
no significant differences in the APACHE II and TISS 
scores among the three groups of ICU patients at the 
start of the study. None of the patients was acidemic, 
and there were no differences in the arterial pH values 
among the patient groups in study 1 (TPN, 7.43 :±: 0.03; 
TPNGLN, 7.44 :±: 0.02; TPNGLN+GH/IGF-I, 7.39 :±: 
0.02). In addition, bicarbonate concentrations indicated 
no depletion of alkaline reserves (TPN, 26 :±: 2 mmol/l; 
TPNGLN, 26 :±: 1.5 mmol/l; TPNGLN+GH/IGF-I, 25 :±: 
2.3 mmolll). There were no significant changes in 
arterial blood gas analysis between study 1 and study 2. 
Plasma urea concentrations were elevated in all groups 
in study 1, indicating a high rate of protein catabolism 
(TPN, 13.0 ± 2.3 mmol/l; TPNGLN, 12.9 :±: 2.5 mmolll; 
TPNGLN+GHlIGF-I, 9.3 + 1.4 mmolll; normal refer-
ence range 4 - 7 mmolll). 
The glucose and insulin data are shown in Fig. 2. 
There was a trend toward increased plasma glucose 
levels in the second studies for all three treatment 
groups. However, this increase only reached signifi-
cance in the TPN and TPNGLN +GHlIGF-I groups (P< 
0.05). Plasma insulin levels increased in study 2 for all 
three treatment groups (TPN, P < 0.01; TPNLGLN, 
P < 0.05); however, this failed to reach Significance in 
the TPNGLN+GHlIGF-I group (P = 0.13). Insulin 
infusion rates in study 2were 1.0 :±: 0.4 U/h in the TPN 
(n = 4) and 1.5 ± 0.6 U/h in the TPNGLN (n = 4) 
patient groups. In the TPNGLN+GH group only one 
patient received 2 U/h insulin during study 2. The 
measured total IGF-I concentrations were similar in all 
three groups in study 1 (TPN, 13.6 :±: 1.8 nmolll; 
TPNGLN, 12.1 :±: 0.9 nmolll; TPNGLN +GH/IGF-I, 
A B 
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Fig. 2. Glucose (A) and insulin concentrations (/3) in study 1 (open 
bars) and study 2 (filled bars). Values are means ± SE. 
10.3 :±: 0.8 nmolll) , and these values were lower than 
those reported from healthy control subjects of a simi-
lar age (16.5 :±: 1.7 nmolll; see Ref. 18). Total IGF-I was 
unchanged after both TPN and TPNGLN; however, as 
expected, there was a Significant increase in study 2 
(48.1 :±: 9.1 nmolll) in the TPNGLN+GH/IGF-I group 
(P < 0.05). IGFBP-1 was significantly decreased in 
study 2in the TPN group (231 :±: 79 vs. 39 :±: 12 ng/ml, 
P< 0.05); however, the changes in the TPNGLN (87 :±: 
35 vs. 132 :±: 86 ng/ml) and TPNGLN+GH/IGF-I (134 :±: 
59 vs. 58 :±: 15 ng/ml) groups were not significant. There 
were no significant changes in cortisol, free thyroxine, 
free triiodothyronine, or glucagon levels between stud-
ies 1 and 2for the three treatment groups. 
Plasma amino acid profiles are shown in Table 2. In 
the group receiving TPN there were Significant in-
creases in plasma serine (P< 0.05), glycine (P< 0.05), 
alanine (P < 0.05), methionine (P < 0.01), and orni-
thine (P< 0.05) levels in study 2. However, the increase 
in total amino acids did not reach Significance (P = 
0.07). Plasma serine (P< 0.05), glutamate (P< 0.05), 
glutamine (P< 0.001), glycine (P< 0.05), alanine (P< 
0.001), methionine (P< 0.05), histidine (P< 0.01), and 
total amino acids (P < 0.01) were all significantly 
increased in the second study in the patients receiving 
TPNGLN. In the group receiving TPNGLN +GH/IGF-I, 
the plasma profiles were similar in studies 1 and 2, 
apart from increases in glutamine (P < 0.05) and 
phenylalanine concentrations (P < 0.05). 
Figure 3 shows the plasma glutamine enrichments 
and concentrations from studies 1 and 2 for the 
TPNGLN patient group during the final 30 min of 
tracer infusion, indicating that steady state was 
achieved. Similar glutamine enrichment and concentra-
tion steady states were achieved for the other two 
patient groups (data not shown). The glutamine meta-
bolic data are summarized in Fig. 4. Glutamine produc-
tion rate and MeR were not affected by any of the three 
treatments. Glutamine uptake was significantly in-
creased in the second study in both the TPNGLN (5.2 :±: 
0.5 vs. 7.4 :±: 0.7 pmol·kg-I·min- I, P < 0.05) and 
TPNGLN+GH/IGF-I (5.2 :±: 1.1 vs. 7.6 :±: 0.8 
pmol· kg-I. min-I, P< 0.05) groups but was unchanged 
in the TPN group. 
BGln was significantly decreased in study 2 in. th; 
TPN group (2.5 :±: 0.2 vs. 2.1 :±: 0.2 pmol· kg-I. mm~ , 
P< 0.01), and although a similar trend was observed m 
the TPNGLN group, this failed to reach Significance 
(2.0 :±: 0.1 vs. 1.7 ± 0.2 pmol·kg-I·min- I, P = O.O~). 
When expressed as a percentage of Endo RaGIn, protem-
derived glutamine release was decreased after treat-
ment with TPN (44 :±: 4 vs. 40 :±: 3%, P < 0.05) and 
TPNGLN (40 :±: 3 vs. 32 :±: 3%, P < 0.05; Fig. 5). In the 
TPNGLN+GH/IGF-I group there was no Significant 
change in BGln (2.1 :±: 0.3 vs. 1.9 :±: 0.2pmol· kg-I. I?in- I). 
The decrease in the percentage of the glutamI~e ~a 
derived from proteolysis also failed to reach sIgmfi-
cance in this group (46 :±: 6 vs. 35 :±: 4%, P = 0.08; 
Fig. 5). 'th 
D was not significantly altered by treatment WI GIn 1 k 1 • -I) TPN (3.2 :±: 0.5 vs. 3.3 :±: 0.5 pmo· g- . mm , 
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Table 2. PlasI1Ja amino acid profiles 
TPN TPNGLN TPNGLN + GHIIGF-I 
Sw(f\ 1 Study 2 Study 1 Study 2 Study 1 Study 2 
Aspartate 34~ 10 38::+::9 14::+:: 6 20::+::6 18::+:: 5 28::+:: 12 
Threonine 49~8 91 ~ 15 57 ::+::6 73::+::8 57::+:: 7 67~ 10 
Serine 46~ 4 lOS::+:: 16* 54 ::+::6 84::+:: 13* 57::+::9 73::+:: 14 
Glutamate 30~8 94::+:: 29 36::+::7 61~14* 43::+:: 26 48::+:: 10 
Glutamine 376::+:: 34 426::+:: 58 338::+:: 22 461::+:: 24+ 307::+:: 65 524::+::71* 
Glycine 153::+:: 29 318::+::68* 145::+:: 13 220::+:: 23* 162::+:: 29 265::+:: 63 
Alanine 200::+:: 35 414::+::72* 170::+:: 20 278::+:: 26+ 183::+:: 42 286::+:: 83 
\·a.line 191 ::+:: 29 222::+:: 28 158::+:: 13 174::+:: 17 148 ~ 24 165::+:: 23 
C\'stine 50~9 70::+:: 17 55~ 14 50::+:: 4 37::+::5 49~8 
Methionine 11 ::+:: 2 27::+:: 2t 17::+:: 2 31::+:: 6* 14::+:: 2 22::+::6 
Isoleucine 36::+::8 32::+:: 4 41::+:: 6 42::+:: 8 27::+::4 30::+::3 
Leucine 116::+:: 19 112::+:: 18 98::+::8 86::+::9 84::+:: 15 79::+:: 12 
Tyrosine 41 ::+:: 9 38~7 49::+::7 36::+:: 12 62::+::22 36::+::4 
Phenylalanine 80~8 lOS::+:: 9 82::+:: 10 105 ~ 20 65::+:: 7 82::+::8* 
Ornithine 32::+::3 95::+:: 22* 40::+:: 5 72::+:: 16 35::+::9 36::+::7 
L\'sine 99::+:: 12 144::+:: 18 105::+:: 12 125::+:: 11 115::+::15 113 ~ 16 
Histidine 41 ~ 4 52~4 38::+::5 61::+:: 8t 46::+::7 54::+::8 
Total 1,546 ~ 149 2,324 ~ 309 1.463~ 94 1,967::+:: lO8t 1,434::+:: 161 1.894::+:: 270 
BCAA 337 ~ 54 365::+:: 49 290::+:: 29 302::+:: 31 260::+:: 40 274::+:: 33 
\'alues are means::+:: SE expressed in \lmol/l. BCAA, branched-chain amino acids. * P< 0.05 study 1 vs. study 2;t P< 0.01 study 1 vs. study 2; 
+P< 0.001 swci.1 1 \'s. swci.I'2. 
TPKGLN (3.1 ± 0.5 vs. 3.8 ± 0.5 pmol· kg-I. min-I), or 
TPNGLI'\+GH/IGF-I (3.0 ± l.0 vs. 3.9 ± 0.7 
pmol.kg-I.min- I). However, the percentage of the glu-
tamine Ra arising from DC1n was significantly increased 
after treatment with TPN (56 ± 4 vs. 60 ± 3%, P < 
0.05) and TPNGLN (60 ± 3 vs. 68 ± 3%, P < 0.05; Fig. 
5). Although a similar trend was seen in the 
TPKGLN+GHlIGF-I group, this failed to reach signifi-
cance (54 ± 6 vs. 65 ± 4%, P= 0.08; Fig. 5). 
DISCUSSION 
This study demonstrates that supplementation of 
TPN with glutamine in critically ill patients restores 
plasma glutamine concentration to nearly normal lev-
els and increases glutamine uptake. A similar increase 
in plasma glutamine concentration and glutamine up-
take was found when combined GH/lGF-I therapy was 
added to TPN with glutamine supplementation. This 
suggests that combined GHlIGF-I therapy does not 
have adverse effects on glutamine metabolism in these 
patients. 
Marked decreases in free glutamine concentrations 
have been reported in catabolic states associated with 
protein wasting. To date it has not been established 
whether this fall in glutamine concentration is a true 
glutamine deficiency or an alteration in glutamine 
homeostasis related to severe illness. Several studies 
have shown that the addition of glutamine or its 
analogs to TPN improves nitrogen balance and reduces 
the fall in muscle glutamine concentration and protein 
synthesis in postoperative patients (3,14,30,33,39). In 
the present study, we found that glutamine supplemen-
tation to TPN increased plasma glutamine concentra-
tion. The patients were fasted for ::> 12 h before the first 
study, but nutritional support was continued through-
out the second study. By using an isotopiC tracer of 
glutamine to measure glutamine metabolism, we were 
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Fig. 3. Plasma glutamine enrichment (atom percent exc~s.s. APE; A) 
and concentration (\lmol/l, B) for total parenteral nutntlOn + GIn 
(TPNGLN) patients in study 1 (0) and study 2 (e). Values are 
means::+:: SE; n = 6. 
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Fig. 4. Glutamine production rate (A), glutamine metabolic clearance rate (MCR; 8). and glutamine uptake (C) in 
study 1 (open bars) and Sruci.l- 2 (filled bars). Values are means::!:: SE. 
also able to demonstrate that whole body glutamine 
uptake was increased. This increased uptake may be 
for use by tissues with high metabolic demands for 
glutamine, such as the immune system and the gastro-
intestinal tract. TPN without glutamine supplementa-
tion failed to normalize glutamine concentration and 
had no effect on glutamine uptake, suggesting that 
glutamine supplementation may be important to meet 
the increased metabolic demands of glutamine-requir-
ing tissues in the catabolic state. 
In a previous study we showed that, despite a 
marked decrease in plasma glutamine concentration, 
plasma glutamine flux was unchanged in critically ill 
patients compared with matched healthy controls. We 
also found that glutamine MCR was increased in these 
patients, suggesting that the primary mechanism for 
the reduced concentration may be an increased effi-
ciency of glutamine transport (IS). In the present study 
when exogenous glutamine was provided, with or with-
out GHlIGF-I treatment, glutamine MCR remained 
elevated. The increased glutamine uptake would thus 
have been facilitated by the increased efficiency of 
glutamine transport. 
Acute glutamine depletion induced by phenylbutyr-
ate in healthy adults has also been shown not to affect 




























Fig. 5. Percentage of endogenous glutamine appearance rate derived 
from protein breakdown (A) and de novo synthesiS (8) in study 1 
(open bars) and study 2 (filled bars). Values are means::!:: SE. 
lahoor (I 2) reported an increased glutamine flux (60%) 
in burns patients compared with controls. In the pre-
sent study there was a decrease in the proportion of 
endogenous glutamine production derived from protein 
breakdown when the patients were receiving nutri-
tional support, although this decrease did not achieve 
Significance in the TPNGLN+GH/IGF-I-treated pa-
tients. 
Exogenous insulin was given when necessary to 
maintain the patients' blood glucose at or below 7 
mmolll, a standard procedure in the leU at St Thomas' 
Hospital. This treatment contributed to the observed 
increase in plasma insulin concentration in the TPN 
and TPNGLN groups. The increase in insulin concentra-
tion was not statistically Significant in the TPNGLN + 
GH/IGF-I group; this may be related to the fact that 
only one patient received exogenous insulin in this 
group. Because insulin plays a central role in protein 
metabolism by reducing protein breakdown (I 0), this 
may account for some of the decrease in glutamine 
production derived from protein breakdown in the TPN 
and TPNGLN groups. Similarly, the insulin deficiency 
of type 1 diabetes mellitus has been shown to increase 
the proportion of the glutamine appearance from pro-
tein breakdown (6). The fact that glutamine production 
rate was unchanged in the present study suggests that 
there was a shift to de novo synthesis of glutamine from 
the exogenous supply of amino acids. . 
Many of the early studies on the effects of glutamme 
supplementation assessed nitrogen balance and pro-
tein synthesis using ribosomal analysis. The improve-
ment in nitrogen balance with glutamine supplementa-
tion led to the assumption that some of the benefits 
associated with glutamine supplementation were medi-
ated through alterations in protein metabolism and the 
preservation of muscle mass. In addition: :xperim~nts 
using animal models had indicated a pOSItive relatIOn-
ship between protein synthesis and glutamine concen-
tration (20, 26). More recently, enteral glutamine infu-
sions in healthy adults have been shown to increase 
protein synthesis (I 6) . However, th~re is no direct 
evidence from studies in humans that mcreased muscle 
glutamine concentration enhances protein synthesis in 
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catabolic states. Whole body protein metabolism in 
critically ill patients was not affected by glutamine 
supplementation of enteral nutrition (24). Interpreta-
tion of the improvement in nitrogen balance needs 
caution. as a significant proportion of this balance may 
be due to replenishment of the muscle glutamine pool 
rather than synthesis of glutamine-containing proteins 
(38). 
The benefits of glutamine supplementation may be 
mediated through other tissues and pathways rather 
than via a direct effect on muscle and protein. Gluta-
mine supplementation has been reported to have a 
beneficial effect on intestinal function and the intesti-
nal mucosa in patients receiving intravenous nutrition 
(35, 36). A decrease in the number of infections and 
reduced hospital stay and costs have been reported in 
bone marrow transplant patients receiving TPN supple-
mented with glutamine (25, 41), suggesting possible 
effects on immune function, and glutamine is recog-
nized to be a substrate for immunocytes (29). An 
improvement in 6-mo survival has also been reported 
in critically ill patients receiving glutamine-supple-
mented TPN, but the mechanism(s) for this improve-
ment remain unclear (13). 
The loss of lean tissue in the critically ill has led to 
the in\"estigation of treatments to preserve lean tissue 
by use of various protein anabolic agents. GH treat-
ment has been shown to improve nitrogen balance, 
increase protein synthesis, and reduce leucine oxida-
tion in parenterally fed catabolic patients (4, 19). The 
demonstration that GH had protein anabolic effects led 
to two European multicenter trials being conducted in 
ICU patients. However, rather than improving mortal-
ity, as was expected, exogenous GH resulted in a 
significant increase in mortality (42 vs. 18%) (34). 
These multicenter studies differed from the present 
study in that the patients were given a variety of 
nutritional supports excluding glutamine supplementa-
tion. In addition, in the present study the GH treat-
ment was given only in combination with IGF-I therapy. 
An increase in protein anabolism as a result of GH 
and IGF-I treatment may result in a decrease in 
glutamine availability, exacerbating the glutamine 
depletion seen in the critically ill. Supporting this 
possibility is the finding that GH reduces skeletal 
muscle glutamine release in catabolic states (28). It is 
therefore possible that decreased glutamine availabil-
ity may have contributed to the increased mortality in 
the multicenter leu trials. Because IGF-I has protein 
anabolic effects, there is also interest in the use of this 
hormone in the treatment of catabolic patients (11, 23). 
In normal subjects, combined GHlIGF-I has been shown 
to have a synergistic effect on protein synthesis (31). 
Thus, in the present study, the effect of combined 
treatment with GH/IGF-I was investigated. These re-
sults show that combined GH and IGF-I treatment did 
not decrease glutamine production rate in these criti-
cally ill patients. The increase in glutamine concentra-
tion and glutamine uptake was similar to that achieved 
in the TPNGLN group, suggesting that this treatment 
did not have adverse effects on glutamine metabolism 
w~en nutritional support was supplemented with gluta-
mme. 
Many of the clinical studies of glutamine supplemen-
tation have studied patients undergoing elective sur-
gery. These are homogenous groups of patients undergo-
ing standard operative traumas, and these subjects are 
generally less severely ill than patients admitted to the 
ICU. The patients for the present study were recruited 
in the ICU from those for whom the clinical decision 
had been made to use parenteral nutrition. We chose to 
study these patients because they represent the group 
in which there is considerable clinical interest in the 
potential benefits of glutamine supplementation, but 
they are a very heterogeneous group, as can be seen 
from the patient details in Table 1. We had originally 
intended to study 12 patients in each group, but 
unfortunately the study was terminated because of the 
withdrawal of GH from use in ICUs after the mortality 
outcome of the GH multicenter trial. Some of the trends 
between the studies, for example the changes in insulin 
and amino acid concentrations, might have reached 
significance if more patients had been studied. 
We have previously shown in the critically ill that 
glutamine uptake is maintained, despite low glutamine 
concentrations, by an increase in the efficiency of 
glutamine transport as demonstrated by the increase 
in glutamine MCR. This is probably due to the in-
creased metabolic demand for glutamine by tissues 
such as the immune system and the gastrointestinal 
tract in the catabolic state. In the present study we 
have shown that, after glutamine supplementation, 
glutamine concentration was restored to normal but 
glutamine uptake was increased. The fact that gluta-
mine MCR remained elevated suggests that an in-
creased efficiency of glutamine transport facilitates the 
increased uptake. The addition of combined GH/IGF-I 
therapy to nutritional support with glutamine supple-
mentation did not affect the increase in whole body 
glutamine uptake or the restoration of plasma gluta-
mine concentration, suggesting that in the presence of 
glutamine supplementation, this hormone treatment 
did not have adverse effects on glutamine metabolism. 
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